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The mammalian Golgi apparatus plays many important physiological functions, 
including protein glycosylation. Glycosylation involves the addition of glycans, or 
complex polymers of sugar and is one of the most abundant post-translational 
modification of proteins. Glycans can have a profound effect on protein structure 
and functions, hence regulating numerous biological processes. While it is known 
that glycan expression is variable with different physiological and pathological 
conditions, their regulatory mechanisms remain poorly understood. Most glycans 
are synthesized by a series of sequential biosynthetic reactions in the Golgi where 
they diversify and become complex structures. Thus, they intimately depend on 
the intricate and compartmentalized organization of the Golgi. However, the 
regulation of Golgi organization is not completely known and how it affects 
glycosylation remain poorly understood.  
 
In this dissertation, I studied the mechanisms that control Golgi organization and 
its glycosylation function. To investigate organizational regulation, I have 
developed a quantitative morphological assay using three different Golgi 
compartment markers and quantitative image analysis, and performed a kinome- 
and phosphatome-wide RNAi screen in HeLa cells to identify molecular 
regulators. Depletion of 159 signaling genes, nearly 20% of genes assayed, 
induced strong and varied perturbations in Golgi morphology. Using 
bioinformatics data, a large regulatory network could be constructed. Specific 
sub-networks involving phosphoinositides regulation, acto-myosin dynamics and 
MAPK signaling provided further insights to Golgi regulatory mechanisms. 
Several cell surface receptors and their corresponding growth factor treatment 
strongly affected Golgi organization, indicating direct impact of extracellular 
signals on Golgi physiology. Secondary screens with different lectins revealed 
that most of these gene depletions also affected glycan biosynthesis, suggesting 
that signaling cascades can control glycosylation through Golgi organizational 
remodeling. Collectively, these results provide a genetic overview of the signaling 
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pathways that control the organization and functions of Golgi apparatus in human 
cells. 
 
In the subsequent part of the thesis, I focused on the regulation of O-GalNAc 
glycosylation initiation. Our previous report demonstrated that the process can be 
induced in the ER through the relocalisation of GalNAc glycosyltransferases 
(GalNAc-Ts) from the Golgi and drives upregulated expression of the Tn antigen, 
prevalent tumor-associated glycan. The process markedly stimulates cell 
migration and was found to be constitutively activated in various carcinomas. To 
examine the regulatory mechanisms of Tn expression in cancer, I have identified 
12 negative regulators through an RNAi screen on signaling genes. All 12 
proteins were found to regulate Tn expression by controlling GalNAc-T 
subcellular localisation. Atypical MAPK ERK8 appeared as a potent regulator 
whose inhibition rapidly induced ER O-glycosylation initiation. ERK8 is partially 
localized at the Golgi where its high basal kinase activity constitutively inhibits 
COPI-dependent retrograde traffic of GalNAc-Ts. This, in turn, inhibits cell 
motility. In human breast and lung carcinomas, ERK8 expression is frequently 
downregulated while O-glycosylation initiation is hyperactivated. Thus, ERK8 
appears as a constitutive brake on GalNAc-T relocation and loss of its expression 
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1.1 OVERVIEW OF THE SECRETORY APPARATUS 
 
The cellular evolution of prokaryotes to eukaryotes is undoubtedly one of the 
transcendent transitions in life. This step took four times longer than the transition 
from insentient matter to life as highlighted by fossil records [1]. Unlike 
prokaryotic cells that only has a plasma membrane barrier to separate the cell 
from the environment, the cytoplasm of eukaryotic cells is further 
compartmentalized into discrete membrane-bound structures known as organelles. 
Compartmentalization results in membrane expansion that enabled the 
development of larger cells (1000-10,000 fold increase in volume) and allowed 
more efficient division of cellular functions. Separation into discrete organelles 
creates microenvironments for specific sets of concentrated and essential 
biochemical reactions, hence, enabling specialization and conferring evolvability 
to the system [2]. 
 
Although performing different functions, there’s a need for communication 
between different organelles, as well as with the environment, so as to regulate 
organellar microenvironment and maintain cellular homeostasis. A major process 
of communication between the compartments that link the cell with the 
environment is mediated by the intracellular vesicular transport pathways. The 
process involves membrane-bound transport intermediates including small 
vesicles or larger carriers and tubules [3, 4] which enable macromolecules such as 
proteins to be ferried between organelles and to the cell surface.  
 
The intracellular transport system is an extensive and complicated network. In 
general, the system is divided into two major pathways: the endocytic and 
exocytic/ secretory pathways. In the exocytic/ secretory pathway, newly 
synthesized proteins and lipids from the endoplasmic reticulum (ER) are shuttled 
to the Golgi apparatus which eventually sorts them to various destinations either 
within the cell or secreted to the exterior. Reverse to this, in the endocytic 
pathway, extracellular materials are internalized from the environment into cells 
3 
 
via endocytosis which is mediated by a set of endosomes, early and late, to the 
lysosomes or the Golgi. In addition, retrieval processes are also essential to 
regulate the trafficking along both pathways. A schematic of the intracellular 
vesicular transport pathways is illustrated in Figure 1-1. At the crossroads of all 
these complex membrane trafficking events is the Golgi apparatus which is the 










Figure 1-1: Schematic of the organization of the secretory apparatus and 
intracellular transport pathways. The scheme demonstrates the extensive and 
complicated network of the endocytic and exocytic/ secretory pathways. 
Retrograde transport steps are indicated by red arrows and anterograde transport 
steps are indicated by blue arrows. Clathrin coats are in green, COPI in blue and 
COPII in pink. The major organelles of the secretory apparatus consists of the 
endoplasmic reticulum (ER), ER-Golgi intermediate compartment (ERGIC), 
Golgi apparatus, early endosome, the late endosome, body, recycling endosome, 
lysosome and the plasma membrane. Situated central to this busy traffic of 
intracellular transport pathway is the Golgi apparatus.  
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1.2 THE GOLGI APPARATUS: STRUCTURE 
 
Situated at the heart of the secretory pathway, the Golgi apparatus is perhaps the 
most suitable model to illustrate intracellular compartmentalization. First 
visualized and described in 1898 as an intracellular reticular apparatus by Camillo 
Golgi [5], the Golgi has since been studied intensely on its morphology. No other 
cell compartment or organelle has been so thoroughly investigated in morphology 
as the Golgi. Efforts to define the Golgi biochemically have been hampered by the 
fact that the organelle is highly integrated within the cellular endomembrane 
system, thus sharing similar biochemical characteristics with the ER and plasma 
membrane. Hence, it remains till today that morphology is the main criterion by 
which the Golgi apparatus is defined. The intriguingly complex structure of the 
Golgi has spurred the use of various techniques in ultrastructural research, ranging 
from standard electron microscopy to the recent correlative light and electron 
microscopy (CLEM), to visualize and understand the mechanisms behind its 
architecture [6]. Indeed, it is one of the most photographed organelles in the cell. 
 
1.2.1 Cisternal organization of the Golgi 
 
Based on these numerous studies, the consensus view of the Golgi is the 
composition of a series of flattened, disk-shaped membrane bound compartments 
known as cisternae, which form the basic structural unit of the Golgi. This unique 
cisternal architecture is conserved throughout eukaryotic evolution as it was 
apparent even in one of the earliest branching extant eukaryotes, the diplomonad 
Giardia lamblia [7]. In most organisms, apart from the budding yeast 
Saccharomyces cerevisae [8, 9] and some protists, the cisternae are piled up to 
form a stacked structure. Cisternae membranes are smooth due to the lack of 
ribosomes and they are usually curved. Depending on the cell type and position in 
the stack, different cisternae differ in their architectural detail. For instance, the 
diameter of the cisternae between distinct organisms can range from 0.7 to 1.1µm 
[10, 11]. The central part of a cisterna is usually quite narrow with a width of 10 
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to 20nm while the edges or rims are more dilated. These rims are perforated with 
gaps or fenestrae of up to 100nm in diameter. Increased number and size of 
fenestraes were found at the exterior cisternae of the Golgi stacks [12]. The 
presence of fenetrates is thought to add surface area to cisternae and introduces 
more curvature to the membranes. This might be essential to the vesicle formation 
and segregation of proteins and lipids [13]. Continuous with the fenestrae is a 
complex system of tubules and coated vesicles for inter-stack connections and 
intracellular transport.  
 
1.2.2 Cisternal stacking of the Golgi 
 
Perhaps the most striking structural feature of the Golgi is cisternal stacking. With 
the exception of the budding yeast and a few protists, in which the Golgi consists 
of several scattered cisternae, Golgi stacks are conserved throughout eukaryotic 
evolution. The number of cisternae in a stack depends on cell type, ranging from 
four to eleven in a typical mammalian Golgi [14] and more than twenty in scale- 
secreting algae [15]. Plants and animal cells can have 500 or more stacks and can 
reach over 25,000 stacks in algal rhizoids.  
 
The polarized Golgi stack 
 
Golgi stacks are polarized structures and are generally divided into three main 
compartments: cis, medial and trans Golgi. Both cis and trans Golgi are largely 
fenestrated tubular-reticular networks (also known as cis Golgi and trans Golgi 
networks) that form the two external faces of the Golgi and flank the medial- 
Golgi. Proximal to the ER is the cis-Golgi which receives and exchanges proteins 
and lipids from the ER whereas the cargo exits and gets sorted from the trans-
Golgi network to different cellular destinations [16]. The cargo traverses through 
the Golgi stack in a cis-to-trans fashion where it gets increasingly post-





Although morphologically indistinguishable, these different compartments differ 
biochemically and functionally. The distinct polarity of the compartments was 
already apparent from early electron microscopy studies. Cisternae from the cis-
Golgi preferentially reduced osmium and appeared blacken while the trans 
cisternae is stained preferentially for acid phosphatase and thiamine 
pyrophosphatase [18, 19], demonstrating distinct compositions. Interestingly, 
several gradients can be found in a Golgi stack: in cisterna fenestration and 
thickness, membrane thickness, pH, resident protein and lipid compositions.  
 
The sizes of fenestraes appear to decrease from the cis to medial cisternae and 
increase again at the trans while the cisterna thickness decreases from cis to trans 
Golgi [12]. This is correlated with the amount of transport events taking place. 
Conversely, membrane thickness was found to increase from the cis to trans face 
[20, 21]. For instance, in the rat liver, trans cisterna membrane is 8nm thick 
compared to the cis cisterna at 6.5nm. This is comparable to the thickness of both 
plasma membrane and ER respectively. This difference in thickness is thought to 
be due to the difference in lipid composition as the concentration of cholesterol is 
higher at the trans-side of the stack and particularly high in the endosomes [22-
24]. The presence of cholesterol fills the space between the two leaflets of the 
lipid bilayer, hence expanding the membrane width. Given that the plasma 
membrane is highly enriched in cholesterol, it can be inferred that the cis-Golgi 
membranes resemble the ER while the trans’ are similar to that of the plasma 
membrane. Differential membrane thickness is thought to be the mechanism for 
the retention of Golgi resident proteins as Golgi proteins have shorter 
transmembrane segments (~15 amino acids) compared to plasma membrane 
proteins (20-25 amino acids) [25]. The luminal pH levels decreases across the 
progression of the secretory pathway by two units, from neutral pH at the ER 
(7.2) to acidic levels at the trans Golgi (6.0) and secretory granules (5.2). Across 
the Golgi stacks, the pH drops by 0.7 units [26]. pH changes are fundamental for 
correct processing and sorting of secreted cargo [27, 28] as well as the correct 
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targeting of resident Golgi proteins such as TGN46 and furin [29]. Finally, each 
Golgi cisternae is studded with distinct sets of resident Golgi proteins. This 
includes the glycosidases, nucleotides sugar transporters, and at least 250 different 
glycosyltransferases, which are arrayed in the order which they function. 
Enzymes involved in the early and late stages of glycosylation are predominantly 
localized at the cis and trans sides respectively [30]. For instance, polypeptide N-
acetylgalactosaminyltransferase (ppGalNAc-T) and GlcNAc-phosphotransferase 
are associated with the cis Golgi, while GlcNAc transferase I, mannosidase I and 
II and phosphodiesterase are localized at the medial Golgi, and ߚ-1,4-
galactosyltransferase and ߙ-2,6-sialyltransferase at the trans side [31]. This allows 
sequential action on the modified glycoprotein as it traverses across the 
compartments. Further elaborations of the glycosylation process will be made in 
the subsequent sections. In addition, proteins that are associated with Golgi 
function, including the matrix proteins, Rabs, SNARE, also exhibit polarized 
distribution. It should be noted that the polarity across the stack is not strict and 
occurs as a gradient-like distribution because the Golgi is in dynamic equilibrium 
with the rest of the secretory apparatus. 
 
Functions of cisternal stacking 
 
The assembly of cisternae into stacks is thought to promote fidelity and 
efficiencies of these biosynthetic processes by spatially separating the enzymatic 
reactions. By concentrating and localizing the enzymes to specific cisternae also 
increases the enzyme-to-substrate ratio. Furthermore, the duration of cargo 
presentation to the enzymes is lengthened with stacking transport vesicle budding 
is confined at the cisternal rims. It was observed that once the cisternae unstack, 
the rate of vesicle budding and transport through the Golgi increases due to more 
accessible membrane areas [32]. Overall, this improves the yield and accuracy of 
the processes. In line with this, some species without Golgi stacks have been 
reported to have fewer glycosylases which suggests that stacking is required for 
cells with more extensive glycosylation processes [33]. Conversely, the rate of 
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cargo trafficking is improved with Golgi stacking. As the stacked cisternae are in 
close proximity, it minimizes the distance travelled by transport vesicles, ensuring 
their efficient movement between cisternae. The efficiency is further promoted 
with tethering complexes, such as the COG complex for intra- Golgi trafficking 
[34], that directly connect the budding vesicles to the target compartment. In 
addition, tubular connections between the proximal heterologous cisternae within 
the stack can be formed at times of increased cargo load, allowing the rapid 
transfer of cargo. This has been observed in spermatids and Sertoli cells [14] and 
more recently, other cell types such as normal rat kidney (NRK) and pancreatic β 
cells [35, 36]. Interestingly, these tubules are only observed in mammalian cells, 
possibly an advanced feature added to cisternal stacking in mammalian evolution. 
In other organisms such as plants where the polarized Golgi stacks are highly 
itinerant, stacking ensures efficient cargo processing and inter-cisternal trafficking 
as the stacks move [37, 38].  
 
Yet, Golgi stacks do not exist in some lower eukaryotes such as the budding yeast 
S. cerevisae and some developmental stages of D. melanogaster but consists of 
scattered cisternae [8] and clusters of vesicles or tubules [39] respectively. The 
scattered cisternae of the yeast can still be subdivided into cis, medial and trans 
Golgi [40] and efficient secretion is still supported in both organisms [39]. In 
addition, phylogenetic studies revealed that multiple Golgi proteins are highly 
conserved across eukaryotic evolution [41], implying that stacking is not an 
absolute requirement for the basic functioning of the Golgi but serves to increase 
complexity of Golgi functions. 
 
Golgi matrix proteins in cisternal stacking 
 
Despite of its central position in the secretory pathway where extensive 
membrane flux exchanges occur (Figure 1-1) and its highly dynamic nature in 
physiological and experimental conditions, how the elegant stacked structure of 
the Golgi is maintained remain contentious. Based on early morphological and 
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biochemical studies, the Golgi stacks were found to be held by proteinaceous 
cross-links between adjacent Golgi cisternae [42-44]. These proteinaceous links 
were later isolated in a detergent and salt- resistant fraction termed as the “Golgi 
matrix”  [45]. The Golgi matrix forms a ribosome-free area surrounding the 
cisternae. Numerous proteins were found to compose the Golgi matrix whereby 
the Golgi reassembly stacking proteins (GRASPs) and golgins form the two major 
groups (Baringa- rementeria, 2009). These proteins are very dynamic and cycle 
between membrane and cytoplasm. The cycling process are usually effected by 
modification such phosphorylation. In addition to Golgi structural maintenance, 
matrix proteins are involved in membrane trafficking and more recently, in novel 
roles such as signaling, microtubule organization and apoptosis [46].  
 
The GRASPs were first identified as the Golgi stacking factors [47, 48]. Both 
GRASPs in mammals, GRASP65 and GRASP55, appear to have redundant roles 
in Golgi stacking as depletion of either one of them resulted in minor effects on 
stacking [49-51], while depletion of both proteins profoundly abolishes stack 
formation [52]. However, loss of the single GRASP in lower eukaryotes such as 
the fly D. melanogaster [53] and T. brucei [54] did not massively perturb 
stacking. On the other hand, GRASP is also present in organisms without Golgi 
stacks [39, 55, 56] while plants have stacked Golgi but lack of a GRASP [57, 58]. 
This suggests that other factors are involved in stack formation and the GRASPs 
have additional functions.  
 
Mechanistically, the GRASPs are capable of trans-oligomerizing, mediated by 
their N-terminal PDZ domains, hence are proposed to tether and cross- link Golgi 
cisternal membranes for stacking [59, 60] (Figure 1-2). In line with this, the trans-
oligomerization domain appears to be absent in organisms with no stacks [61]. 
GRASPs are anchored to Golgi membranes via N-terminal myristoylation site and 
its interaction with the elongated coiled–coil golgins, whereby GM130 interacts 
with GRASP65 [47, 62] while Golgin45 with GRASP55 [63]. Extending out of 
Golgi membranes alike tentacles, golgins could mediate long-range tethering of 
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newly generated Golgi cisterna during cisternal maturation, before the homo-
dimerization of GRASPs for Golgi stacking [64]. This is coherent with their 
participation in several membrane tethering events [65] and GM130 appear to act 





Figure 1-2: A model for the formation of Golgi stack. During Golgi assembly 
or cistemal maturation of newly formed cisternae, the cisterna is first tethered to 
the cis-Golgi through a long-range golgin-mediated attachment. When the cisterna 
are in close proximity, this allows GRASP65 on both Golgi cisterna to interact via 
PDZ1-mediated trans-oligomerization, resulting in cross-linking and stacking of 
the Golgi cisterna. GRASP55 oligomerization is required to cross-linking 
cisternae in the stack. The model is modified from [64]. 
 
 
1.2.3 Golgi ribbon formation 
 
Unlike in cells of lower organisms, such as protozoa, some fungi and insects, 
where the Golgi exists as discrete stacks scattered in the cytoplasm, the Golgi in 
vertebrates exhibit more complex organization. A typical vertebrate Golgi 
comprise of multiple stacks that are interconnected to form a continuous ribbon-
like structure and is localized in the perinuclear and usually pericentriolar region 
[67]. Ultrastructural analysis revealed that the compact stacks are laterally linked 
by a reticulated network of branching and rejoining tubules, also known as the 
non-compact zone [12]. These ~30nm diameter tubules can sometimes stretch 
over several micrometers to bridge the adjacent stacks and can also project 
backwards to the same cisterna that they emanate from or to other structures such 
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as the vesicular tubular structures (VTCs) from the cis- and medial-cisternae [12-
14]. These tubules can not only link heterologous cisternae of similar positions in 
the adjacent stacks but sometimes also connect cisternae at different levels of the 
stacks [14]. Although the significance behind perinuclear ribbon organization of 
the vertebrate Golgi is not completely comprehended, various factors involved in 
the ribbon formation have been studied and will be elaborated in the subsequent 
paragraphs. 
 
Microtubules in Golgi ribbon formation 
 
Intimately linked to the feature of structural continuity between stacks is the 
perinuclear localisation next to the centrosomes. Loss of structural continuity of 
the ribbon often correlates with dispersion from perinuclear positioning. This 
suggests a functional association with the microtubule cytoskeleton. As the major 
microtubule-organizing centre (MTOC) of the cell, the centrosomes emanate a 
polarized radial array of microtubule filaments that gathers Golgi stacks in close 
proximity at the perinuclear region for ribbon biogenesis. This assembly and 
clustering is mediated by the motor protein dynein, that transports the stacks 
along microtubules towards the centrosome [68] (Figure 1-3). Interestingly, 
although the centrosomes are the main MTOC, it is dispensable for Golgi ribbon 
formation. This is evidenced by the ability of dispersed Golgi membranes to self-
organize into a continuous structure without the presence of centrosomes [69, 70].  
 
Indeed, the Golgi itself can also form an MTOC that locally nucleate and 
polymerize microtubules, forming an asymmetric network (Figure 1-3) [71, 72]. 
Golgi-nucleated microtubules is dependent on γ-tubulin ring complex (γ–TuRC) 
which anchors on Golgi membranes based on association with various Golgi 
proteins such as GMAP210 [73], GCC185 [72] and GM130 [74]. Distinct 
mechanisms are involved in microtubule formation at different Golgi 
compartments. While microtubules at the trans Golgi are controlled by 
microtubule-stabilizing protein CLASP associated with golgin GCC185 [72], 
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those nucleated at the cis Golgi require GMAP210 and γ–tubulin-interacting 
proteins AKAP450 via GM130 binding [73, 74].  
 
Thus, microtubules are essential for ribbon biogenesis whereby two sets of 
independently nucleated microtubule arrays from the centrosomes and Golgi act 
in concert for the assembly and positioning of the ribbon structure. Perturbations 
of microtubule integrity such as depolymerization of microtubules with 
nocodazole or loss of dynein function scatters the ribbon into separate stacks 
throughout the cytoplasm [75-79]. Upon nocodazole washout, the dispersed Golgi 
stacks were found to cluster locally at the cell periphery by Golgi-derived 
microtubules and subsequently moved along the centrosome-derived microtubules 
towards the perinuclear region [68, 80]. Ribbon assembly would not be possible if 
either step is perturbed, subsequently affecting Golgi functions such as polarized 
secretion and directional cell migration [81].   
 
Golgi matrix proteins in Golgi ribbon formation 
 
Once the Golgi stacks are clustered at the perinuclear region, they are laterally 
tethered together and linked to form a continuous ribbon (Figure 1-3). Formation 
of lateral connections between homotypic cisternae between stacks is assisted by 
Golgi structural proteins and also presumably by the Golgi-derived microtubules. 
It is speculated that both factors also confer specificity to allow linking between 
homotypic cisterna. For instance, microtubules from both cis and trans sides of 
the Golgi could confer geometric constaints to stacks which promotes ribbon 
formation [72, 74].  
 
Golgi structural proteins such as the GRASPs were initially shown to mediate 
stacking between heterotypic cisternae, having complementary roles with each 
other [42, 43, 82]. More recently, they were found to participate in the lateral 
linking between stacks by tethering homotypic cisterna but in a non-redundant 
fashion, as single depletions resulted in ribbon unlinking [50, 51]. While the role 
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of GRASP55 in ribbon formation is not completely confirmed [83], GRASP65 
appears to be convincingly involved in ribbon formation. Conferred with the 
ability to trans-oligomerise, GRASP65 was proposed to mediate ribbon formation 
by forming homo-oligomers to tether homotypic cisternae in close proximity [44, 
84]. Other Golgi structural proteins such as the golgins, were also found to be 
involved in Golgi ribbon maintenance and seem to cooperate with the GRASPs in 
the process [45, 50, 85-89]. As golgins are extended proteins, they could provide 
long-range tethering for lateral linking between Golgi stacks before the trans-
oligomerization of the GRASPs [64].  
 
Although the mechanisms remain speculative, it has been proposed that the matrix 
proteins are essential for Golgi ribbon biogenesis and confer its identity. This is 
highlighted by experiments using laser microsurgical removal of Golgi 
membranes [90] or dominant negative Sar1 microinjection after Brefeldin A 
(BFA) drug washout [91] which demonstrated the appearance of the matrix 
proteins in a continuous ribbon structure before the resident Golgi enzymes. 
However, the results have been contested by other reports that show redistribution 
of the matrix proteins to the ER at higher at higher Sar1 mutant expression [92, 
93]. More recent reports show that these proteins are highly dynamic and the 
Golgi-like remnants after BFA treatment [94, 95] and mitosis [96] are argued to 
be ER exit sites based on colocalisation with ERES markers. Collectively, while it 
is known that Golgi matrix proteins are important for Golgi organization, whether 
it serves as a stable template to confer Golgi identity or the Golgi forms de novo 
remains to be further proven. 
 
 
Lateral linking of the Golgi ribbon 
 
Lateral links between homotypic cisternae are formed by tubuloreticular 
structures (Figure 1-3). While the processes and molecular machinery that lead to 
this lateral fusion event remain obscure, recent results suggest that tubules 
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emanating from the Golgi play a major role and appear to be regulated by the 
phospholipid remodeling enzymes: phospholipase A (PLA) and lysophospholipid 
acyltransferases (LPATs); both exhibiting antagonistic roles. While PLA 
promotes tubulation through the formation of lysophospholipid (LPLs) [97], 
LPATs revert LPLs back to phospholipids and block tubule formation [98]. 
Mechanistically, tubular formation by PLA could arise from the conversion of 
cylindrically-shaped phospholipids to conically-shaped LPLs at specific sections 
of a single leaflet of the lipid bilayer, inducing membrane curvature [99]. 
Conversely, LPATs transfer fatty acids from acyl-CoA donors to LPLs, reforming 
phospholipids and inhibiting membrane curvature.  
 
This phospholipid interconversion was recently discovered to influence Golgi 
structure and function. The precise mechanisms are still not known but several 
possibilities have been proposed. Firstly, the lipid conversion generates 
membrane curvature for tubules and/ or vesicular carriers that could be involved 
in lateral linking between Golgi cisternae and membrane trafficking events [99-
101]. Secondly, a concentration gradient of lipid species could be formed that 
recruits effector proteins, such as vesicular coat machinery [102, 103], to Golgi 
membranes. The generated LPLs and fatty acids could also influence signal 
transduction and metabolic pathways.  
 
To date, four cytoplasmic PLA (PAFAHIb, cPLA2α, PLA2G6 and iPLA1γ) and 
an integral membrane LPAT (AGPAT3/LPAAT3) enzyme have been implicated 
in membrane trafficking processes and Golgi structural regulation, although the 
combination of PLA2 and LPAT enzymes involved remains to be unraveled [97, 
104]. Lateral links in Golgi ribbon are thought to be mediated primarily by the 
PAFAHIb enzymes, which could act in concert with dynein and microtubules to 
facilitate the coalescence of Golgi stacks at the peri-centrosome region [105]. The 
dynamic balance of membrane fluxes at the Golgi that is mediated by the 
membrane trafficking activities of PAFAHIb and other PLA enzymes could also 
be a critical influence on ribbon maintenance. For instance, PAFAHIb influences 
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trafficking at the TGN and endosomes [106] and cPLA2α facilitates intra-Golgi 
trafficking [107].  
 
Another question revolves around the mechanisms and molecular machinery that 
initiate tubule formation. Recent findings identified the involvement of the COPI 
coat in driving membrane bud formation at Golgi and tubule or vesicle formation 
depends on the relative activities of cPLA2α and LPAAT3(γ) [108]. This led to 
speculations that the COPI coat machinery could be involved. Yet, conversely, 
BFA treatment also evokes tubule formation from the Golgi. BFA acts by 
inhibiting COPI regulators ARF GEFs which causes dissociation of the COPI coat 
from Golgi membranes. In other words, BFA-induced Golgi tubules are 
independent of the COPI coat. It is possible that both COPI-dependent and COPI–
independent mechanisms are involved in controlling tubule formation at the 
Golgi.  
 
The mechanisms involving extension of the tubules from the initiating Golgi 
membrane protrusions also remain to be characterized. This requires directed 
force to pull membranes into tubules, hence actin- and microtubule-associated 
molecular motors are ideal candidates for this process. Indeed, it is clear that these 
cellular motors are essential for the intracellular movement of Golgi stacks; actin-
based myosins are required for the plants and fungi while microtubule-associated 
motors in vertebrates. It was found that tubules induced by BFA appear to require 
microtubule plus-end directed kinesin motors. Formation of BFA-induced tubules 
was prevented when dominant negative inactive mutant of KIF1C was expressed 
[109]. Supporting this, Golgi-nucleated microtubules are involved in gathering 
Golgi stacks for ribbon formation. It is thus possible that interstack tubules are 
elongated by kinesin activity along these local microtubules.  
 
In addition, actin-associated myosins might also contribute to tubule formation 
(Figure 1-3). A recent report suggests that unconventional myosin MYO18A 
interacts with Golgi phosphoprotein (GOLPH3), which is recruited to the Golgi 
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through phosphoinositol-4-phosphate binding. This interaction provides the 
tensile force for tubulation and allowing extension of the Golgi ribbon [110]. In 
addition, actin polymerisation at the Golgi region can be induced through the 
activation of formin mDia via LPL-induced Rho activation. This was found to 
induce Golgi dispersal in a mechanism involving myosin-II activity [111]. 
Mentioned previously, LPL promotes tubule formation, this suggests that the 
coordination of Rho activity by LPL might link membrane buds to myosin and 
actin filaments, which pulls the buds to form tubules. The formation of tubules for 
lateral linking might involve the concerted action of actin and microtubules. 
Indeed, Golgi protein WHAMM (WASP homology associated with actin, 
membrane, and microtubules) binds to microtubules and activates Arp2/3 
complex-mediated actin polymerisation which promotes tubule formation from 
the Golgi [112]  
 
Based on these various studies, while it is clear that tubules are required for 
coupling Golgi stacks to form a continuous ribbon, the mechanisms of how the 
tubules are initiated, extended and fuse with homotypic cisternae of different 







Figure 1-3: Model of Golgi ribbon assembly. (A) Microtubules (red lines) that 
are nucleated and polymerized at the Golgi emulate to contact other Golgi stacks 
in the vicinity. The Golgi stacks are then clustered together by moving along 
microtubules towards the minus ends. (B) The clustered stacks then move along 
centrosomal nucleated microtubules by dynein motor towards the perinuclear 
region next to the centrosomes. (C) and (D) Tubular structures elongate on 
microtubules (red lines) and/or actin filaments (blue lines) further link the 
clustered stacks to form a continuous ribbon.   
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Functions of the Golgi ribbon  
 
The Golgi ribbon is only found in vertebrates. This is intriguing as such a 
sophisticated structure would pose a challenge for processes particularly mitosis 
that requires even partitioning between the two progeny cells. To ensure faithful 
inheritance to the daughter cells, the Golgi ribbon would have to undergo multiple 
steps: disassembly and vesiculation, division and reassembly. This involves a 
non-trivial effort in terms of coordination and energy. This, hence suggest that 
natural selection favors ribbon structure in higher organisms and there must be 
exclusive reasons and advantages for its maintenance and inheritance. The ribbon 
structure could serve to broaden the repertoire of Golgi functions in vertebrates.  
 
Interestingly, the primary function of the Golgi, membrane trafficking, does not 
rely on the ribbon structure. Disruptions in the ribbon structure minimally affected 
intra-Golgi trafficking and general secretion to the plasma membrane [36, 50, 75, 
113]. It has been proposed that a continuous ribbon is required for uniform 
glycosylation of cargo, by allowing lateral diffusion of glycosylation enzymes 
between Golgi stacks. This is highlighted in the loss of golgin GM130 and 
GRASP65 which reduced to Golgi into ministacks and led to changes in glycan 
patterns [50] while others have observed changes in diffusion rate of 
glycosylating enzymes [52, 68, 114]. However, opposing results were also 
observed [115], making it hard to conclude. This may be due to differences in 
experimental conditions and tested glycosylation enzymes and cargo. Thus, it 
warrants a systematic analysis of Golgi ribbon integrity and glycosylation 
function to better address this.  
 
In contrast, formation of the Golgi ribbon is clearly required for advanced 
functions of cell polarization and directed secretion. The orientation of the Golgi 
in the cell is in particular importance to specialized functions including cell 
migration [116, 117], polarized secretion of lytic granules in cytotoxic T cells 
[118], distinguishing apical-basal epithelia axis [119] and regulated dendritic 
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growth in neurons [120]. For instance, during cell migration, the Golgi has to 
remodel and reposition at the leading edge of the cell to mediate delivery of new 
membrane and secretory cargo to the cell periphery (Figure 1-4). Disrupting the 
Golgi integrity would impair cell polarization and directed cell migration [116, 
121, 122]. In addition, the ribbon structure also substantially increased the total 
volume of the Golgi and this is important for specialized secretory cells. It was 
found that while insulin producing β cells of mice are 3.7-5.8µm3, the Golgi stack 
comprised of 3.1-3.6µm3 [123]. Finally, unlinking of the ribbon is an intrinstic 
G2/M checkpoint requirement before mitosis [124-126]. Although the reasons and 
the mechanistic basis of how morphology is sensed are not known, it suggests that 
the Golgi ribbon is closely linked to cell events and cell fate. Indeed, the Golgi 
ribbon appeared unlinked and fragmented in many diseases including 






Figure 1-4: The Golgi ribbon is required for cell polarization and directed 
secretion in a migrating cell. The Golgi ribbon orientates towards the leading 
edge of the migrating cell. Golgi-derived microtubules extend to the cell 
periphery and allow delivery of transport carriers containing secretory cargo such 
as cell adhesion factors as well as new membrane to the leading edge of the cell. 
The model is modified from [64]. 
 
 
Signaling regulation on the Golgi apparatus 
 
As highlighted in Figure 1.1, the cell transports a large amount of proteins and 
lipids in the secretory pathway and this is essential for its growth, survival, 
communication and homeostasis. Conversely, the secretory pathway also needs to 
accommodate and respond to internal and external stimuli in order for the cell to 
adapt to the surrounding environment and varying endogenous contexts. Signal 
transduction detects and converts the stimulus on the cell into a specific cell 
response. It usually starts with a signal to receptor and ends with a effect in cell 
function. It is now well documented that the secretory pathway is responsive to 
signaling cascades.  
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In particular, the Golgi is centrally located in the secretory pathway and bears the 
responsibilty of modifying and sorting of proteins and lipids that are trafficked in 
the secretory pathway. It, hence, needs to be able to sense and integrate 
endogenous and exogenous signals from various sources to maintain cellular 
homeostasis. Indeed, over the last ten years, several signaling molecules localise 
to Golgi membranes. These proteins were found to phosphorylate key Golgi 
proteins that resulted in modulation of Golgi organization or its functions in 
response to intracellular and extracellular cues [127-129]. Hence, the Golgi is 
highly responsive to endogenous and exogenous stimuli and its functional 
organization is deeply integrated to various signaling events in order to 
accommodate cellular requirements. 
 
The most well-established and best studied to date is the mitotic kinase cascade. 
During mitosis, the Golgi apparatus progressively disperses to allow correct 
partitioning into the two daughter cells at metaphase. Several signaling players 
including CDK1, RAF, MEK1, ERK1c, Plk1 and Plk3 [130-135] have been 
identified to participate in the process and they phosphorylated various Golgi 
proteins including GRASPs and golgins to mediate Golgi fragmentation. 
Surprisingly, the unlinking of the Golgi at the G2/M phase is required for mitotic 
entry, suggesting the existence of a novel ‘Golgi mitotic checkpoint’ [126, 136]. 
How this checkpoint occurs remains elusive at the moment but it suggests that the 
unlinking of Golgi membranes might trigger a set of signaling cascades to 
regulate mitotic entry.  
 
In addition to endogenous stimuli as observed with mitosis, it is now emerging 
that the Golgi and the secretory pathway also responds to signaling cascades 
induced by exogenous stimuli such as hormones, nutrients or growth factors. This 
modifies various aspects of its functional organization in response to the 
qualitative and quantitative demands required for cell growth, survival and 
homeostasis. For instance, general secretion is increasingly found to be regulated 
at the Golgi level in addition to our current understanding of regulation at the ER. 
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Several molecules such as protein kinase D (PKD) [137], PI4 kinases [138], p38 
MAPK [138-141] and protein kinase A (PKA) activation [142, 143] were found 
to remodel the Golgi structure and facilitate cargo flux from the TGN. For 
instance, PKD is present at the TGN where it activates PI4KIIIβ which generates 
lipid PI4P for the formation of post-Golgi carriers. PI4P is able to recruit various 
membrane trafficking effectors important for various aspects of vesicle budding 
and fission [144]. This is supported by the finding that in situations when 
secretion is inhibited, such as serum and nutrient starvation, phosphoinositide 
phosphatase Sac1 is recruited to the Golgi where it locally depletes PI4P levels 
and reduces export from the Golgi [141]. Stimulation of mitogens in serum 
starved cells led to redistribution of Sac1 back to the ER in a p38/MAPK-
dependent manner, rescuing reduced secretion. This elegantly demonstrates the 
nutrient sensing ability of the Golgi that allows the modulation its secretion 
according to the changing cell environment and needs. The Golgi also generates 
its own signaling in response to variable cargo load to modulate its own 
functional organization. Local activation of SFKs at the Golgi was observed upon 
increase in incoming secretory cargo [145]. This appears to be mediated by the 
binding of KDEL receptor with incoming luminal chaperones entering the Golgi. 
Subsequently, SFK activation promotes secretion and facilitates intra-Golgi 
trafficking to adapt to the cargo flow.  
 
Another clear example of a cellular process influencing Golgi function in 
response to external cues is during directional cell migration. When cells migrate 
towards a chemoattractant, the Golgi has to remodel and reorientate towards the 
leading edge of the cell [121]. This is required to establish cell polarity and ensure 
delivery of new membrane and secretory cargo to the leading cell periphery. 
Phosphorylation of GRASP65 at serine residue 277 by ERK has been shown to to 
be crucial to mediate this process [116]. Strikingly, the same residue on 
GRASP65 was also reported to be phosphorylated by CDK1 during mitosis that 
allows the disassembly of the Golgi [146], further substantiating the importance 
of GRASP65 in regulating Golgi integrity. Nevertheless, how cell polarity and 
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specific trafficking of material to the leading edge is regulated remains to be 
discovered. Like in the regulation of secretion, the Golgi also generates signaling 
for its own reorientation during cell migration. It was found that germinal-centre 
kinases III (GCKIII), MST4 and YSK1, are recruited to the Golgi by GM130 
which promotes their activation [147]. Unlike GRASP65, GM130 is not 
phosphorylated by these kinases but appears to serve as a scaffold at the Golgi. 
Given that GCKIII also phosphorylate polypeptide 14-3-3ζ, it might help recruit 
the Par complex to the Golgi. The Par complex is a master regulator of cell 
polarity [148]. Furthermore, Cdc42, a well-known activator of Par complex, was 
also found to be recruited via dynamin-binding protein DBMBP, by GM130 
[149]. Altogether, these findings demonstrate that there is a polarity complex 
localised on Golgi membranes that is recruited by GM130. Hence, GM130 is 
likely to play a central role in cell migration.  
 
The Golgi also serves as a platform for localised signaling and this spatially 
organizes signaling cascades, allowing differential signaling outputs. Signaling 
molecules, particularly the Ras proteins [150, 151] and members to the Raf-MEK-
ERK signaling cascade, are associated to Golgi membranes by palmitoylation or 
by scaffold proteins. It was found that both H-Ras and N-Ras are palmitoylated on 
Golgi membranes [152]. Remarkably, targeting Ras to the ER elevated survival 
and proliferation rates of NIH3T3 fibroblasts while control fibroblasts expressing 
Ras at the plasma membrane die after two to three days [153], further indicating 
differential results with signaling from different locations. Similarly, Ras targeted 
to Golgi membranes can also activate downstream signaling molecules [153, 
154]. Downstream of Ras is the Raf-MEK-ERK signaling cascade which was 
found to be spatially organized by scaffold proteins. Interleukin-17 receptor D 
(IL17RD/ Sef) localises MEK and ERK to the Golgi [155] and sequesters them 
from translocating into the nucleus upon activation. Golgi localised peptidyl-
tRNA hydrolase 2 (PTRH2/BIT1) also binds to ERK1/2 which blocks its activity 




Collectively, these various examples highlight the importance of signaling 
cascades regulating Golgi structure and functions. Although the mechanistic 
details still remain poorly understood, future work will have to focus on the 
regulation of the machineries involved. While it is well-established that the Ras-
MEK-ERK pathway regulates many aspects of the secretory pathway, many other 
signaling molecules are likely involved that remains undiscovered. To further 
grasp the extent of the regulatory mechanisms on the Golgi, systems biology 
would be an appropriate tool to study the regulation in a systematic and unbiased 
genome-wide manner. This would greatly advance our understanding in the 
interplay between signaling and the secretory pathway which aid further insights 
to how the secretory pathway can act in a processive and precise system. 
 
 
1.3 GLYCOSYLATION FUNCTION OF THE GOLGI 
 
Central to the secretory pathway in all eukaryotic cells, the Golgi apparatus is 
well-established for its role as a processing, membrane trafficking and sorting 
center in the transport of secretory proteins and lipids to their appropriate 
destinations. Among the most common processes occurring at the Golgi is 
glycosylation and this will be reviewed in the subsequent sections. 
 
Glycosylation is the enzymatic process involving covalent attachment of 
carbohydrate moieties, also known as glycans, on luminal and transmembrane 
proteins and lipids that passage through the secretory pathway. This process is 
probably as ancient as life itself as all life-forms ranging from unicellular archaea 







1.3.1 Glycan diversity in mammals 
 
Unlike other biopolymers such as nucleic acids and amino acids, glycan synthesis 
is not template-driven. The result is a vastly large diversity of glycan structures 
that could be generated. Mature glycans may range from a single sugar molecule 
to a complex polymer of more than 200 sugars and could be potentially further 
modified with sulphate, phosphate, acetate or phosphorylcholine. Glycans are also 
often branched. For example, a complex N-glycan structure could encompass up 
to six branches or antennae with each antenna made up of multiple repeating 
disaccharide units.  
 
In mammals, glycan structures are assembled from ten monosaccharides: fucose 
(Fuc), galactose (Gal), glucose (Glc), N-acetylglucosamine (GlcNAc), N-acetyl-
galactosamine (GalNAc), glucuronic acid (GlcA), iduronic acid (IdoA), sialic acid 
(Sia), mannose (Man) and xylose (Xyl) (Figure 1-5) [161-163]. The combination 
of these different monosaccharides with differences in their anomeric state (α 
versus β), glycosidic linkages (1–3 versus 1–4, etc.), branching, length and their 
substituted components (phosphate, sulfate, etc.) adds to the diversity of glycans 
that can be generated. Glycan addition to substrate proteins and lipids also creates 
different subsets of glycoconjugates. Glycans can be added to proteins through 
amide linkages to asparagine residues (N-glycosylation, through glycosidic 
linkages to serine and threonine side chains (O-glycosylation) [164, 165], 
hydroxylysine (collagen) or Tyr (glycogenin) or through carbon-carbon linkages 
to the C2 position of tryptophan (C-mannosylation). The former two 












Furthermore, glycans can be attached between glycosylphosphatidylinositol [166] 
anchors and proteins, serving as a bridge [167]. Within the O-glycans, there are at 
least six different types of attachments in vertebrates (Table 1.1). Many are 
branched except glycosaminoglycans which are linear glycans, that are often 
sulphated, and involve a different mechanism [168]. On the other hand, lipid 
glycosylation generates glycolipids (glycosphingolipids), including sialic acid-
bearing gangliosides [169]. In addition, there are unique glycans that are 
unattached to any substrates and this includes hyaluronan that is secreted into 
extracellular regions [170]. In contrast, the yeast only utilises four 
monosaccharides for glycan formation: Man, GlcNAc, Glc and Gal and the most 
common glycans are usually a simple structure of branching repeats of Man sugar 







Table 1.1: Consensus motifs and enzymes responsible for various 




Therefore, the mammalian glycan repertoire, also known as the glycome, is 
theoretically tremendously vast and diverse. Although the actual number of the 
entire glycome is not known, due to the limited existing knowledge of glycan 
determination, it was predicted to be 10-10,000 larger than the proteome [174]. 
However, constraints are also provided by the synthesis and regulatory 
mechanisms. The glycosylation machinery in the cell encompasses an array of 
several hundreds of glycosylating enzymes and nucleotide sugar transporters, 
altogether spanning about 1% to 2% of the genome [175]. This magnitude of 
genomic commitment further stresses the central role of glycoconjugate 
biosynthesis in humans. Further supporting this is the abundance of glycoproteins 
generated in the cell which forms about 50% of the proteome. Hence, as the most 
common post-translational modification process for proteins, the process has a 
broad impact on metazoans.  
 
Glycan addition is important for the functionality of the final glycoprotein product 
and this is essential for its activity, stability and localization. The incorporation of 
Type  Linkage Enzyme  Consensus sequence Domain Examples
N-glycosylation GlcNAc-β‑Asn OST N‑X-(S/T)(standard sequons) Nascent polypeptides
N‑X‑C, N‑G, N‑X‑V
(non-standard sequons)
O-glycosylation GalNAc-α-Ser/Thr ppGalNAc-Ts Isoform specific Mucins
GlcNAc-β-Ser/Thr OGT No set consensus
Cytosolic,
nuclear proteins
GlcNAc-β-Ser/Thr EOGT Unknown EGF Notch, Dumpy
Xyl-β-Ser XYLT1, XYLT2
a-a-a-a-G-S-G-a-(a/G)-a
(‘a’ represents Asp or Glu)
Heparin, proteoglycan
core proteins
Fuc-α-Ser/Thr POFUT2 C-X-X-(S/T)-C-X-X-G TSR
Thrombospondin,
ADAMTS family
POFUT1 C-X-X-X-X-(S/T)-C EGF Notch, clotting factors
Glc-β-Ser POGLUT1 C-X-S-X-(A/P)-C EGF Notch, clotting factors
Man-α-Ser/Thr POMT1, POMT2 I-X-P-T-(P/X)-T-X-P-X-X-X-X-P-T-X-(T/X)-X-X α‑dystroglycan
Gal-β-Hyl
GLT25D1, 
GLT25D2 X‑Hyl-Gly (collagen repeats) Collagen, adiponectin





C-mannosylation Man-α-Trp Unknown W-X-X-W TSR
Thrombospondin,
ADAMTS family
Glypiation Pr‑C(O)EthN‑6‑P‑Man Transamidase No set consensus THY1, NCAM1
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glycan structures also creates structural and functional diversity to proteins. In 
fact, glycans carry much more finely tuned information that could not be 
accomplished by a simpler polypeptide modification. This is highlighted by 
differences in in vivo serum half lives and potencies of peptide hormone 
erythropoietin with different glycan structures [176]. Therefore, by conferring 
additional information at the molecular and cellular level that expands the simple 
genome-encoded protein functions, glycans introduce biological complexity to 
eukaryotes  [177].  
 
1.3.2 Biological roles of glycans 
 
Glycans are prominent in the intracellular, cell surface and secreted proteins. 
They influence a wide range of important biological functions including structural 
roles, protein maturation and turnover, cell adhesion, receptor function and cell 
signaling, molecular trafficking and clearance, self-recognition, immune 
surveillance and pathogen invasion and some of these appear to be conserved in 
evolution of multicellular vertebrates [159]. 
 
Protective role of glycans 
 
It is without doubt that glycans play many protective, organizing and stabilizing 
roles in the cell. Every eukayorytic and various prokaryotic cells are coated with a 
layer of polysaccharide coat known as the glycocalyx which can represent a 
substantial physical barrier. The attachment of glycans, such as proteoglycans, to 
extracellular matrix molecules are required for maintaining tissue structure, 
integrity and porosity and can also, in turn, contribute to matrix organization. In 
addition, the orientation of glycans in the extracellular regions prevents the 
attached underlying proteins to be targeted by proteases and antibodies [178]. For 
instance, mucins, large glycoproteins that are heavily O-glycosylated, line the 
surfaces of epithelial cells and goblet or mucous cells of the tracheobronchial, 
gastrointestinal, and genitourinary tracts. In the gastrointestinal tract, mucins 
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constitute the mucosal layer to protect the tissue from gastric proteases [179]. 
Another structural role of glycans is the involvement as an insulating warehouse 
for biological important molecules. For example, glycosaminoglycan chains of 
the extracellular matrix in the basement membrane of epithelial and endothelial 
cells were found to contain many heparin-binding growth factors. This serves to 
prevent the factors from diffusing away from the localised region, inhibit their 
degradation, maintain their activities and allow them to be released under 
stimulated conditions [180, 181].  
 
Role of glycans in cell-cell interaction  
 
Glycans at the cell surface modulate cell-cell and cell-matrix interactions by 
providing ligands for cell adhesion, macromolecule interactions and pathogenic 
invasion [157, 182]. This is often mediated by specific lectin-glycan binding and 
is best exemplified in the interactions between selectins and the sialyl-Lewis X 
oligosaccharide ligand in various cell adhesion systems. In particular, the process 
is important for the tethering and rolling of the circulating leukocytes on the 
endothelium of the vasculature to allow infiltration of the leukocytes into the 
surrounding tissues to execute inflammation and maintain immune system 
homeostasis [183]. Glycan-lectin interaction is also required for fertilization of 
mammalian embryos and loss of some glycans was found to block the process 
[184-186]. 
 
Glycans also affect cells' sensitivity to extracellular signals by modulating 
interactions between cell surface receptor and their ligands. This, in turn, alters 
the downstream signal transduction events in the cell. This could occur by 
regulating signaling thresholds of the receptors. For instance, glycan 
heterogeneity on cytokine and adhesion receptors modifies ligand occupancy 
thresholds for intracellular signaling at different cell physiological states [187]. 
The glycan expressed could also determine the receptor residency duration at the 
cell surface by preventing its endocytosis or by organizing them in membrane 
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microdomains, thus modulating the time and magnitude of the signaling. For 
example, modifications of N-glycan structure by GlcNAc-transferase V 
(GlcNAcT-V) on epidermal growth factor, transforming growth factor–β and 
cytokine receptors delays removal by endocytosis via galectin interaction [188].  
 
Role of glycans in intracellular processes  
 
Apart from cell surface and extracellular events, glycan are also essential for 
various intracellular processes. Glycan structures on newly translated 
glycoproteins are critical for proper protein folding, ER-localised protein quality 
control and the subsequent maintenance of protein solubility and conformation 
which is required for passage and selective protein targeting across the secretory 
apparatus [189, 190]. For instance, the targeting and transport of hydrolases to the 
lysosomes relies on the recognition of mannose-6-phosphate residues by specific 
mannose-6-phosphate receptors [190]. 
 
Glycan variations in different physiological settings 
 
Glycan structures can vary greatly between cell and tissue types and physiological 
states. This is observed during maturation and activation of dendritic cells which 
alter lectin recognition by other immune cells [191]. Glycan chains at the cell 
surface were also reported to be more branched in high nutrient conditions and 
this is likely to favor cell growth and subsequently differentiation [192]. 
Furthermore, we have shown that growth factor stimulation promotes relocation 
of pp-GalNAc-Ts from the Golgi to the ER, which, in turn, increases expression 
of short O-glycans and promotes cell migration [193, 194]. Distinct glycan 
structures have biologically significant roles in the specific cell/tissue type. 
Distinct glycan structures are utilized by different cells in the alteration of the 
rates of cell surface glycoprotein endocytosis. For instance, cell surface 
maintenance of glucose transporter 2 in pancreatic β cells requires the 
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construction of a specific N-glycan that is recognized by pancreatic lectin 
receptors. The mechanism, in contrast, does not exist in hepatocytes [195]. 
 
Altered glycan structures are observed in a broad spectrum of pathological 
situations such as cancer [196, 197], immune disorders [198], diabetes [159] and 
genetic diseases like congenital disorders of glycosylation (CDG) [174] and cystic 
fibrosis [199]. Although the mechanistic links in cancer and diabetes are less clear 
than for genetic disorders at the moment, alterations in the glycan profiles can be 
observed during many malignant transformations [200] and there is an emerging 
link between cancer metastasis and glycosylation. Interestingly, there is a general 
tendency for tumor cells to express immature and usually short or truncated cell 
surface glycans, usually with alterations in density and patterns which are rarely 
found in normal tissues. These altered glycans was proposed to confer 
proliferative, survival, antigenic and adhesive properties to the cancer cells and 
increase their metastatic potential and invasiveness by reducing contact inhibition 
between cells. For instance, it was observed in mammary cancer cells that express 
the short O-glycans sialyl-Tn, there were increased growth and migration rates in 
mammary cancer cell lines and expression is associated with poor prognosis in 
breast cancer patients [197, 201]. These aberrant glycans can serve as a source for 
diagnosis, prognosis, monitoring disease progression and developing therapies 
and immunization against cancer [202-204]. 
 
1.3.3 The glycosylation machinery in the cell 
 
Glycans are constructed by the combined action of an intricate array of 
glycosyltransferases and glycosidases, collectively termed as glycosylating 
enzymes, as well as nucleotide sugar transporters that are localized in the 
secretory apparatus. It is estimated that approximately 700 proteins are involved 
in the glycan synthesis in mammals, whereby most of them reside at the Golgi. 
Although the initiation of glycosylation usually occurs in the ER, the subsequent 
addition or trimming of different sugars and branching, i.e. the construction of 
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complex oligosaccharide chains to generate a mature glycoprotein/glycolipid, is 
accomplished in the Golgi. Hence, emphasis will be placed on glycosylation at the 
Golgi in the subsequent sections. 
 
The primary determinants of glycan structure at the Golgi are the 
glycosyltransferases which catalyze the transfer and glycosidic linkage of a 
monosaccharide molecule from a simple nucleotide sugar donor substrate (for 
example, UDP-GalNAc, GDP-Fuc, or CMP-Sia) to an acceptor substrate (sugar 
of a glycan chain or protein/lipid). Some glycosyltransferases could also catalyze 
the transfer of two different sugars, usually to generate a string of repeating units 
such as the proteoglycans. Currently, there are more than 250 glycosyltransferases 
known to reside at the Golgi in mammals. This number is huge in mammals 
possibly because of the increased number of enzyme isoforms that catalyze the 
same reactions. For instance, while there are 20 mammalian sialyltransferases 
[205], Drosophila and yeast have one and none respectively [206]. Similarly, 
there are 20 ppGalNAc-Ts in humans and much fewer in the Drosophila (12) and 
C. elegans (9) [207]. In contrast, only a few glycan biosynthetic enzymes at the 
Golgi are glycosidases which remove monosaccharides to form intermediates that 
are subsequently acted on by glycosyltransferases. This is particularly relevant to 
N-glycan formation which involves the trimming of mannose residues as an 
intermediate step to generate complex and hybrid-type chains.  
 
Structure of Golgi glycosyltransferases 
 
The similarity shared by Golgi glycosyltransferases is their secondary structure. 
Golgi glycosyltransferases are mostly type II transmembrane proteins with 
transmembrane domain flanked by a short amino-terminal cytoplasmic tail and a 
long carboxy-terminal domain that comprises of a stalk-like stem region followed 
by a globular catalytic domain (Figure 1-6). In contrast, ER glycosyltransferases 
are mainly multitransmembrane proteins span the ER membrane. The carboxy-
terminal domain of Golgi glycosyltransferases extends within the lumen of the 
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Golgi in order to act on glycosylated substrates that passage through the 
organelle. Only a few exceptions to this configuration include GlcNAc-
phosphotransferase (a multisubunit complex) and the GlcNAc-1-phosphodiester 
α-N-acetylglucosaminidase (type I membrane-spanning) that are involved in the 
synthesis of the mannose-6-phosphate targeting signal of newly synthesized 
lysosomal hydrolases. Interestingly, some glycosyltransferases contain more 
functional domains in addition to the catalytic domain. For example, ppGalNAc-
Ts have a lectin domain that binds to existing GalNAc on substrates. 
Glycosyltransferases are often glycosylated by other glycosyltransferases or 
sometimes, they can auto-glycosylate. This glycosylation event is required for 
proper folding and functioning of the enzyme.  Some glycosyltransferases may 
also be cleaved in their stem region at the Golgi to be secreted in the cell surface 
or extracellular region [208, 209]. The reasons and the range of enzymes involved 







Figure 1-6: Structure of a typical Golgi glycosyltransferase. The Golgi 
glycosyltransferase is typically a type II transmembrane protein (shown in brown: 
a sialyltransferase). The glycosyltransferase comprise of a short cytoplasmic tail, 
transmembrane domain, extended stem region and a globular catalytic domain 
that is shown binding CMP-Sia from which it transfers Sia to Gal on a complex 
N-glycan on a glycoprotein (green). 
 
 
Golgi localisation and retention of glycosylating enzymes 
 
Biochemical and ultrastructural studies indicate glycosylating enzymes are 
exquisitely distributed to distinct Golgi cisternae and organized in the order which 
enzymes function. While early acting core glycan forming enzymes are enriched 
in the early cis- and medial-Golgi compartments, late acting capping enzymes are 
localized predominantly in trans Golgi compartment [30]. This localization 
segregation spatially organizes different enzymatic reactions to ensure the 
sequential construction of the growing glycan chain as it traverses across the 
successive cisternae. However, it does not mean that the glycosylating enzymes 
are rigidly confined in the Golgi compartment. As mentioned in the previous 
sections, the Golgi is a highly dynamic organelle central to the multiple 
membrane exchanges in the secretory pathway. Various Golgi trafficking models 
have been proposed for proteins that may influence cellular glycan expression. 
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According to the prevailing cisternal maturation model for membrane transport in 
the Golgi, Golgi resident proteins such as the glycosylating enzymes retain their 
steady-state Golgi localization by retrieval back to the “newer” cisternae. In 
contrast, the vesicular transport model proposes the existence of stable Golgi 
cisterna containing glycosyltransferase while the cargo traffics from cis to trans 
Golgi via vesicular transport. Thus, the mechanisms involved in how 
glycosyltransferases retain Golgi compartmental segregation are extensively 
explored.  
 
Various factors have been identified including sequence motifs in the cytosolic, 
transmembrane or stem regions of the enzyme, formation of an enzyme complex, 
length of transmembrane domain and association with a localization or activity 
chaperone. Sequence motifs on the enzymes could lead to homo-oligomerisation 
and retention as observed with sialyltransfases (Colley et al. 1992; Fenteany and 
Colley 2005). Enzymes that participate sequentially in a common glycosylation 
pathway may also form a complex by a mechanism known as the kin recognition. 
For example, GlcNAcT-I interacts with a-mannosidase II and GlcNAcT-II which 
all act chronologically in the synthesis of N-glycans [85, 210-212]. These enzyme 
aggregates may reach a size that can be excluded from transport vesicles. This is 
in support of the vesicular transport model but not the cisternal maturation model 
which involves movement of glycosylating enzymes in vesicles. It has been 
proposed that Golgi glycosyltransferases generally have a shorter transmembrane 
domain than proteins that span the plasma membrane which promotes Golgi 
retention (Munro 1995). This correlates with the membrane thickness of the 
secretory system and the plasma membrane whereby the latter is thicker. Golgi 
glycosyltransferases could interact with a protein chaperone that is required for its 
localization or activity. For instance, a number of glycosyltransferases in the yeast 
contain a sequence motif at the N-terminus that binds to peripheral sorting protein 
Vps74p. Vps74p interacts with COPI vesicles and mediates their Golgi retention 
[213, 214]. Additionally, the Drosophila glycosaminoglycans enzyme pipe, 
requires another protein known as “windbeutel” to localize to the Golgi [215]. 
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Furthermore, T-synthase/ C1GalT1 needs to form a complex with a chaperone 
COSMC in the ER in order to constitute an active enzyme in the Golgi [216, 217].  
 
1.3.4 Glycosylation reactions in the Golgi 
 
As illustrated in Table 1.1, a variety of glycosylation reactions on proteins has 
been identified and among the most prevailing processes occurring at the Golgi 
are N-glycosylation and O-glycosylation. Here we describe the current 
understanding of their general structure, common biosynthesis and processing 




N-glycosylation initiation  
 
N-glycans are covalently attached to asparagines residues of the polypeptide chain 
by an amide linkage [218]. The process is initiated on the cytoplasmic face of the 
ER which begins with the transfer of a GlcNAc sugar to dolichol phosphate (Dol-
P), a polyisoprenol lipid, to generate the dolichol pyrophosphate N-
acetylglucosamine (Dol-P-P-GlcNAc) precursor (Figure 1-7). The subsequent 
steps involve the stepwise construction of the N-glycan with 14 sugars of 
mannose and glucose, along with the flipping of the Dol-P precursor into the 
lumen of the ER, to generate the mature N-glycan precursor Glc3Man9GlcNAc2-
P-P-Dol (also known as the lipid-linked oligosaccharide precursor) that is ready 
for transfer to the asparagines of nascent proteins during translation [219]. The 
transfer requires the multisubunit oligosaccharyltransferase (OST) complex on the 
luminal face of the ER [220]. Subsequent to the polypeptide transfer, the three 
glucose sugars of the N-glycan are removed to generate the Man9GlcNAc2Asn 
structure for lectin chaperone calnexin and calreticulin to prevent hydrophobic 
aggregation and disulphide bonding during folding and to increase the ER 
retention time for proper protein folding [221]. In addition, removal of the 
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terminal α1-2 mannose targets misfolded glycoprotein for proteasomal 
degradation in a process termed as the ER-associated degradation (ERAD) for 
protein quality control [221, 222]. This initial step in the ER is conserved in all 
eukaryotes and has major influence in protein folding and quality control before 
exiting the ER. 
 
N-glycosylation in the Golgi: Formation of complex N-glycans 
 
Upon entry at the cis Golgi, N-glycans normally carry eight or nine mannose 
residues (Figure 1-7). In some vertebrate cell types, a few ‘high-mannose’ glycans 
can reach the cell surface [223]. However, almost all N-glycans on glycoproteins 
are subjected to trimming and extension on their passage through the Golgi. The 
cis Golgi contains α1-2 mannosidases IA, IB and IC which further trims 
additional mannose residues and generates the Man5GlcNAc2Asn intermediate. 
This intermediate forms the substrate for the synthesis of hybrid and complex N-
glycans by medial Golgi glycosyltransferase GlcNAcT-I that transfers the 
GlcNAc to Man5GlcNAc2Asn. Incompletely processed N-glycans that did not 
achieve Man5GlcNAc2Asn configuration cannot undergo further remodeling into 
hybrid and complex structures. Hybrid N-glycans are formed with the elongation 
of the GlcNAc arm with galactose and sialic acid while maintaining the remaining 
five mannose residues.  
 
The majority of N-glycans are complex structure. Complex N-glycans are formed 
firstly, by the action of α-mannosidase II at the medial Golgi on 
GlcNAcMan5GlcNAc2Asn which trims the two mannose residues terminal α1-3 
mannose and α1-6 mannose to form GlcNAcMan3GlcNAc2 (Figure 1-7). A 
second GlcNAc is then added to C-2 of the mannose α1–6 in the core by 
GlcNAcT-II to generate the precursor for all biantennary, complex N-glycans. 
This comprises of two antennae or branches. More branches can be initiated with 
the addition of GlcNAc to C-4 of the core mannose α1-3 by GlcNAcT-IV and C-6 
of the core mannose α1-6 by GlcNAcT-V to yield tri- and tetra-antennary N-
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glycans. The fifth branch can be initiated at C-6 of the core mannose α1-3 by 
GlcNAc-IX. Lastly, another branch can begin at the C-4 of the core mannose α1-3 
by GlcNAcT-VI. Hence, the resulting biantennary N-glycan can be branched up 
to six times and subsequently, each branch is extended by the addition of different 
sugars including galactose, GlcNAc, GalNAc, sialic acid and disaccharide units 
[224]. These further sugar additions occur mostly at the trans Golgi which 
expands the array of mature, complex N-glycans. A galactose is often added after 
GlcNAc and the branch is usually lengthened by tandem repeats of galactose and 
GlcNAc known as poly-N-acetyllactosamine or polyLacNAc. In addition, fucose 
can be added in a α1-6 linkage to the GlcNAc adjacent to the asparagines in the 
core.  Finally, the “capping” of the glycan chain usually involves the α-linking of 
sialic acid residue which protrudes away from the β-linked polyLacNAc structure, 
allowing these terminal sugars to be presented to glycan binding proteins such as 








Figure 1-7: Schematic of the N-glycosylation pathway. GlcNAc-T refers to N-
acetylglucosamine transferase; FucT refers to fucosyltransferase; SiaT refers to 
Sialyltransferase; β4GalT refers to β1-4galactosyltransferase. 
 
 
The processing steps described above occur in predominantly in vertebrates. In 
contrast, this final hybrid and complex N-glycan structure is not found in lower 
organisms such as the yeast and Drosophila. The yeast do not truncate the 
Man8GlcNAc2Asn that enter the cis Golgi, but further add mannose residues to 
produce the oligomannose with many branched mannose residues known as the 
yeast mannan [171]. Most Drosophila N-glycoproteins contains high mannose N-
glycans that sensitive to cleavage by endoglycosidase H (EndoH) [225, 226]. 
Although complex N-glycans can be found, they have fewer sugars compared to 
the vertebrates’. Similarly, the N-glycans of C. elegans comprise of high mannose 
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and complex structures but with fewer sugars and may include phosphorylcholine 
attachment to GlcNac [227]. 
 
N-glycans in health and disease 
  
Mutant cells or organisms with perturbations in N-glycosylation have shed light 
to biological functions of N-glycans, their effects on the biochemistry of 
glycoproteins and on how the glycosylation pathway operates. For instance, 
defects in N-glycosylation have been linked to a group of human diseases termed 
as the congenital disorders of glycosylation (CDG) [174]. Mouse mutants of the 
N-glycosylating machinery in particular have shed huge insights on the functions 
of N-glycans. For example, the deletion of the Mgat1 gene that encodes GlcNAcT 
-I inhibits the formation of complex and hybrid N-glycans. While this deletion in 
Lec1 cultured cells does not affect viability and growth, mice with this deletion 
die early during embryonic development, suggesting the relevance of the complex 
N-glycans in growth and development of an organism. Indeed, complex N-
glycans are required to retain the growth factor and cytokine receptors at the cell 
surface as those lacking of branches of complex N-glycans have shorter cell 
surface residence time and attenuated signaling. In addition, mice lacking of 
siayltransferases, fucosyltransferases, or branching N-GlcNAcTs that produce 
complex N-glycans suffer from defects in immunity or neuronal cell migration, 
inflammation or lung emphysema. Furthermore, increased branching of N-glycans 
has been observed during cancer formation and progression, which has been 
found to be attributed to increased transcriptional expression of GlcNAcT-V 
(Mgat5).  Thus, the N-glycosylation machinery have been studied as a target for 




O-glycosylation is defined by the addition of glycan sugars onto serine (Ser) and 
threonine (Thr) residues of glycoproteins. Several sugar types can be added to the 
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Ser/Thr to yield different classes of O-linked glycans, such as α-linked O-
GalNAc, α or β-linked O-galactose, α or β-linked O-glucose, α-linked O-fucose, 
α-linked O-mannose, β-linked O-GlcNAc and β-linked O-xylose [229-232]. 
Among these, O-GalNAc glycans is the most abundant type whereby O-GalNAc 
glycosylation is found in more than 10% of human glycoproteins and more than 
50% of the glycoproteins passing through the secretory pathway. Interestingly, 
this process only occurs in eumetazoans while N-glycosylation is present in lower 
eukaryotes [233]. Traditionally considered as the classical O-GalNAc 
glycoproteins are mucins and mucin-like proteins that contain PTS (Pro, Thr and 
Ser) repeats carrying dense clusters of O-glycans in a heterogeneous manner [234, 
235]. Hence, O-GalNAc glycosylation are often termed as mucin O-glycosylation. 
However, recently, it is increasingly evident that O-GalNAc glycans are widely 
distributed in regions of many different proteins that do not have mucin-like 
features [236-239]. 
 
O-glycosylation initiation is mediated by ppGalNAc-Ts 
 
The initial step O-GalNAc glycosylation involves the transfer of GalNAc sugar 
from UDP-GalNAc to the hydroxyl of Ser/Thr residues α-linked with an O-
glycosidic bond which is catalyzed by a ppGalNAc-T (Figure 1-8). In humans, up 
to 20 different ppGalNAc-T isoforms are localised in the Golgi with distinct but 
partially overlapping substrate specificities [240-242]. ppGalNAc-Ts are 
evolutionary conserved in all eukaryotes with numbers appear to increase across 
evolution: C. elegans, Drosophila and humans have 9, 12 and 20 GalNAc-T 
isoforms respectively [207, 243, 244]. This is in contrast to other types of protein 
O-glycosylation which usually involves only one or two isoenzymes. Hence, O-
GalNAc glycosylation is arguably the most complex form of protein glycosylation 
because of the incomparable cell- and protein-specific regulation of the O-
GalNAc glycan attachment sites and eventually, the nature of the O-




Deciphering the specificities of each of the 20 GalNAc-T isoforms is an arduous 
task. At current status, the defined amino acid sequences for GalNAc addition 
remain unknown although it is characterized that proline residues near the sites of 
addition are usually promote GalNAc addition, possibly by increasing exposure of 
Ser/Thr residues in a β-turn conformation [240]. In addition, unique to other 
glycosyltransferases, it has an additional lectin-like domain at the carboxyl 
terminus that binds existing GalNAc residues on glycoproteins [245]. This 
influences the further GalNAc addition by other GalNAc-Ts in the glycosylated 
protein substrate. Phylogenetic analysis allowed the classification of GalNAc-Ts 
into subfamilies of similar functions [243, 246]. Subfamily members may have 
similar substrate selectivity but generally show tissue specific expression, 
resulting in partial functional redundancy. The catalytic sites of GalNAc-Ts 
appear to be the driver for substrate selectivity as these residues are conserved 
within isoforms of different organisms while there is poor conservation between 
isoforms. This suggests that during evolution, orthologous GalNAc-Ts maintain 
similar substrate repertoire and newly evolved GalNAc-Ts acquire new substrate 
preferences, allowing a diverse range of substrates to be O-glycosylated. It also 
means that through the differential control of the GalNAc-Ts present, it provides 
an effective mechanism select for the repertoire of proteins to be O-glycosylated 
in the cell. The localisation of the GalNAc-Ts is also critical for O-glycan 
synthesis. It was found that different GalNAc-T isoforms have been found to be 
located throughout the Golgi in HeLa cells [247].  
 
Only recently, in vivo isoform-specific O-glycosylation has been identified for 
some proteins. For instance, GalNAc-T3 is essential to glycosylate a specific site 
in Fibroblast growth factor 23 (FGF23) and prevent inactivation by proprotein 
convertase in humans. Loss of GalNAc-T3 function leads to Familial tumoral 
calcinosis [248]. Similarly, GalNAc-T2 is required for site-specific O-
glycosylation of angiopoietin-like protein 3 to prevent proprotein convertase 
inhibition [249]. In mice, GalNAc-T1 is important for O-glycosylation of 
Osteopontin and Bone sialoprotein [250]. However, for most of the other O-
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GalNAc glycosylated proteins, the specific sites and ppGalNAc-T enzymes that 
act on it remains elusive. It was predicted that over 700 proteins could be 
potentially regulated by site-specific O-glycosylation and proprotein convertase 
processing (Gram Schjoldager et al, 2011). Thus, there are obviously many 
undiscovered site-specific O-glycans with important biological roles that awaits to 
be uncovered.  
 
The Tn antigen 
 
GalNAc addition to glycoproteins generates the Tn antigen (GalNAcα1-Ser/Thr), 
which in the terminal form represents the simplest structure of O-GalNAc glycan 
(Figure 1-8). The Tn antigen is normally not expressed in normal tissues as it is 
rapidly modified by downstream glycosyltransferases upon GalNAc addition. 
Thus, the glycan is antigenic. Tn expression is associated with a number of human 
disorders and diseases such as cancer, Tn syndrome and immunoglobulin A (IgA) 
nephropathy [251]. In particular, the high prevalence of Tn in cancers of multiple 
tissue types led to its classification as a tumor-associated cancer antigen. More 
than 70-90% of cancers of the breast, colon, lung, bladder, cervix, ovary, 
stomach, and prostate exhibit Tn expression [252-254]. Tn expression also 
correlates with metastatic potential and poor prognosis of cancer patients, 
suggesting its significant influence on tumor progression [251]. This led to 
extensive investigations as a cancer biomarker [252-254]. The mechanisms of 
how Tn expression links to cancer progression are not well understood at the 
moment. It has been suggested that Tn antigen present on Mucin1 may lead to 
immunosuppressive effects by binding to macrophage galactose type lectin 
(MGL) on immature and tolerogenic dendritic cells, hence allowing the tumor to 
avoid immunosurveillance [255]. Furthermore, various cell surface receptors such 
as low-density lipoprotein (LDL) receptor [256, 257], transferrin receptor [258], 
P-selectin glycoprotein ligand-1 (PSGL-1) [259] and dystroglycan [260] have 
been observed to exhibit Tn expression or incomplete O-glycosylation, it is 
postulated that Tn expression perturbs cell surface protein expression and/or 
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biological activity, hence affecting cell proliferation or adhesive/ migratory 
properties of cancer cells. Indeed, our group has recently found that increased Tn 
expression promotes adhesion and migration in cells [194].  
 
Synthesis of O-GalNAc glycan Core structures 
 
The transfer of the initiating O-GalNAc to the protein forms the branchpoint of O-
GalNAc glycosylation. The initiating GalNAc can serve as an acceptor of at least 
three other glycosyltransferases which adds a galactose, GlcNAc or sialic acid and 
generating the Core 1, Core 3 and sialyl-Tn antigen respectively. The first two 
occurs in normal cells while the sialyl-Tn (Siaα2-6GalNAcαSer/Thr) structure, 
like Tn antigen, is prevalent in diseases and often observed in cancers [261-263]. 
In normal cells, including the previously mentioned Core 1 and 3, a total of eight 
different core structures could subsequently be derived by the action of different 
core forming enzymes, whereby Core 1 through 4 constitute the more common 
structures. It is of note that in contrast to other glycosylation reactions such as N-
glycosylation (Section 1.3.4.1) or O-mannosylation, no lipid-linked intermediates 
are involved in O-GalNAc glycan biosynthesis and unlike N-glycosylation, the 
initiating process normally occurs at the cis Golgi instead of the ER. Lastly, in the 
subsequent processing steps of O-GalNAc glycans in the Golgi do not encompass 
any glycosidase trimming of the glycan chain. 
 
Core 1 (Galβ1-3GalNAc-Ser/Thr) structure is generated by the addition of 
galactose by a Core 1 β1-3 galactosyltransferase (also known as C1GalT1 or T-
synthase) and it forms the precursor for Core 2 O-glycan. This is in contrast to 
Core 3 structure (GlcNAcβ1-3GalNAc-Ser/Thr) which forms the precursor for 
Core 4 O-glycan. Core 1 synthesis is most common occurring as it is generated in 
most cell types due to the ubiquitous expression of C1GalT1 [264], thus is 
essential for organism’s functioning. Indeed, the disruption of C1GalT1 in mice is 




The activity of C1GalT1 requires a specific molecular chaperone termed as 
Cosmc, an ER protein that mediates proper folding of C1GalT1 and preventing its 
ubiquitin degradation in the ER [266]. Absence of functionality of either cosmc or 
C1GalT1 results in defects in Core 1 synthesis and high expression of Tn antigen. 
Indeed, loss of Cosmc is associated with Tn-related human diseases including IgA 
nephropathy and a rare condition called the Tn syndrome [251]. Although it was 
proposed that loss of Cosmc could explain high Tn expression in neoplasm [267], 
it could not explain all incidences [194]. Core 1 O-glycan in its terminal form is 
known as the T antigen. Like the Tn antigen, its expression is uncommon in 
normal tissues and observed in cancer and inflammatory bowel disease [254]. 
However, it is rare that the T antigen is exposed without further substitution but 
usually substituted by sialic acid at the C-3 of galactose and then C-6 of GalNAc, 
forming sialyl-T antigen and disialyl-T antigen (DiSia3,6Core 1) respectively 
[268]. The addition of sialic acid also prevents further modification of Core 1 by 
adding a negative charge to the glycan. Sialyl-Core 1 glycans are often observed 
on the cell surfaces of many leukemia and tumor cells [197].   
 
Normally in many tissues including the intestinal mucosa, Core 1 is branched by 
the addition of GlcNAc to GalNAc of the Core 1 structure by Core 2 β1-6 N-
acetylglucosaminyltransferase or β6-GlcNAcT/C2GnT to yield the Core 2 O-
glycans (GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr) [269]. Alternatively, the Core 1 
structure can be elongated to form extended Core 1 O-glycans by GlcNAc 
addition to the galactose of Core 1 by β3-GlcNAcT-3. This prevents further 
substitution by C2GnT as the enzyme is highly specific to unmodified Core 1 
structure. There are at least three isoforms of C2GnT: C2GnT1-3 and they can be 
subcategorized into two major types: leukocyte-type/L-type comprising of 
C2GnT-1 and -3 and mucin-type/M-type comprising of C2GnT-2. The L-type 
enzymes synthesize only the Core 2 structure while the M-type is also involved in 
Core 4 synthesis and other GlcNAcβ1-6-linked branches. Both isoforms subtypes 
also show differential tissue expression whereby the L-type is ubiquitous in many 
tissue types particularly in the bone marrow and thymus tissues (including 
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product B- and T-cells) while the M-type is restricted only in mucin-secreting cell 
types such as the gastrointestinal tissues. The synthesis of Core 2 glycans was 
found important for immune system physiology. Its expression is regulated during 
lymphocyte activation and cytokine stimulation [270, 271]. Core 2 glycan 
expression is also correlated with tumor progression whereby leukemia and other 
cancer types exhibit abnormally upregulated Core 2 levels [272]. It is proposed 
that the branched nature of Core 2 glycan can shield the exposure of mucin 
peptide epitopes. Interestingly, HIV also upregulates Core 2 formation in T-cells 
through C2GnT-1 expression to induce Galectin-1 mediated T-cell death [273]. 
 
Unlike Core 1 and 2 which is generated in most tissue types, Core 3 O-GalNAc 
glycans (GlcNAcβ1-3GalNAcαSer/Thr) appears to be synthesized in the mucous 
epithelia of the gastrointestinal and respiratory tracts as well as the salivary 
glands. This is due to the high expression of Core 3 β1-3 GlcNAc-T (also known 
as C3GnT) in these tissues [274, 275]. Loss of C3GnT expression in 
gastrointestinal cancers have been proposed to upregulate sialyl-Tn antigen and 
Core 1 O-glycans and this switch serves as a good biomarker for colonic and 
rectal cancers [276, 277]. C3GnT catalyses the addition of GlcNAc to the 
initiating GalNAc sugar. Generally, unmodified Core 3 is subsequently branched 
by C2GnT-2 to form Core 4 (GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr) and 
extended to complex chains. Core 3 may also be substituted with sialic acid in a 
α2-6 linkage to the GalNAc sugar or with galactose in β1-4 linkage to GlcNAc of 
the Core 3 structure.  
 
Synthesis of complex O-GalNAc glycans 
 
Beyond the Core glycan formation involves primarily elongation steps. The 
galactose residue of the Core 1 glycan and both galactose and GlcNAc branches 
of the Core 2 structure may be extended by elongation GlcNAc-Ts and 
galactosyltransferases to form repeating units of GlcNAcβ1-3Galβ1-4 (poly-N-
acetyllactosamine) sequences. Elongation reactions can also encompass the 
formation of GalNAcβ1-4GlcNAc- (LacdiNAc) and Galβ1-3GlcNAc- sequences 
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that are less common. The terminating structures of the O-glycan chains are 
commonly blood group A (GalNAcα1-3(Fucα1-2)Gal-), blood group B (Galα1-
3(Fucα1-2)Gal-), blood group O (Fucα1-2Gal-), Lewis antigens (Galβ1-3(Fucα1-
4)GlcNAc-, Galβ1-4(Fucα1-3)GlcNAc-, Siaα2-3Galβ1-4(Fucα1-3)GlcNAc-, 





Figure 1-8: Schematic of the O-glycosylation pathway. Biosynthesis of core 1 
and 2 O-glycans which occurs in most tissues is shown in the left. Biosynthesis of 
core 3 and 4 O-glycans that is restricted to mucous epithelia is shown on the right. 
GalNAc-T refers to polypeptide N-acetyl galactosamine transferase; C1GalT1 
refers to β1-3 galactosyltransferase; C2GnT refers to Core 2 β1-6 N-
acetylglucosaminyltransferase; C3GnT refers to Core 3 β1-3 N-
acetylglucosaminyltransferase; GlcNAc-T refers to N-







Functions of O-glycans 
 
O-GalNAc glycosylation is an essential process particularly to eumetazoans 
because of its importance in the formation of cell surface and secreted mucins in 
mucous of the ocular, gastrointestinal, respiratory, genitourinary tracts. The O-
GalNAc glycans of the mucous glycoproteins generates barrier that is essential for 
tissue lubrication, protection from physical and chemical damage, and preventing 
pathogen infection [235, 278]. This is due to the hydrophilic and negatively 
charged nature of O-glycans, which promote water and salt binding, contributing 
to the viscosity and adhesiveness of mucous. The viscosity also allows bacteria 
and particles to be trapped and removed easily. High density O-glycan addition 
could also shield the underlying protein epitopes from recognition by antibodies 
and proteases. For instance, more than 80% of the molecular weight of the mucin 
glycoprotein comprise of O-glycans and this protects from protease degradation in 
the gut [279]. O-glycans on cell surface receptors are also important for regulating 
receptor stability and expression levels [280]. O-GalNAc glycans are particularly 
important for the functioning of the immune system. For instance, the attachment 
of leukocytes to the capillary endothelium during lymphocyte homing or 
extravasation of leukocytes to the surrounding tissues during inflammation is 
mediated by the interaction of P-selectin with sialyl-LewisX attached on Core 2 O-
glycans. Loss of C2GnT-1 expression, which generates the Core 2 glycan, in mice 
severely disrupts the functioning of the immune system [281]. This system is 
taken advantage by cancer cells for metastasis. They commonly express sialyl-
LewisX and use selectin-binding as a mechanism to invade tissues [282].  
 
1.3.5 Regulation of mammalian glycosylation 
  
Although the biological functions of glycans are well studied, the mechanisms 
regulating the glycan structure variation are still yet to be fully understood [159]. 
Unlike other biopolymers such as nucleic acids and amino acids, glycan synthesis 
is not template-driven [177] but constructed by the combined and sequential 
50 
 
action of the numerous glycosyltransferases and glycosidases in the secretory 
apparatus. Although generally one enzyme catalyses one saccharide linkage 
applies to almost all the steps in glycan biosynthesis, the existence of numerous 
enzyme isoforms as well as hierarchical and competing relationships between the 
enzymes further increases the complexity and heterogeneity of glycan formation 
in different cell types and physiological processes.  
 
Given the dynamic nature of glycosylation in the secretory pathway, multiple 
mechanisms have been proposed to regulate glycan formation. Gene expression of 
glycosylating enzymes appears to have a major impact on glycan construction. 
This is reflected by differences in RNA expression signatures of the glycosylation 
machinery in different cell types and developmental stages [283]. However, gene 
transcription cannot fully explain all glycan variations in different physiological 
conditions such as the rapid cell surface glycan changes of differentiating stem 
cells [284] and cell-cell and cell-matrix changes during cell migration [159].  
 
Glycan expression can be regulated at the post-transcriptional and post-
translational levels. For instance, some glycosyltransferases require to be 
glycosylated or interaction with molecular chaperones to be active, suggest a 
possible mechanism for glycan regulation. Mentioned previously, the activity of 
C1GalT1 requires the presence of its molecular chaperone Cosmc and loss of 
Cosmc leads to failure of Core 1 O-glycan formation [266]. The conditions of the 
enzymatic environment such as pH could also have some effects on activity [240, 
285]. A potential mechanism proposes the phosphorylation of the glycosylating 
enzymes and modulating their trafficking and substrate access. However, they are 
mostly type II transmembrane proteins and have a short cytoplasmic tail, the 
likelihood of a phosphorylation motif in this short protein sequence is low. 
Another putative mechanism involves the cleavage of the glycosylating enzymes 
from their membrane anchored locations and abolish their glycan forming 
activities. This hypothesis is supported by the findings of catalytic domain 
fragments of glycosyltransferases in most body fluids which appears to be 
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upregulated during physiological settings such as inflammation [286]. However, it 
remains elusive the range of enzymes affected and the exact purpose of the 
extracellular release given that the concentrations of extracellular nucleotide sugar 
donors are too low for enzyme substrate binding affinities. 
 
Most glycosylation reactions take place in the Golgi and the majority of the 
glycosylation machinery in the cell resides there. The Golgi is known to host 
more than 250 glycosyltransferases, glycosidases and nucleotide sugar 
transporters. With such an astonishing number of proteins in a confined space in 
addition to the competitive nature of various glycosyltransferases, it is remarkable 
that the Golgi can synthesize the various glycan structures with precision and 
speed even without a direct quality control system as in the ER. There must be 
multiple systems to correctly coordinate and control the glycan outcome. Spatial 
compartmentalization by Golgi cisternae allow the concerted action of the 
glycosylating enzymes and provide the optimal environment for them to function, 
and thus plays a major role in glycan formation [287]. Hence, the factors that 
affect the structure and organization of Golgi membranes as well as the luminal 
Golgi environment are likely to execute a major influence on glycan synthesis.  
 
pH changes in the Golgi lumen was found to alter glycosylation by affecting the 
localisation and trafficking of glycosyltransferases [288, 289], the activity of the 
enzymes [285], the formation of functional heteromeric complexes [290] and 
substrate and sugar transport [291-293]. pH disruption also often result in 
perturbed Golgi morphology [291, 292], which could also affect glycan synthesis 
by physically segregating the enzymes from the substrates or from each other. In 
the first case, pH increases in the Golgi lumen was found to induce 
mislocalisation of the α(2,3)-sialyltransferase from the trans Golgi into endosomal 
compartments and led to inhibition of terminal α(2,3)-sialylation [289]. It was 
postulated to be due to the impairment of enzyme retrieval to their correct 
compartments. Enzyme activity also depends on the optimal pH of the 
environment. This is not surprising given that there is a 0.7 unit pH reduction 
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from cis to trans Golgi and glycosylating enzymes involved in different steps of 
glycan processing are localised separately. It was observed that by increasing pH 
from 6.5, the optimal pH for β1-4-galactosyltransferase and α2,3-sialyltransferase, 
to pH7.0-7.2, their activities reduced significantly by 50-60% [285]. Heteromeric 
complex formation of glycosylating enzymes participating in common pathways 
is required for efficient glycan synthesis and it was found recently that defective 
acidification inhibits complex formation [290]. An anion channel named Golgi 
pH regulator (GPHR) was recently identified to regulate Golgi pH. Mutant cells 
lacking of GPHR exhibit retarded transport of glycoproteins, coupled with the 
expression of truncated glycoproteins and glycolipids [291, 292]. Disrupted Golgi 
luminal pH has been observed in numerous cancer cell types and it correlates with 
perturbed glycosylation [294], suggesting that aberrant glycosylation in cancer 
cells are partially due to Golgi pH changes.  
 
Other factors in the Golgi lumen that is vital for proper glycan formation includes 
the biosynthesis and availability of nucleotide sugar donors. This depends on the 
expression levels and efficiencies of the nucleotide sugar transporters and 
pyrophosphorylases that work in concert for the import of nucleotide sugar 
diphosphates into the lumen [295]. Inhibition of either protein can abolish the 
addition of specific sugar types onto glycan structures [296, 297]. Interestingly, 
loss of sugar transporters also slow down cargo passage through the Golgi and 
accumulate glycoproteins with shortened glycans in the Golgi which do not 
proceed to the cell surface. This was observed when sialic acid and fucose 
transporters were depleted or mutated in Lec2 CHO cells. Eventually, ER stress 
pathways were also activated, possibly to prevent further accumulation of proteins 
[298]. Unlike the pH of the Golgi, the impact of this augmented form of 
glycosylation on mammalian physiology is not known. Nevertheless, it remains 
an avenue for which glycans are modulated.  
 
Glycosyltransferases are mostly constitutively active in nature; hence direct 
modulation of their activities in the Golgi lumen would also alter glycan 
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expression. Recent discoveries identified inhibitors of glycosyltransferase 
activities. An example is the GlcNAcT-I Inhibitory Protein (GnT1IP) which is a 
testis-specific glycoprotein that binds and blocks the activity of GlcNAcT-I. 
GlcNAcT-I is required to initiate the branching of N-glycans to form complex and 
hybrid structure. The interaction of GnT1IP blocks this pathway and also 
mislocalises GlcNAcT-I from its medial Golgi position to earlier compartments, 
finally leading to increased expression of high mannose glycans [299]. High 
mannose N-glycan increases cell adhesive properties and hence was speculated to 
facilitate Sertoli-germ cell attachment during spermatogenesis. Another example 
is the transmembrane BAX inhibitor moif-containing family (TMBIM) of 
proteins which inhibit Gb3 synthase which synthesizes glycolipid Gb3, receptor 
of Shiga toxin [300]. 
 
Maintenance of the Golgi structure and organization is a major aspect in glycan 
regulation. A main highlight of this is found in the mutations in the conserved 
oligomeric Golgi (COG) complex. The COG complex comprises of eight subunits 
which are essential for vesicle tethering of retrograde carriers and scaffolding for 
the Golgi structure. Mutations of members in the COG complex resulted in glycan 
changes [301]. For instance, mutation in COG1 member was identified in a CHO 
mutant ldlC which has multiple glycosylation defects in N- and O-glycoproteins 
as well as glycolipids [302]. More importantly, defective glycosylation that result 
from COG mutations are the cause of genetic diseases known as the congenital 
disorders of glycosylation [303-306].  
 
Both the network and cisternal organization of the Golgi are essential for proper 
glycan formation. In the former, loss of lateral linking between Golgi stacks led to 
variable levels of glycosylating enzymes among the fragmented mini-stacks 
which was due to reduced lateral motility of the enzymes [50]. On the other hand, 
cisternal unstacking was observed to induce N-glycosylation defects in Fms, an 
M-CSF cytokine receptor for maintaining macrophages in an anti-inflammatory 
state. Hypo-N-glycosylated Fms remains in the immature form and accumulates 
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at the Golgi. This impacts macrophage functioning and was proposed as a 
mechanism utlitised by HIV to induce immunodeficiency (Hiyoshi M et al, 2011). 
Changes in cisternal levels of specific glycosyltransferases by relocation also 
impacts glycan output. We have reported that a number of O-glycosylation 
initiation enzymes ppGalNAc-Ts are rapidly re- localized from the cis Golgi to 
ER upon the growth factor stimulation and Src activation [193]. The process is 
mediated by COPI vesicles. Relocation to the ER resulted in marked increase in 
O-glycosylation initiation, leading to high densities of O-GalNAc added to the O-
glycoproteins and hence promotes the expression of the terminal O-GalNAc or Tn 
antigen. The process has implications in metastasis and invasion in cancer as it 
promotes cell adhesion and migratory properties. Indeed, this relocation event is 
observed quite frequently in at least 60% of breast carcinomas and various cancer 









From the above mentioned indications, protein glycosylation modifies multiple 
proteins and can have a profound effect on protein structure and functions. The 
process ultimately influences multiple biological processes that are important for 
the cell and organism physiology. The bulk of glycan synthesis occurs at the 
Golgi where they diversify and become complex structures. As glycans are 
constructed in a series of sequential glycosylation reactions at the Golgi, it is 
without doubt that the Golgi organization is critical for proper glycan 
construction.  
 
Despite of its complex structure, the mammalian Golgi is actually highly dynamic 
and its morphology changes under different physiological settings. Several 
regulatory mechanisms that control Golgi organization and functions have 
recently been discovered. For instance, ERK controls the Golgi re-modeling and 
re-orientation to the leading edge of the cell for cell migration [116] while PKD 
controls cargo flux out of the TGN [139, 140]. This suggests that the complex 
Golgi organization is likely to be under the influence of multiple regulators. 
However, the molecular regulators of Golgi organisation have not been 
completely identified and how they affect glycosylation remains poorly 
understood. Identification of these regulators would provide further understanding 
to the mechanisms involved in controlling Golgi organization and glycosylation in 
health and disease. Ultimately, it has implications in guiding the design and 
development of therapeutics for diseases associated with aberrant Golgi 
morphology and function [307, 308]. Finally, the data could also aid in the study 
of the long-standing question of Golgi structure-function relationship. Therefore, 





( I ) Identification of the genetic basis of Golgi organization and glycosylation 
function using RNAi screening. 
 
Current studies on Golgi regulation often centered on a few genes and most did 
not attempt to characterize their role in glycosylation. Here I aim to understand 
Golgi regulation under the influence of multiple genes in the genome. To fulfill 
this objective, RNAi screening is the method of choice as it offers the possibility 
of systematically probing the loss-of-function effects of a large number of genes 
in the genome. In this study, a kinome- and phosphatome-wide siRNA screen was 
employed given that signaling proteins are the main pivots for most regulatory 
events in the cell. The screen involved individual silencing of 948 known and 
putative human signaling genes and analysing their impact on the Golgi 
morphology from markers of three different compartments of the Golgi. 
Automated machine learning, known as support vector machine learning (SVM), 
was used to classify and quantify the various Golgi morphological phenotypes. 
Genes that affect any of the markers significantly were identified as regulator of 
Golgi organization and further tested in secondary assays for their effects on 
glycosylation. Secondary assays involved the use of several lectins that recognize 
different glycan structures to characterize glycan changes. 
 
( II ) Characterization of the regulatory mechanisms of O-GalNAc glycosylation 
initiation in cancer. 
 
The second part of the thesis sought to further understand the regulatory 
mechanisms of a particular glycosylation event. O-glycosylation initiation 
normally occurs at the Golgi and is mediated by the GalNAc glycosyltransferases 
GalNAc-Ts. Our previous report demonstrated that O-glycosylation initiation can 
take place in the ER when GalNAc-Ts are induced to relocate from the Golgi 
(Gill, 2010). The process promotes the expression of the aberrant glycan, Tn 
antigen, that is prevalent in tumors of multiple tissue types. How this process is 
activated remains unclear. Hence, identification of the molecular players with 
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RNAi screening would gain further insights to the regulation of this process and 
eventually could provide potential targets for Tn-related cancer therapy. A potent 
regulator of this pathway was characterized in detail to understand the regulatory 


















2.1.1 General reagents and chemicals  
The general reagents and chemicals used in this study and their corresponding 
sources are listed in alphabetical order in Table 2.1. 
 
Table 2.1: List of general reagents and chemicals 
Reagent/Chemical  Source
Agarose Bio- Rad 
Ampicillin Sigma Aldrich 
β-mercaptoethanol Merck 
Dulbecco’s Modified Eagle Medium 
(DMEM)  
Gibco 
Dithiothreitol (DTT)  Sigma-Aldrich 
DNA ladder – 100bp  New England Biolabs 
DNA ladder – 1kb  New England Biolabs 
Deoxyribonucleotides (dNTPs) New England Biolabs 
Ethidium bromide  Bio-rad 
Fetal bovine serum (FBS)  Hyclone 
Formaldehyde  Sigma Aldrich 
GelRedTM Nuclei Acid Gel Stain Biotium  
Geneticin ® Reagent (G418)  Invitrogen 
HiPerfect transfection reagent Qiagen 
Hoescht 33342 Invitrogen 
Kanamycin  Sigma Aldrich 
Luria Broth (LB) medium  Biopolis Shared Facilities (A*STAR) 
NP-40 Alternative  Sigma Aldrich 
OptiMEM Invitrogen 
Penicillin-Streptomycin stock solution 
(100x) 
Invitrogen 
Phosphate saline buffer  Biopolis Shared Facilities (A*STAR) 
Phosphatase inhibitor cocktail tablets 
(Phos-STOP)  
Roche 
Poly L- lysine Sigma Aldrich 
Protein Ladder (Precision Plus 
ProteinTM Dual Color) 
Biorad 
Protease inhibitor cocktail tablets 
(Complete EDTA free)  
Roche 
Sodium Dodecyl Sulfate (SDS)  Biorad 
Sodium Fluoride Sigma Aldrich 
Sodium orthovanadate Sigma Aldrich 
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TRIS- Base Sigma Aldrich 
TRIS- HCL Sigma Aldrich 
Triton ® X-100  Merck  
Trypsin  Biopolis Shared Facilities (A*STAR) 
Tryptone-yeast extract broth (TY) 
medium  
Biopolis Shared Facilities (A*STAR) 





All restriction enzymes were purchased from New England Biolabs. KOD DNA 
polymerase was purchased from Calbiochem. Reverse transcriptase SuperScript-





Table 2.2 shows the list of primary and secondary antibodies used in this study. 
 
Table 2.2: List of primary and secondary antibodies 
 
Primary Antibody Source
Actin monoclonal antibody (mouse)  Abcam 
Arf1 polyclonal antibody (mouse)  Novus Biologicals 
Beta COP polyclonal antibody 
(rabbit) 
Abcam 
Cosmc polyclonal antibody (rabbit) Abcam 
C2GNT1 polyclonal antibody 
(rabbit) 
Abcam 
ERK8 polyclonal antibody (rabbit) Sigma Aldrich 
FLAG monoclonal antibody (mouse)  Sigma Aldrich 
GFP polyclonal antibody (rabbit)  Abcam 
Giantin polyclonal antibody (rabbit)  Abcam 
PY20 monoclonal antibody (mouse) Abcam 
TGN46 polyclonal antibody (sheep) AbD Serotec 





GalNAc-T1 monoclonal antibody 
(mouse) 
U. Mendel and H. Clausen (University 
of Copenhagen, Copenhagen, 
Denmark) GalNAc-T2 monoclonal antibody 
(mouse) 
Tn monoclonal antibody (mouse) 
Secondary Antibody Source 
AlexaFluor ® 488 anti-rabbit Invitrogen 
AlexaFluor ® 488 anti-mouse Invitrogen 
AlexaFluor ® 594 anti-rabbit Invitrogen 
AlexaFluor ® 594 anti-mouse Invitrogen 
AlexaFluor ® 594 anti-sheep Invitrogen 
AlexaFluor ® 594 Streptavidin Invitrogen 
AlexaFluor ® 647 anti-rabbit Invitrogen 
AlexaFluor ® 647 anti-mouse Invitrogen 
Anti-rabbit IgG, peroxidase-linked 
antibody 
GE Healthcare 







All siRNAs used in this study were obtained from Dharmacon, now Thermo 
Fisher.  
 
2.1.5 Drugs and recombinant proteins 
 





Table 2.3: List of drugs and recombinant proteins 
 
Drugs  Source
α-armanitin Tocris Bioscience 
Brefeldin A (BFA) Merck 
FR180204 Tocris Bioscience 
Golgicide A (GCA) Sigma Aldrich 
Imidazole Sigma Aldrich 
IPA3 Tocris Bioscience 
Latrunculin B Sigma Aldrich 
Monensin Sigma Aldrich 
Nocodazole Sigma Aldrich 
Ro31-8220 Calbiochem 
SP600125 Tocris Bioscience 
Recombinant proteins Source 
Platelet-derived growth factor 
(PDGF) 
R & D systems 
Epidermal growth factor (EGF) R & D systems 
Insulin growth factor (IGF-1) R & D systems 
Transforming growth factor beta 
(TGF-B) 





Helix Pomatia lectin (HPL) conjugated with 647nm fluorophore was purchased 
from Invitrogen. All other lectins PNA, ConA, LCA, PHA-L and MAL-II that are 
conjugated with 594nm fluorophore as well as ECA and DSL that are conjugated 
with 488nm fluorophore and were purchased from Vector Labs.  
 
2.2 CELLS AND VIRUSES 
 
2.2.1 Cell culture 
 
Wildtype HeLa (human cervical epithelial cells) and HeLa-MannII-GFP (HeLa 
cells expressing GFP-tagged Mannosidase II) cell lines were obtained from V. 
Malhotra’s laboratory (Centre for Genomic Regulation, Barcelona, Spain). 
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HEK293T (human kidney epithelial cells constitutively expressing simian virus 
40 (SV40) large T antigen) cell line was a gift from V. Tergaonkar (IMCB, 
Singapore). Skov3 (human ovarian epithelial cells) was a gift from E.Bard 
(IMCB, Singapore). 
 
All cells were grown at 37°C in a 10% CO2 humidified incubator. HeLa cells 
were grown in high glucose DMEM supplemented with 10% FBS. HEK293T 
cells were grown in high glucose DMEM supplemented with 15% FBS. 
Cells were routinely subcultured or passaged in accordance to the following 
procedure: after media aspiration, the cells were first washed with PBS to remove 
residual medium, then dislodged from the culture flask by incubating the cells in 
trypsin (0.25% w/v, Ca2+- and Mg2+-free) for 3 minutes at 37°C. The dislodged 
cells were resuspended in fresh media supplemented with 10% FBS and seeded 
onto new culture flasks or assay plates.  
 
2.2.2 Producing lentivirus in HEK293T cells 
 
HEK293T cells were seeded onto three poly-L-lysine-coated T175 culture flasks 
and incubated at 37°C in a 10% CO2 humidified incubator for 6 hours. The cells 
were transfected with packaging plasmids (pLp1, pLp2, pVSVG) and pLenti 
expression plasmid containing a fluorophore- tagged protein using calcium 
phosphate transfection method. Briefly, the plasmids were first mixed in BBS 
solution and calcium phosphate was added to the mixture dropwise. The mixture 
was vortexed for 20 seconds before incubating at room temperature for 20 
minutes for the formation of transfection complexes. The transfection complexes 
were added the HEK293T cells and incubated at 37°C for 24 hours. The culture 
medium was then aspirated and replaced with fresh DMEM supplemented with 
15% FBS. The cells were incubated for an additional 24 hours before the 
supernatant was collected for virus harvesting. Viral supernatant was filtered 
using 0.45μm syringe to remove cell debris and centrifuged at 18,000 rpm for 3 
hours at 4°C. The virus pellet was resuspended in PBS supplemented with 20% 
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sucrose. The resuspended virus was then distributed to 100µl aliquots and snap-
frozen using liquid nitrogen before stored at –80°C.  
 
2.2.3 Generating stable cell lines using lentiviral transfection 
 
HeLa cells were seeded at 30,000 cells per well of a 24-well plate and allowed to 
settle overnight at 37°C in a 10% CO2 humidified incubator. The lentiviral stock 
was then added to the cells the following day and incubated overnight at 37°C. 
Cells were monitored under fluorescence microscope on the subsequent days to 
check for infection. To ensure homogenous expression in the cell line, cells 
expressing the fluorophore- tagged protein were sorted using fluorescent-activated 
cell sorting (FACS). The sorted cells were then further propagated and cell stocks 
were stored in liquid nitrogen. 
 
2.3 MOLECULAR CLONING 
 
2.3.1 Preparation of competent cells 
 
Escherichia coli (E. coli) strain One Shot® TOP10 from Invitrogen was streaked 
onto a LB agar plate (1% bactotryptone, 0.5% bacto-yeast extract, 1% NaCl and 
1.5% agar, pH7.0) and incubated overnight at 37°C. A single colony was then 
picked and inoculated in 200ml of 2X TY broth. Culture was allowed to grow 
overnight at 37°C with aeration by shaking at 220rpm. An inoculum of the 
overnight culture was diluted 100 times in 600ml of 2X TY medium and 
incubated at 37°C with shaking until a reading of 0.6-0.8 was attained for the 
absorbance at 660nm (A660). This was followed by chilling the culture on ice for 
1 hour before they are pelleted by centrifugation at 3,000g for 15 minutes at 4°C. 
The pellet was re-suspended in 100ml pre-chilled CCMB80 solution and 
incubated on ice for a further 30 minutes. The process of centrifugation was 
repeated and cells were re-suspended in 5ml pre-chilled CCMB80 buffer with a 
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further incubation on ice for 30 minutes. The competent cells were then aliquoted 
(50μl) on ice and stored at -80°C. 
 
2.3.2 Polymerase chain reaction 
 
The PCR reaction mix is typically prepared using the recipe below: 
 
 
Sterile Water  variable 
10x KOD hotstart Buffer  5 µl 
MgSO4 (25mM)  4 µl 
dNTPs (2mM)  5 µl 
DMSO 2.5 µl 
cDNA template variable (10-100ng) 
KOD hotstart polymerase  1 μl  
Forward Primer (10uM ) 2 μl 
Reverse Primer (10uM)  2 μl 
Total  50 µl 
 
 
PCR reactions were typically carried out by 1 cycle of denaturation at 94°C for 2 
minutes, followed by 30-40 cycles of polymerase chain reaction consisting of 
denaturation at 94°C for 20 seconds, primer annealing for 20 seconds at 50-60°C 
(depending on primer melting temperatures) and DNA extension at 70°C. 
Duration for DNA extension at 70°C depends on the length of amplicon and was 
calculated according to the polymerase’s extension rate of approximately 25 base 
pairs (bp) per second. The primers and the optimised annealing temperature used 












ERK8 forward + 





ERK8 reverse + 






2.3.3 DNA agarose gel electrophoresis 
 
6X DNA loading buffer (0.25% (w/v) bromophenol blue and 0.25% (w/v) xylene 
cyanol FF and 20% (w/v) glycerol) was added to DNA samples prior to their 
separation by electrophoresis in 1.0-1.5% (w/v) agarose in TAE buffer (40mM 
Tris-acetate and 2mM EDTA) supplemented with 1:10000 GelRedTM, at constant 
voltage of approximately 100-120V. DNA bands were visualised with UV 
illumination. 
 
2.3.4 Gel purification 
 
Purification of DNA fragments following gel electrophoresis was performed 
using QIAquickTM Gel Extraction Kit (Promega) according to manufacturer’s 
protocol, except that elution of DNA from silica columns were deionized water 
(ddH2O). DNA products obtained were quantitated using NanoDropTM 1000 
Spectrophotometer to establish its concentration and purity levels. 
 
2.3.5 Plasmids and plasmid constructions 
 
Plasmids encoding N-terminus eGFP-tagged full-length wildtype Arf, N-terminus 
eGFP-tagged Arf with point mutant Q71L (Arf (Q71L)), N-terminus eGFP-tagged 
Muc-PTS and C-terminus eGFP-tagged ER-2Lec were a gift from D.J. Gill 
(IMCB, Singapore). C-terminus mCherry-tagged Src with point mutant 8A7F and 
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6N7F (Src(8A7F) and Src(6N7F)) were a gift from S.Wang (IMCB, Singapore). 
VSVG-tsO45 plasmid was a gift from V. Malhotra’s laboratory (Centre for 
Genomic Regulation, Barcelona, Spain). VSVG-tsO45 was subsequently cloned 
into pLenti6.3_ CmChe_DEST to generate a C-terminal mcherry tagged version. 
cDNA encoding full-length ERK8 (GenBank/EMBL/DDBJ accession no. 
NM_139021) purchased from OriGene Technologies, Inc.  ERK8 full-length 
wildtype and mutants were subsequently cloned into pcDNA6.2_NmChe_DEST 
and pLenti6.3_ NmChe_DEST gateway vectors to generate N-terminal mCherry 
tagged versions. cDNA encoding Metridia Luciferase was purchased from 
Clontech and subsequently cloned into pLenti6.3_ V5_DEST gateway vector. 
Construction of all wild-type and mutant plasmids used in this study is described 
below: 
 
cDNA from the original plasmids were PCR amplified using attB-containing 
primers (described in Section 2.3.2) and cloned using Gateway® Technology 
(Invitrogen). The attB-flanked PCR products were cloned into an attP-containing 
donor vector (pDONR221) using BP-clonase II (Invitrogen) to generate an entry 
clone. The BP reaction mix was prepared as follows: 
 
attB-PCR product 150ng 
pDONR221  150ng 
5X BP Clonase II 0.5 µl 
TE buffer pH8.0 variable  
Total  10 µl 
 
The reaction mix was incubated overnight at 25°C. The following day, 1μl of 
2μg/μl Proteinase K solution was added to the reaction and incubated at 37°C for 
10 minutes. For bacteria transformation, 1μl of the reaction mix was added to 
50μl of competent One Shot® TOP10 E. coli (see Section 2.3.1) and incubated on 
ice for 30 minutes. The mixture was then heat shocked at 42°C for 1 minute and 
chilled on ice for another 2 minutes. Competent cells were resuspended in 200μl 
2X TY buffer and recovered on shaker at 37°C for 30 minutes before plating on 
an LB agar plate containing 35μg/ml kanamycin for selection of successful 
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transformants. Single colonies were picked, amplified in 2X TY buffer and 
screened for incorporation of DNA insert through restriction digest using 
appropriate enzymes and DNA sequencing (Section 2.3.7). 
 
All point mutants were introduced into pDONR221 entry clone by PCR using 
overlapping mutagenic primers and KOD polymerase. The entry clones were then 
subcloned into gateway destination vectors using LR-clonase II (Invitrogen). The 
LR reaction mix was prepared using the recipe below: 
 
Entry clone 150ng 
Destination vector 150ng 
5X BP Clonase II 0.5 µl 
TE buffer pH8.0 variable  
Total  10 µl 
 
 
The subsequent procedures are similar to the BP reaction as described above, with 
the exceptions that the competent cells were plated on an LB agar plate containing 
100μg/ml ampicillin for selection of successful transformants, and all constructs 
were verified by restriction digest using appropriate enzymes and DNA 
sequencing (Section 2.3.7) before use. The primers used for mutagenesis in this 

















ERK8 T175A+Y177F forward ccaggccgtgGcagagtTcgtggccacac 
ERK8 T175A+Y177F reverse gtgtggccacgAactctgCcacggcctgg 
 
 
2.3.6 Plasmid purification 
 
The Nucleobond® Plasmid DNA purification kit (Macherey-Nagel) was utilised 
for large-scale extraction of plasmids from E. coli cells. Briefly, a single colony 
was picked after antibiotic selection and scaled up into a 200ml culture by 
shaking overnight at 37°C. Bacteria cells were pelleted by centrifugation at 
4,000g for 15 minutes and resuspended in Buffer S1 in the presence of RNAse A 
(100mg/ml). This was followed by cell lysis with the addition of Buffer S2 for 5 
minutes and neutralisation with Buffer S3. The precipitates were clarified using 
an equilibrated Nucleobond® column. After two rounds of washing with the wash 
buffer solution provided, plasmid was eluted with 15ml elution buffer N5. The 
eluted plasmid DNA was precipitated with isopropanol, washed and dried with 
70% ethanol, and reconstituted with 500-1000μl ddH2O. Plasmid yield and 
quality was determined using NanoDropTM 1000 Spectrophotometer. 
 
2.3.7 DNA sequencing 
 
Plasmid DNA (200-500ng) was added to a sequencing mix comprising of 1X Big 
Dye termination mix (1st Base), 3.2pmol of appropriate primer topped up to 10ul 
with ddH2O. Thermal cycling was carried out by 25 cycles of denaturation at 
95°C for 10 seconds, annealing at 55°C for 10 seconds, and extension at 60°C for 
4 minutes. The reaction products were precipitated by addition of 2 volumes of 
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100% ethanol with 0.1 volume of 3M sodium acetate (pH5.2), incubation on ice 
for 10 minutes and finally centrifugation at 14,000 rpm. The pellet was washed 
with 70% ethanol, air-dried and sequenced by an automatic DNA sequencer 
(Applied Biosystems, Model 3730XL). Sequencing data obtained were analyzed 
by Chromas program. 
 
2.4 SIRNA SCREENING 
 
2.4.1 siRNA plate preparation and transfection 
 
The primary siRNA screen to identify signaling regulators of Golgi morphology 
was performed using a commercial genomic siRNA library (Dharmacon 
siGenome) (Thermo-Fisher) in 384 well format. The RNAi library consisted of 
pools of 4 distinct siRNAs targeting each of the known 948 human kinases, 
phosphatases and related genes. 2.5 μl of 500nM siRNA was printed into 
blackwalled 384-well plates (384-well black μclear, Grenier) with Velocity 11. 
The pilot screen plate that consist of membrane trafficking regulators were 
assembled manually into 384-well plates (384-well V-bottom plates, Grenier).  
siRNA plates for secondary screens were prepared by assembling cherry picked 
siRNA tubes. Deconvoluted siRNAs were custom-ordered from Thermo-Fisher. 
The pilot membrane trafficking, cherry-picked and deconvoluted siRNA libraries 
were robotically printed onto 384-well plates as for the primary screen.  
 
Reverse siRNA transfection was performed by pre-mixing 0.25 ml of Hiperfect 
(Qiagen) with 7.25 ml of Optimem (per well) for 5 minutes, then adding the 
mixture to the siRNA for complexation for 20 minutes, followed by addition of 
2000 HeLa MannII-GFP cells per well with the Multidrop combi (Thermo-
Fisher). In the pilot membrane trafficking plate, some wells without siRNA were 
treated with 10 μg/ml BFA, 6 μg/ml nocodazole, 1 μg/ml monensin, or 1 μg/ml 





2.4.2 Immunofluorescence staining  
 
After 3 days of siRNA knockdown, the cells were fixed with 4% 
paraformaldehyde in D-PBS for 10 minutes, washed with D-PBS and 
permeabilized with 0.2% Triton X-100 for a further 10 minutes. The cells were 
then stained with primary antibody diluted in 2% FBS in D-PBS for 2 hours at 
room temperature or overnight at 4°C. Cells were subsequently washed three 
times for 5 minutes with 2% FBS in D-PBS and stained for 20 minutes with 
secondary antibodies (Alexa Fluor, Invitrogen), HPL and Hoechst 33342 diluted 
in 2% FBS in D-PBS. The cells were then washed three times for 5 min with D-
PBS before high-throughput confocal imaging. siRNA plates were performed in 
duplicates. 
 
2.4.3 Automated image acquisition and processing 
 
During automated image acquisition, four sites per well (each imaged at four 
excitation wavelengths of 405, 488, 561 and 635 nm) were acquired sequentially 
with a 20x Plan Apo 0.75 NA objective on a laser scanning confocal high 
throughput microscope (ImageXpress Ultra, MDS Analytical Technologies). For 
the analysis of Golgi morphology, a web application was created to access links 
and meta-information on the proprietary database provided with the acquisition 
software (MDCStore, MDS) and to launch a dedicated image analysis application 
called HCSU (high content screening unit) which performs image segmentation 
and feature extraction. HCSU is composed of a set of optimized algorithms 
written in C and C++. On a single computer dedicated to image processing, a java 
application manages the parallelization of HCSU on multiple CPUs. 
Implementations of the algorithms are homemade. 
 
2.4.4 Selection of primary and validated hits  
 
To select for primary hits in the Golgi morphology screen, threshold 
determination was performed for each phenotypic score using the derivative 
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method [309]. Specifically, this corresponds to cutoff phenotypic scores of 0.44 
(cis diffuse), 0.43 (cis fragmented), 0.33 (cis condensed), 0.21 (medial diffuse), 
0.4 (medial fragmented), 0.43 (medial condensed), 0.44 (trans diffuse), 0.4 (trans 
fragmented) and 0.35 (trans condensed). Each of the scores corresponds to a z-
score of >2. Genes with one or more phenotypic scores above the cutoff values 
were selected as hits. Thresholds for the deconvoluted siRNA validation screen 
were defined as 50% of the primary screen cutoff scores. 
 
2.4.5 Bioinformatics analysis 
For the hierarchical clustering of Golgi morphology phenotypes, the 
‘Agglomerative Hierarchical Clustering’ method was applied using ‘Euclidean 
Distance’ as distance metric and ‘Complete Linkage’ as the linkage criteria. The 
clusters were picked manually by visual analysis of the heatmap which identified 
six major groups of genes. Annotation information for each gene was gathered 
from Gene Ontology, GeneCards (www.genecards.org), NCBI 
(http://www.ncbi.nlm.nih.gov/gene) and Phosphosite 
(http://www.phosphosite.org/). Gene enrichment was analysed using DAVIDS 
bioinformatics (http://david.abcc.ncifcrf.gov/). Protein networks were created 
using data from STRING (http://stringdb.org/), Pathway studio and Human 
Protein Reference Database (HPRD) (http://www.hprd.org/) which are imported 
into Cytoscape software (http://www.cytoscape.org/) for network arrangements. 
 
2.4.6 Lectin secondary screen  
 
2.4.6.1 Transfection and fluorescent staining 
 
siRNA transfection on HeLa cells was performed as in the primary screen 
(Section 2.4.1) and fixed with 4% paraformaldehyde in PBS for 10 minutes, 
washed with PBS, then incubated for 1–2 hours at room temperature with the 
respective fluorescently labeled lectins (20 mg/ml) in D-PBS containing 2% FBS. 
Cells were then washed three times for 10 minutes each with 2% FBS in D-PBS, 
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incubated with Hoechst 33342 in PBS for 10 minutes to stain nuclei, and washed 
another two times for 10 minutes each with PBS. For biotin-conjugated lectins, 
the Hoechst staining was preceded by 1 hour incubation with streptavidin-FITC or 
streptavidin-Alexa594 (2 mg/ml) in 2% FBS/D-PBS. Cells were then imaged 
using the high-throughput ImageXpress Ultra with 2–4 sites imaged per well. 
Each lectin was assayed at least in duplicate. 
 
2.4.6.2 Image analysis 
 
Images of cells were analysed using MetaXpress software (Molecular Devices). 
The Transfluor HT module was used to quantify the lectin intensity and cell 
number for each site, and the average intensity per cell obtained for each well. It 
was observed that for most lectins, there was a correlation between lectin intensity 
per cell and cell number, hence for each plate of 181 genes, a plot of intensity per 
cell vs cell number was fit to a log equation (y = y0 + a log x, where y0 and a are 
constants) to obtain the expected intensity per cell for no siRNA knockdown (red 
solid curve). The same fit was performed on the control transfection reagent-
treated wells (TR) in the same plate (black solid curve), and the mean absolute 
deviation of the TR wells (mean |dtr| = mean |Itr - Ix,tr|, where Itr is the intensity per 
cell for the given well, and Ix,tr is the expected intensity per cell for the cell count 
of the given well) was calculated as a measure of the experimental variation in the 
assay. The deviation of each gene’s intensity per cell from the expected value at 
its given cell number was then calculated (di = Ii - Ix,i, where Ii is the intensity per 
cell for the given gene, and Ix,i is the expected intensity per cell for the cell count 
of the given gene), and expressed in terms of the mean absolute deviation of the 
TR wells, which we then call the “normalized lectin signal”. Finally, we defined 
significant perturbation of lectin staining as a normalized lectin signal of at >4 or 





2.4.7 Validation of lectin specificities 
 
PNA and HPL: Peanut Agglutinin and Helix Pomatia lectin and are highly 
specific for O- glycans. PNA recognizes terminal core 1 O-glycans (T antigen) or 
Gal-β1,3-GalNAc-α1-Ser/Thr [310]. HPL is specific for terminal α-linked O-
GalNAc glycans. Knockdown [311] of C1GALT1, the Core 1 
galactosyltransferase that generates the core 1 glycan structure recognized by 
PNA, abolishes the already-low PNA staining while increasing HPL staining 
because of the increase in terminal O-GalNAc. Similarly, loss of C1GALTC1 
(cosmc), a molecular chaperone required for C1GALT1 activity [216], also led to 
reduced PNA and increased HPL stainings.   
 
ConA: Concanavalin A binds mainly α-D-mannosyl and α-D-glucosyl groups, 
having a high affinity for the N-glycan trimannosyl core, thus it tends to reveal 
high mannose N-glycans [312]. KD of MGAT1 (mannosyl α1,3-glycoprotein 
β1,2-N-acetylglucosaminyltransferase) which transfers the first GlcNAc residue 
onto the mannosyl core of N- glycans and is thus essential for the conversion of 
high-mannose to hybrid and complex N-glycans. Its absence prevents further 
trimming of the oligomannose structure, promoting more high-mannose glycan 
structures, and its KD indeed increased ConA staining relative to a GFP KD 
control.  
 
LCA: Lens culinaris agglutinin- A has high affinity for Fuc-α1,6-GlcNAc-N-Asn 
containing N-glycans [312]. As a control, we knocked down FUT8 (fucosyl 
transferase 8) which catalyzes the addition of fucose in α1,6 linkage to the first, 
Asn-linked GlcNAc residue of N-glycans. Its absence prevents the formation of 
this core fucose structure and its KD indeed decreased LCA staining. 
 
PHA-L: Phaseolus vulgaris leucoagglutinin has specificity for tri- and tetra-
antennary N-glycans, binding preferentially to GlcNAc in a β1,6 linkage with the 
trimannosyl core [313, 314]. To impair N-glycan synthesis, we co-knocked down 
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STT3A and STT3B, subunits of the oligosaccharyltransferase complex which 
initiates N-glycosylation by catalyzing the transfer of a lipid-linked high mannose 
oligosaccharide to an asparagine residue on nascent polypeptide chains, and the 
KD inhibits PHA-L binding.  
 
ECA: Erythrina cristagalli lectin has a preference for the disaccharide galactosyl-
β1,4-N-acetylglucosamine, therefore recognizing mostly extended complex N- 
and O-glycans that are not capped by a sialic acid [315]. KD of SLC35A3 (Golgi 
UDP-GlcNAc transporter) reduces the availability of UDP-GlcNAc substrate 
necessary for the addition of GlcNAc to extend both N- and O-glycans; KD of 
MGAT1 or C1GALT1 inhibits the extension of N-glycans or O-glycans, 
respectively, and thus Gal-β1,4-GlcNAc structures. Thus KD of any of the three 
genes led to a reduction in ECA staining.  
 
DSL: Datura stramonium lectin has a relatively broad specificity for poly- 
LacNAc extended N-and O- glycans as well as tri- and tetra-antennary N-glycans  
[316, 317]. Like PHA-L, co-KD of STT3A and STT3B decreases the initiation of 
N- glycosylation which hence inhibits DSL binding.  
 
MAL-II: Maackia amurensis lectin II binds preferentially to O-linked glycans 
containing the trisaccharide Sia-α2,3-Gal-β1,3-GalNAc [318]. Sialidase treatment 
reduces MAL-II staining. 
 
2.4.7 Secondary Met-Luc secretion screen 
 
HeLa cells were stably transfected to express secreted Metridia Luciferase 
(Clontech) using lentivirus transduction (HeLa Met-Luc). siRNA transfection of 
HeLa Met-Luc cells was performed as in the primary screen (Section 2.4.1). After 
3 days, the cells were washed once with PBS and fresh media was added to allow 
Met-Luc secretion. In some wells without siRNA, media containing either 10 
μg/ml BFA, 6 μg/ml nocodazole, 1 μg/ml monensin, or 1 μg/ml latrunculin B was 
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added instead. 25µl of supernatant per well was extracted after 4 hours, and the 
amount of secreted Met-Luc quantified using the Ready-to-Glow secreted 
luciferase reporter assay (Clontech). The raw signals were divided by the cell 
number (quantified by DAPI staining and imaging), logged, and then normalized 
to the mean of the control transfection reagent-treated (TR) wells. We used the 
standard deviation (SD) of TR wells as a measure of assay variation, and defined 
significant perturbation of Met-Luc secretion as a deviation of more than 3 SDs 
from the TR mean. This corresponded to normalized secretion values of about 
0.95 and 1.05. 
 
2.4.8 VSVG secretion assay 
HeLa cells were stably transfected to express the temperature sensitive mutant of 
VSVG protein (VSVG-tsO45) tagged with mcherry at the C-terminus. siRNA 
transfection of HeLa-VSVG cells was performed as in the primary screen. Two 
days after siRNA transfection, the cells were transferred to 40ºC and incubated for 
16 hours to allow accumulation of VSVG in the ER. The cells were then 
incubated at 32ºC for 15 minutes in the presence of 100 μg/ml of cycloheximide 
before fixation. 
 
2.5 HIGH RESOLUTION FLUORESCENCE MICROSCOPY 
 
Cells were seeded onto glass coverslips in 24-well dishes (Nunc). After the 
respective treatments, cells were fixed with 4% PFA-4% sucrose in D-PBS, 
permeabilised with 0.2% Triton-X for 10 minutes and stained with the appropriate 
markers using the same procedure performed in the primary siRNA screen. To 
effectively observe ERK8 localisation at the Golgi, the cells were permeabilised 
with 0.2% Triton-X for 2 hours and stained with anti-ERK8 antibody diluted in 
2% FBS in D-PBS overnight. For Beta COP staining, cells were permeabilised 
with 0.05% NP40 for 5 minutes twice, washed with D-PBS twice for 5 minutes, 
blocked with 2% bovine serum albumin (BSA) for 1 hour at room temperature, 
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followed by staining with anti-Beta COP antibody diluted in 2% FBS in D-PBS 
overnight.  
 
After staining, cells were mounted onto glass slides using FluorSave and imaged 
at room temperature using an inverted confocal microscope (Olympus IX81) 
coupled with a CCD camera (model FVII) either with a 60x objective (U Plan 
Super Apochromatic [UPLSAPO]; NA 1.35) or 100x objective (UPLSAPO; NA 
1.40) under Immersol oil. Images were acquired and processed using Olympus 
FV10-ASW software. 
 
2.6 PROTEIN EXPRESSIONS AND ANALYSIS 
 
2.6.1 Transient expression of plasmid DNA in mammalian cells 
 
Plasmids were transfected into HeLa cells using FuGENE® HD (Promega) 
transfection reagent. Cells were seeded a day before transfection in DMEM 
supplemented with 10% FBS. On the day of transfection, plasmid DNA and 
FuGENE® HD were added to Opti-MEM and incubated for 15 minutes at room 
temperature. The transfection complex was added to each well containing cells 
seeded at 90% confluency and incubated at 37°C in a 10% CO2 humidified 
incubator for 16 hours before harvesting for further analysis. 
 
HEK293T cells were transfected using a calcium phosphate method. HEK293T 
cells were seeded 8–24 hours before addition of transfection complex to obtain an 
optimal confluency (80–90%) for transfection. On the day of transfection, 1ml 
transfection complexes composed of 10–30 μg of DNA diluted in 250 mM 
calcium phosphate and mixed with BBS buffer (140 mM sodium chloride, 0.7 
mM disodium hydrogen phosphate, and 25 mM N,N-Bis(2- hydroxyethyl)-2-
aminoethanesulfonic acid [BES], pH 6.95 [20°C]) by vortex were incubated at 
room temperature for 15 minutes before addition to cells. 
 




Cells were washed twice using ice-cold D-PBS before scraping in D-PBS. Cells 
were centrifuged at 300g for 5 min at 4°C and were lysed using lysis buffer 
(containing 0.5% NP-40 Alternative (Calbiochem), 200mM NaCl and 50mM Tris 
buffer, pH 8.0) in the presence of protease (Roche) and phosphatase (Roche) 
inhibitors at 4ºC on a 20rpm shaker for 30 minutes. Lysates were clarified by 
centrifugation at 14,000g for 10 minutes at 4ºC and the supernatant was collected. 
Clarified lysate protein concentrations were determined using Bradford reagent 
(Bio-Rad Laboratories, Hercules, CA) before sample normalisation. Samples 
were diluted in lysis buffer with 4x SDS loading buffer and boiling at 95°C for 2 
minutes. They were then resolved by SDS-PAGE electrophoresis using bis-tris 
NuPage gels as per manufacturer’s instructions (Invitrogen) and transferred to 
PVDF membranes which was blocked using 3% BSA dissolved in TBST (50 mM 
Tris [pH 8.0, 4°C], 150 mM NaCl, and 0.1% Tween 20) for 2 hours at room 
temperature. Membranes were washed to remove traces of BSA before incubation 
with antibodies as per manufacturer’s instructions. Membranes were washed 5 
times with TBST before incubation with secondary HRP-conjugated antibodies 
(GE Healthcare). Membranes were further washed 5 times with TBST before 
ECL exposure. 
 
2.6.3 ER-trapped GalNAc-T activity reporter assay 
 
HEK293T cells were seeded into 10-cm petri dishes 24 hours before transfection 
and were transfected with the ER-trapped mucin construct (GFP-MUC5-PTS) 
using the calcium phosphate method. The growth media was then replaced the 
following day and the cells were further incubated for 24–48 hours before ERK8 
inhibitor treatment for 4 hours. Cells were harvested and lysed as previously 
mentioned. All subsequent steps were performed either on ice or at 4°C. 
Immunoprecipitation (IP) samples were incubated with 1–2 μg of HPL-
conjugated agarose (Sigma-Aldrich) overnight at 4°C. The next day, IP samples 
were washed for 5 times with 1 ml of IP wash buffer (50 mM Tris [pH 8.0, 4°C], 
100 mM NaCl, 0.5% NP-40 alternative, 1 mM DTT, and complete protease 
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inhibitor [Roche]). Samples were diluted in IP wash buffer and 4× SDS loading 
buffer before boiling at 95°C for 2 minutes. Samples were then resolved by SDS-
PAGE electrophoresis as mentioned above. 
 
2.6.4 GalNAz metabolic labeling 
 
HeLa cells were treated with siRNA for 3 days before metabolically labelling 
with 20 µM GalNAz for 6 hours. Ro-31-8220 was added to cells during GalNAz 
metabolic labelling for 4 hours treatment before harvesting. Cells were harvested, 
lysed and measured for protein concentration as previously mentioned. 50µg of 
protein lysate was added with 500µM of FLAG- phosphine to label GalNAz-
incorporated proteins and the samples were incubated overnight under constant 
agitation. The next day, the samples were diluted in lysis buffer with 4x SDS 
loading buffer and boiling at 95°C for 2 minutes and resolved by SDS-PAGE 
electrophoresis. Membranes were incubated with anti-FLAG antibody overnight 
to visualize GalNAz incorporation. 
 
2.7 GROWTH FACTOR AND DRUG TREATMENTS 
 
For growth factor stimulation, cells were seeded overnight and serum-starved for 
16 hours before incubation with EGF (100 ng/ml), PDGF (50 ng/ml), IGF1 (100 
ng/ml) or TGF-B1 (2 ng/ml) in serum-free DMEM for various durations before 
fixing. 
 
For drug treatments, cells were seeded and incubated with the drugs of different 









Brefeldin A (BFA) 2µg/ml 
FR180204 100µM 
Golgicide A (GCA) 50nM 
Imidazole 5mM 
IPA3 10µM 







2.8 SCRATCH WOUND ASSAY 
 
Cells were seeded onto fibronectin-coated 35-mm plastic tissue culture dishes 
(Ibidi GmbH) and grown to confluence for 16–24 hours. A wound was manually 
generated using micropipette tip before washing to remove cell debris. Live phase 
contrast imaging was performed at 37°C using a Zeiss Axiovert microscope 
(model 200M; Zeiss Microimaging; Thornwood, NY) equipped with a CCD 
camera (AxioCam HRc) with a 20× objective (LD Plan-NEOFLUAR; 20×; N.A. 
0.4). Frames were acquired at 5-minute intervals for at least 7 hours. The rates of 
wound closure were calculated by extracting images of the movie every hour and 
measuring the wound area (µm2) using ImageJ (National Institutes of Health). 
 
2.9 HUMAN FROZEN TISSUE ARRAY ANALYSIS  
 
2.9.1 Tissue array staining 
 
Frozen human tumour microarrays FBN406a, FMC407 and BRF404 were 
purchased from US Biomax, Inc., United States. The slides were dried and fixed 
in chilled 1:1 acetone:methanol for 10 minutes at room temperature. 
Subsequently, the slides were washed 3 times with TBST and blocked with 10% 
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goat serum-PBS for 30 minutes. Subsequent staining with ERK8 (0.9 μg/ml), 
VVL-biotin (4 μg/ml) and Hoescht (1:10,000) was performed overnight before 
staining with secondary antibody anti- rabbit Alexa Fluor 488 (1:1000) and 
Streptavidin-Alexa 594 (1:400) for 30 minutes. Slides were counterstained with 
DAPI and then mounted (Vectashield). 
 
2.9.2 Tissue array imaging and quantification 
 
The arrays were first automatically imaged (using constant acquisition 
parameters) using a 10× objective (LD Plan-NEOFLUAR; 10×; N.A. 0.4) on a 
motorized stage coupled to a Zeiss inverted confocal microscope equipped with a 
CCD camera (AxioCam HRc). Images of the cores were exported as from Zeiss 
Zen2011 software to enable quantification of ERK8 and VVL staining in tumour 
cores.  
 
To quantify the levels of ERK8 or Tn (VVL) expression in a tissue core, the 
images were first converted to 8-bit images on ImageJ. The area above the 
threshold set for background staining (Threshold for ERK8 and VVL was 30 and 
DAPI was 40) then quantified. Area of ERK8 and VVL was normalised to the 
total area of the core represented by nuclei (DAPI) staining. The values of each 
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Central to the secretory pathway in all eukaryotic cells, the Golgi apparatus is 
pivotal for post-translational modifications, in particular glycosylation, of lipids, 
lumenal and membrane-associated proteins and sorting of these secretory cargos 
to their appropriate destinations. In addition to these well established ‘classical’ 
functions of the Golgi, there has been mounting evidences of numerous other 
functions that converge at the mammalian Golgi. These neo-functions of the 
Golgi include mitosis [319], cell migration [116, 121], apoptosis [320, 321], 
cytoskeletal organization [68, 322], calcium storage and release [323, 324] and 
signal transduction [127, 128]. For all these functions, the Golgi organization is 
important.  
 
In spite of uncovering these diverse and unprecedented functions of the Golgi, the 
mechanisms controlling Golgi organization and its functions are not completely 
known. In recent years, various signaling mechanisms that control Golgi 
organization and function have increasingly been discovered [127, 129]. For 
example, ERK controls remodeling and re-orientation of the Golgi towards the 
leading edge for cell migration [116]. On the other hand, mitogen-activated 
protein kinases (MAPKs) MEK and ERK as well as various signaling proteins act 
to fragment the Golgi in preparation for mitosis [130-135] and the resulting Golgi 
fragmentation, in turn, forms a G2 mitotic checkpoint [124, 125, 319, 325]. 
Furthermore, the flux of secretory cargo release from the TGN was found to be 




Interestingly, the Golgi also senses and responds to endogenous signals, 
generating signaling cascades to modulate its own organisation and function. This 
is highlighted by the local activation of Src family kinases (SFKs) by the Golgi in 
response to variable amounts of membranes and cargo [145]. SFK activation, in 
turn, promotes intra-Golgi trafficking and secretion, likely through Golgi structure 
remodeling. In addition to responding to external cues for cell migration [116], 
the Golgi also generates signaling for its own re-orientation, as observed by the 
local activation of the germinal centre kinases III (GCKIII) upon Golgi 
recruitment [117, 326]. Activation of GCKIII kinases, in turn, phosphorylates 14-
3-3ζ protein which could recruit the cell polarity regulator, the Par complex, to the 
Golgi to mediate its orientation [148]. Notably, the Golgi also serves as a platform 
for spatially localising signaling cascades where they propagate differential 
signaling outcome and hence, different cellular responses. A well-known example 
is the specific localisation of Ras GTPases at the Golgi [153, 154] that 
spatiotemporally activate the signaling cascades. It was proposed that the Raf-
MEK-ERK cascade is activated downstream of Golgi-localised Ras, resulting in 
differential MAPK outputs [150, 151] and establish different physiological 
outcomes [327, 328]. In line with this, ERK is tethered to Golgi membranes 
where it is directed to different substrates [155, 156, 329]. 
 
By contrast, the regulation of glycosylation at the Golgi remains poorly 
understood. Our recent report highlights that O-GalNAc glycan synthesis can be 
regulated by re-localisation of O-glycosylating enzymes from the Golgi to the ER. 
This relocation event is stimulated by growth factors and mediated by signaling of 
tyrosine kinase Src [193, 240]. 
 
Collectively, these examples suggest that the organisation and functions of the 
mammalian Golgi are likely under multiple regulatory controls. Current studies 
commonly examine Golgi regulation by one or a few genes and different studies 
have variations in experimental setups. Furthermore, their effects on glycosylation 
are frequently not explored. Given the highly integrated and dynamic nature of 
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the Golgi, modifying a single aspect could also affect others. Thus, this calls for 
systematic evaluation of Golgi phenotypes so as to obtain a system’s view of 
Golgi regulation. In mammalian cells, RNAi screening is a method of choice to 
study Golgi regulation in a coordinated and unbiased fashion. In this chapter, I 
describe the use of an RNAi screen to identify the genetic basis of Golgi 
regulation. The screen involved a systematic analysis of the signaling complement 
of the genome: kinases, phosphatases and related genes to uncover signaling 
regulation on the mammalian Golgi organisation. Subsequently, I explored the 





3.2 RESULTS: RNAi screening reveals molecular regulators of Golgi 
organization and functions. 
 
3.2.1 Identification of screening conditions 
 
To assess Golgi organisation in mammalian cells, I chose to fluorescently label 
each of the three Golgi compartments (cis, medial and trans) with their specific 
markers. This would allow us to assess cisternal stacking and overcome the 
resolution limits of conventional microscopy. Adjacent Golgi cisternae can be as 
close as 50 nm apart and the cis-to-trans dimension of Golgi stacks range between 
200 and 400 nm [330]. By simultaneous imaging and pattern comparison between 
markers, this enables us to detect compartment specific effects. Although they 
appear morphologically indistinguishable under normal conditions, the 
compartments can be segregated when perturbed [331-333]. Furthermore, Golgi 
compartments are known to differ greatly both biochemically and functionally 
such as their biosynthetic tasks, resident protein and lipid composition, pH and 
membrane trafficking events involved [26, 334-336]. Labeling all three 
compartments would map the influence of a gene to the specific compartment and 
membrane trafficking process. Hence, this serves to better dissect the regulation 
of Golgi organisation. 
 
I have selected human cervical carcinoma HeLa cells for their elaborate Golgi 
ribbon morphology. HeLa cells have been commonly used in studies to dissect 
regulatory mechanisms of Golgi organisation [211, 337-339]. In addition, their 
high amenability to siRNA transfection [340] further substantiated their use in the 
RNAi screen. 
 
The cis compartment was represented with Helix pomatia lectin (HPL) staining. 
HPL binds specifically terminal GalNAc residues added to cargo proteins by 
GalNAc-Ts, the O-GalNAc glycosylation initiation enzymes [341]. As GalNAc is 
rapidly modified by the downstream galactosyltransferase C1GalT in subsequent 
87 
 
Golgi compartments, HPL staining has been shown to be restricted to the cis 
Golgi [342]. Furthermore, the staining intensity of HPL reflects the expression 
levels of terminal O-GalNAc (also known as the Tn antigen), a well-known tumor 
associated carbohydrate marker. Hence, it provides another aspect that could be 
derived from this high-content screen which is in the dissection of Tn regulation. 
This will be further discussed in Chapter 4 of this dissertation. Technically, the 
use of fluorophore conjugated HPL would add ease and speed to the high 
throughput cell staining procedure and the staining is strongly detectable on the 
automated confocal microscope. Altogether, these further supported HPL as a 
convenient readout for the cis Golgi integrity. The medial Golgi was marked by 
GFP tagged Mannosidase II (MannII-GFP) that was stably expressed in the HeLa 
cells. The only concern of the stable expression was to obtain a homogenous level 
of expression for imaging. This was circumvented by flow cytometry sorting for 
high expressing cells for the screen. To reveal the trans Golgi network, I have 
selected a specific antibody staining for TGN46 protein. Finally, nuclear DNA 
staining was used to identify individual cells and to demarcate the cell boundaries 
in our automated image analysis software.   
 
Under physiological conditions, all three markers colocalize significantly at the 
immunofluorescence level using a 100X objective. This is consistent with the 
resolution limit of conventional microscopy, which is unable to distinguish 
between cisternae (Figure 3-1). However, despite this colocalisation in normal 
cells, the three proteins have, in fact, different dynamics and compartmental 
distributions. On the cis side of the Golgi complex, HPL reveals the activity of 
GalNAc-Ts, which cycle to the ER independently of other Golgi enzymes [193]. 
While MannII-GFP is a medial Golgi marker expected to cycle at a slow rate 
between the Golgi complex and the ER [343], TGN46 is distributed to the TGN 
compartment and has been reported to traffic continuously between the plasma 







Figure 3-1: An imaging-based screen to identify Golgi organisation 
phenotypes. HeLa MannII-GFP (medial Golgi) cells were stained with cis Golgi 
marker HPL and trans Golgi network (TGN) marker TGN46. Compartments co-




3.2.2 A pilot siRNA screen on membrane trafficking regulators revealed 
three main Golgi morphologies. 
 
In order to explore the range of Golgi phenotypes that could be observed, I 
screened a custom-designed set of 63 known regulators of membrane traffic. 
These regulators, including SNAREs and Rabs, participate in vesicle budding and 
fusion [345, 346]. I have also tested drugs such as brefeldin A (BFA), nocodazole, 
monensin and latrunculin B, which are known to perturb the Golgi in different 
ways [347]. For each perturbation, 2000 cells were reverse transfected with 
siRNAs spotted in 384-well imaging plates. 72 hours after siRNA transfection, 
some untransfected wells were treated with the drugs for one hour before fixing 
and staining for the nucleus, cis and trans Golgi compartments. The cells were 




Visual inspections on each treatment revealed that depletion of several of these 
genes perturbed Golgi morphology. Through this exercise, I defined three major 
classes of perturbed Golgi morphology that were visually identifiable and labeled 
them “diffuse”, “fragmented” and “condensed” (Figure 3-2A and B). Diffuse 
Golgi morphology is typically observed after Brefeldin A treatment. This 
morphology usually reflects the relocation of Golgi markers to the ER. With a 
fragmented Golgi, granular structures are still visible, but they appear no longer 
connected in a perinuclear half-moon shape. Fragmentation has been reported in 
multiple studies and occurs for example after nocodazole or monensin treatment 
[347, 348]. Fragmentation is sometimes attributed to a loss of the connections 
between Golgi stacks [349, 350]. The condensed Golgi usually appears compact 
and rounded in a perinuclear location. This morphology has been previously 
reported to occur upon latrunculin treatment [351] and upon various genetic 
perturbations [352, 353].  
 
Cellular images of selected gene depletions that resulted in strong Golgi 
phenotypes were used to train our automated image classification tool to 
recognize and classify Golgi phenotypes for each Golgi marker (Figure 3-2B). 
This image classification tool involved support vector machine (SVM) learning 
and will be further discussed in Section 3.2.3. The initial SVM trained with the 
pilot screen set was further refined with more examples from the subsequent 
signaling genes screen, altogether constituting the set of “Reference 
morphological phenotypes”, (Figure 3-2B and Table 3.1) to achieve a final SVM 
model for phenotypic readout. 
 
The dramatic Golgi phenotypes observed from the depletions of membrane 
trafficking genes validated the screening protocol and assay method. In addition, 
the screen also identified controls for our subsequent screens. Three SNAREs 
were, hence, selected based on their prototypical effects on the Golgi apparatus: 
Syntaxin 3 (STX3) with a fragmented morphology, SNAP47 with a condensed 
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morphology and Syntaxin 5 (STX5) with a marked diffuse distribution for the cis 
marker HPL but almost unaffected MannII-GFP and TGN46 stainings (Figure 3-
2A). Diffuse HPL staining in STX5 knockdown is accompanied with intensity 
increases (see Chapter 4). The siRNA transfections were verified to be efficient 
given that more than 80% of cells showed reduction in MannII-GFP levels when 
treated with GFP siRNA and increased HPL staining in STX5 depleted cells 







Figure 3-2: A pilot screen of membrane trafficking regulators revealed three 
Golgi phenotypes. (A) Examples of the three identified Golgi phenotypes. STX5 
knockdown induced a diffuse phenotype specifically for the cis Golgi while STX3 
and SNAP47 knockdown induced a fragmented and condensed Golgi in all three 
compartments respectively. Scale bar: 30µm. (B) Schematic overview of the 
screening process. The pilot screen was imaged using x20 objective and visually 
screened for changes in Golgi organisation. Three Golgi phenotypes were 
identified and used to train a preliminary Support Vector Machine (SVM) for 
quantitative scoring of treatments. Images of selected genes from the signaling 
genes screen (Table 3.1) were used to refine SVM training and obtain a final 
score. (C) Workflow of the siRNA screen. Screen plates were loaded with 
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controls for the three phenotypes for quality control in each plate. Non targeting 
siRNA (NT siRNA) knockdown using GFP siRNA and STX5 knockdown 
demonstrate homogeneous gene depletions in all wells seeded with the siRNAs. 





Table 3.1 List of drug and gene siRNA treatments (Reference morphological 
phenotypes) for training the SVM. 
 
 
3.2.3 Golgi phenotypes can be automatically classified using nine phenotypic 
features. 
 
In order to quantify and classify the various Golgi phenotypes induced by gene 
knockdown, we have developed an automated image analysis and classification 
approach. The work was performed in collaboration with Dr. Victor Racine. To 
obtain phenotypic analysis at the individual cell level, nuclei were segmented 
based on DNA staining (Figure 3-3A). A cell territory was defined around the 
mass center of each nucleus (Figure 3-3B). Cell image features were then 
extracted for the nucleus (108 features) and the three Golgi markers’ staining (22 
features) (Figure 3-3C and D). The features ranged from intensity-based, 
segmentation-based and colocalisation analyses [354]. We found that a single 
image feature is insufficient to capture nuclei or Golgi phenotypes. Therefore, we 
used Support Vector Machine (SVM) machine learning [355] to find 




A first SVM was trained to recognize and exclude out-of-focus, badly segmented 
and mitotic cells (Figure 3-3E). Another SVM was thereafter trained to recognize 
the three types of morphology, diffuse, fragmented and condensed, using 
reference phenotypes that were visually detected in the pilot screen (Figure 3-3F 
and Table 3.1). The five most discriminative image features from the pool of 22 
computed Golgi features were selected for each of the three phenotypes. Image 
feature scores from the reference phenotypes defined the cutoff boundaries in the 
five-dimensional feature space. For instance, one of the image features that was 
selected to define cutoff for the fragmented phenotype is the number of granular 
structures (Obj[1].nbSubstructures) and axis length after ellipse fitting for the 
condensed Golgi (Obj[2].sigma.y). We found that this method provided better 
phenotypic discrimination (Figure 3-3F and G). The cutoff boundaries of the 
SVM were further refined and reinforced with cell images from the signaling 
genes screen (“Reference morphological phenotypes”) (Figure 3-2B and Table 
3.1). The Golgi morphology of individual cells was described by the SVM 
classifier as a set of nine binary phenotypic features (PFs), ranging from Cis-
Condensed to Trans-Diffuse (Figure 3-3G). To elaborate, the Golgi compartment 
of a cell was assigned as either displaying one of the three phenotypes or 
unaffected (normal). All three Golgi compartments were evaluated exclusively, 
giving rise to nine PFs (Figure 3-3G). At the gene level, the percentage of 
analyzed cells positive for each of the nine PFs was computed (Figure 3-3H). This 
is reflective of the extent of Golgi perturbations. For example, BFA treatment, 
which led to extensive diffused Golgi phenotype, scored significantly higher than 
SNAP23 depletion that has a moderate phenotype. Hence, the phenotype of each 
gene knockdown or cell treatment condition was assigned a signature with nine 
phenotypic scores. This signature is represented in a graphical manner by a 
colour-coded pie chart (Figure 3-3I). Correlation analysis of the screens’ 
phenotypes indicated that the nine scores are non-redundant (Figure 3-5D). 
 
The performance of the SVM classifier was bench-marked against three 
individuals at the cellular level with a representative set of 300 cells and found to 
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be comparable to human classification. At the gene level, we compared SVM and 
experimenter classification with 120 wells displaying different phenotypes and 
found more than 90% agreement, indicating that our automated image analysis 






Figure 3-3: An automated image analysis method for Golgi phenotypic 
classification. (A) Cells were stained for the nucleus and Golgi compartments and 
(B) identified based on their nuclear staining (colored masks). (C) Cell boundaries 
were defined from the centers of mass of the nuclei. (D) Multiple image features 
for each channel of each cell were extracted. (E) Mitotic, apoptotic or closely 
apposed cells were detected by a specific SVM and discarded from further 
analysis. (F) During SVM training, reference images for each phenotypic feature 
(PF) (Table 3.1) were used to select the five most discriminative image features to 
derive SVM functions that define phenotypic boundaries in this five-dimensional 
space. (G) To quantify Golgi phenotypes in test images, the three SVM functions 
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were applied to each of the three Golgi staining: cis (shown), medial and trans, to 
determine PFs. These features are binary (1=yes or 0=no) for individual cells and 
exclusive within one channel. For instance, the cis Golgi of one cell can only be 
fragmented, diffuse, condensed or normal. Individual cells were eventually 
attributed nine binary PFs, three for each of the three channels. (H) Illustration of 
phenotypic score calculation for a gene. Each of the nine phenotypic scores for a 
gene corresponds to the fraction of analyzed cells with the particular PF. (I) The 
nine morphological scores constitute a phenotypic signature displayed in a colour-
coded pie-chart. White sectors represent cells with normal Golgi morphology. 
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3.2.4 159 signaling genes regulate Golgi organisation. 
 
To probe Golgi regulatory mechanisms, I next screened 948 siRNAs targeting 
kinases, phosphatases and related genes (Figure 3-4A). The morphological 
analysis gave highly reproducible results between the two replicates, suggesting 
low experimental variations (Figure 3-4B). To avoid quantifying effects 
associated with apoptosis or cell necrosis, I discarded genes with a significant 
effect on cell number. Based on the average number of nuclei for all treatments in 
the screen, I eliminated those that resulted in less than 200 nuclei detected (Figure 
3-4A). Furthermore, I found no correlation between any of the phenotypic scores 
with cell number, arguing against any bias induced by cell viability issues (Figure 
3-4C). Similarly, a lack of correlation between the intensities of Golgi 
compartments and cell counts indicated cell number did not affect intensities 
(Figure 3-4D). 
 
Subsequently, I determined significance thresholds for each of the nine 
morphological features based on the first derivative of ranked data as described in 
[356]. Each threshold corresponds to a z-score of two or more. A gene was 
classified as a hit when at least one Golgi compartment was significantly 
perturbed, hence identifying 181 primary hits (Figure 3-4A). I further confirmed 
the hits by examining individual images to ensure that the knockdowns induced 
visually significant perturbations on the Golgi. To remove false-positive hits due 
to off- target effects, I next tested if the phenotypes scored could be reproduced 
by at least two independent siRNAs out of the four (deconvoluted siRNA) used in 
the original pools in the screen. This validated 159 hits for which the possibility 
of off-target effect is greatly reduced (Table 3.2). This represents about 20% of 
the signaling genes tested, which is a surprisingly large proportion. I, in 
collaboration with Dr Germaine Goh, further screened the validated hits for 








Figure 3-4: A large proportion of signaling genes regulate Golgi structure. 
(A) Schematic workflow of the signaling genes screen. Gene knockdowns having 
a total cell number of more than 200 were excluded from the final SVM 
classification. Thresholds for primary hit identification were defined using the 
derivative method for each of the nine PFs, resulting in 181 primary hits. The 
primary hits were re-tested with the four individual siRNAs present in the pool 
(deconvoluted siRNA) of the primary screen and 159 hits were validated (Table 
3.2). These validated hits were then further screened for glycosylation (lectin 
intensity assay; Figure 3-19) and secretion (Met-luc secretion assay; Figure 3-16) 
changes. (B) A scatter plot demonstrating reproducibility in the phenotypic scores 
between the two screen replicates in the medial fragmented scores. Good 
reproducibility between replicates was observed in the scores of all nine PFs. (C) 
Plot of total cell count versus phenotypic scores reveals absence of correlation 
between cell number and Golgi phenotype. All nine PFs demonstrated absence of 
correlation with cell number. (D) Plots comparing the intensities of Golgi 






3.2.5 Golgi phenotypes from the signaling screen were diverse. 
 
The primary screen revealed that numerous signaling genes are essential for the 
maintenance of normal Golgi organisation (Table 3.2). With our analysis method, 
the relative intensities of morphological perturbations are encoded in the 
percentage of cells classified as perturbed. Comparing the data from the 
membrane traffic and signaling genes screen, it is apparent that depletions of 
several signaling genes have an effect on the Golgi more pronounced than most 
well known regulators such as the SNAREs (Figure 3-5A). Using the significance 
thresholds from the signaling screen, I could find only 10% (6 out of 63) of 
membrane trafficking regulators, as opposed to 20% in the signaling genes, 
resulted in equally significant Golgi perturbations. This suggests that these 
signaling hits could regulate Golgi organisation in multiple ways. 
 
The perturbations of Golgi phenotypes observed were diverse, ranging from 
perturbations specific for one cisternal marker (SCYL3, trans Golgi) to 
perturbations affecting all three markers with either a condensed (IGF1R), 
fragmented (ITPKA) or diffuse (PIK4CA) appearance (Figure 3-5B and C). 
Consistent with results in the pilot screen, the morphological scores for each of 
the three Golgi markers were highly correlated with each other in the fragmented 
or condensed phenotypes (for example Cis-fragmented and Medial-fragmented: 
correlation coefficient of 0.95) (Figure 3-5D). By contrast, the scores of the Golgi 
markers did not correlate well between each other for the diffuse morphology 
(Figure 3-5D). 
 
The diffuse Golgi morphology is reminiscent of an ER pattern, suggesting that the 
marker displaying this morphology has been relocalized at least partially to the 
ER. When I co-stained some of the diffuse cis-Golgi hits with the ER marker 
calreticulin, I could observe and quantify significant increase in colocalisation 
between calreticulin and HPL (Figure 3-6A and B). This indicates that the 
glycosylation enzymes GalNAc-Ts, whose activities are revealed by HPL, have 
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been relocalized to the ER. Interestingly, depletions of several genes induced 
specifically GalNAc-Ts but not MannII-GFP ER relocation (Figure 3-5B). This is 
consistent with the notion that the trafficking of different Golgi enzymes is 
independently regulated as our group has previously reported [193]. 
 
Hierarchical clustering using the scores of nine PFs revealed six major 
morphological groups (Figure 3-5B). The two dominant groups are those that 
display condensed Golgi (61 genes) or fragmented Golgi (53 genes) for all 
markers (Figure 3-5B). For these phenotypes, the three markers colocalize 
extensively, as much as in untreated cells, either in fragments or in a perinuclear 
condensed structure (Figure 3-5D). A reduction of the nine morphological 
features in two dimensions by principal component analysis (PCA) resulted in 
these two groups appearing relatively compact and well- separated (Figure 3-5E, 
yellow and blue dots). The separation also indicated that these two Golgi 
morphologies occur mutually exclusive of each other, suggesting antagonistic 
effects of the two groups of genes on the Golgi. In the other four groups (67 genes 
in total), the phenotypes were at least partially diffuse and were more 
heterogeneous. Most genes presented a varied mix of fragmented and diffuse 
phenotypes, consequently they appeared more spread in the two dimensional PCA 
phenotypic space (Figure 3-5E, pink, purple, red and orange dots). For these 
phenotypic groups, staining of the three Golgi markers are generally less well 
colocalized than in the control (see example SCYL3 in Figure 3-5C).  
 
Because each marker is specific for different Golgi compartments, the partially 
diffused phenotypes suggest a perturbation of cisternal organisation. By contrast, 
condensed and fragmented phenotypes imply an alteration of the network 
organisation of the Golgi stacks, within which cisternal organisation is 
maintained. By extension, the large number of genes in these two groups suggests 
that many signaling pathways affect the overall network structure of the Golgi 







Figure 3-5: A diversity of Golgi phenotypes could be observed from signaling 
gene depletions. (A) Morphological scores of signaling genes (red dots) 
compared with membrane trafficking genes (blue dots) and control wells (gray 
dots). CD, MD, TD, CF, MF, TF, CC, MC and TC refer to cis diffuse, medial 
diffuse, trans diffuse, cis fragmented, medial fragmented, trans fragmented, cis 
condensed, medial condensed, and trans condensed, respectively. (B) Hierarchical 
clustering of 181 primary hits using the nine PFs. The range of phenotypic scores 
is represented by green (high score) to red (low score) in the heatmap. Six major 
morphological groups were identified and color-coded: condensed (blue words), 
trans diffuse (pink), medial diffuse (purple), cis and trans diffuse (red), 
fragmented (yellow), diffuse and fragmented (orange). (C) Corresponding images 
of the genes highlighted in colored rectangles in (B). IGF1R depletion (blue label)  
resulted in all Golgi compartments condensed; SCYL3 (pink)  in strongly diffuse 
trans compartment; ITPKA (yellow) in all Golgi compartments fragmented; 
PIK4CA (orange) in a mix of diffuse and fragmented for all compartments. Scale 
bar: 30 µm. (D) Correlation plots of the nine phenotypic features. (E) Principal 
component analysis (PCA) of the nine phenotypic features revealed the 
distributions of the six morphological groups. Color coding corresponds to the six 








Figure 3-6: Diffuse Golgi morphology is likely due to relocation of marker to 
the ER. (A) Genes that exhibited a cis diffuse Golgi upon depletion show 
extensive colocalisation between cis Golgi marker HPL and ER marker 
calreticulin. Images were acquired with 60x magnification. Scale bar: 10 μm. (B) 
Colocalisation between the cis Golgi and ER markers was measured using 
Pearson’s correlation coefficient of the two markers’ staining. Cells were 
analyzed using MetaeXpress Translocation-Enhanced analysis module. Values on 
graphs indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-tailed unpaired t- 




3.2.6 A large signaling network regulates Golgi apparatus organisation. 
 
The number of signaling gene depletions affecting Golgi organisation is large. To 
further understand the nature of signaling regulation on the Golgi, in collaboration 
with Dr Pankaj Kumar, I mapped the 111 hit kinases (out of 181 primary hits) 
from the screen on a phylogenetic tree of kinases [357]. This reveals that all the 
major families are involved in Golgi regulation (Figure 3-7). By extension, this 




Figure 3-7: A map of 111 hit kinases on the phylogenetic tree of kinases 
reveals Golgi regulation by all kinase families. Hit kinases are labeled in red 
words. Seven main kinase families are indicated in different color branches: 
Calcium/calmodulin-dependent protein kinase (CAMK) family in blue, 
Containing CDK, MAPK, GSK3, CLK families (CMGC) in grey,  Homologs of 
Yeast Sterile kinases (STE) in brown, Casein kinase 1 (CK1) family in aqua, 





If these enzymes act directly on the organelle, one could expect a high number of 
phosphoproteins associated with Golgi membranes. To test this, we conducted a 
systematic search for proteins with a Gene Ontology (GO) Cellular Component 
(CC) containing the term “Golgi” and found 854 proteins. In the PhosphositePlus 
database, almost half (413) of these Golgi associated proteins were found to carry 
at least one phosphorylated residue (Figure 3-8A). Additionally, to ensure that the 
network generated would be as stringent as possible, the additional filter of 
“membrane trafficking” GO Biological Process (BP) term was applied, resulting 
in 135 out of 413 proteins being retained. Hence, 135 proteins are annotated in 
databases to be localized at the Golgi, phosphorylated and regulate membrane 
traffic. We next evaluated how our screen hits could be associated with these 135 
Golgi phosphoproteins. Using only experimental-based evidences in the STRING 
database, 37 Golgi phosphoproteins were found to interact with 86 of our screen 
hits. We used these interactions and the available GO Cellular Compartment 
annotations to draw a map of the Golgi regulatory network (Figure 3-8B). These 
results suggest that the effects that are observed are likely due to direct regulation 









Figure 3-8: Protein network analysis of hits reveals multiple connections 
between signaling molecules and Golgi proteins. (A) Step-wise construction of 
the Golgi regulatory network. 413 of the 854 proteins localized at the Golgi in the 
Gene ontology (GO) database were also found in the Phosphosite plus database. 
A functional filter using Biological Process GO yielded 135 phosphorylated 
proteins present at the Golgi and functioning in membrane trafficking. Using 
protein–protein interaction information from three databases (String, Pathway 
Studio and HPRD), 37 of these curated phosphorylated Golgi proteins were 
reported to have a direct interaction with 86 hits. (B) A preliminary map of the 
Golgi regulatory network arranged based on available Cellular Compartment GO 
for all 123 genes. Signaling hits are represented in their gene signatures while 




3.2.7 Specific sub-networks further reveal Golgi regulatory mechanisms. 
 
To better understand the relationships between Golgi proteins and the screen hits, 
I probed further in the Golgi regulatory network and incorporated in-depth 
literature searches to reconcile the Golgi phenotypes observed with the regulatory 
mechanisms involved. The sub-networks are reviewed in the following sections: 
 
3.2.7.1 New players in the Golgi phosphoinositide regulatory network 
 
Phosphoinositides are known to regulate membrane dynamics at the Golgi level 
[358]. Phosphatidylinositol 4-phosphate (PI4P) in particular is enriched in Golgi 
membranes and is known to regulate multiple molecular events [358] (Figure 3-
9). Depletion of both PI4P kinases PIK4CA and PIK4CB, which phosphorylate 
PI, resulted in strong perturbations of Golgi organisation. The lack of 
compensation and differences in phenotype suggest that both kinases regulate 
different pools of PI4P as previously suggested [359, 360]. Specifically, PIK4CA 
appears to regulate PI4P at the level of ER exit sites as recently shown [361], 
while PIK4CB appears to function at the Golgi itself [362].  
 
PIP4 can be phosphorylated into PI4,5P2 and it has been suggested that PI4,5P2 
may play an important role in Golgi membrane dynamics, but the kinase 
responsible has remained unknown [363-365]. Here, I found that depletion of 
PIP5K1A, which produces PI4,5P2, also resulted in a significant fragmentation of 
the Golgi (Figure 3-9).  
 
I also observed a condensed Golgi phenotype upon depletion of PTEN, a 
phosphatase with specificity for the position 3 of PI3,4,5P3 (Figure 3-9), 
consistent with a previous report that localized PTEN2 at the Golgi [366]. 
Previous reports have also suggested a role for PI3,4,5P3 at the Golgi, identifying 
multiple possible effectors [367-369]. A class I PI3 kinase, PIK3CA, has recently 
been found to localize at the TGN in macrophages and to be important for the 
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release of cytokine-containing carriers at the TGN [370]. Depletion of the same 
kinase PIK3CA in my screen induced mild Golgi fragmentation, albeit below my 
cutoff threshold, suggesting that its role at the TGN is not limited to macrophages.  
 
Finally, I have also integrated in this sub-network the diacylglycerol (DAG) 
kinase zeta (DGKZ), which produces a strong phenotype. Indeed, PI4,5P2 can be 
converted into DAG by the phospholipases C, PLCB2 and PLCE, which both 
have been localized at the Golgi [371, 372]. These results demonstrate the 
screen’s capacity to identify known players and suggest novel regulators of the PI 





Figure 3-9: Phosphatidylinositol (PI) network regulators identified in the 
screen. Depletion of either PIK4CA or PIK4CB resulted in a highly diffuse and 
fragmented Golgi. PI4P is possibly converted into PI4,5P2 by PIP5K1A as 
indicated by fragmentation of the Golgi upon knockdown. Depletion of PTEN, 
the phosphatase for PI3,4,5P3, exhibited a condensed Golgi phenotype. 
Diacylglycerol (DAG), a downstream product of PI4,5P2 is converted into 
phosphatidic acid (PA) by DGKZ whose knockdown resulted in a fragmented 
Golgi. Different PI species can recruit various membrane trafficking effectors 
(green nodes). Black arrows indicate non-phosphorylation based activation. Dark 
green nodes and light green nodes represent phosphorylated Golgi proteins and 





3.2.6.2 Regulators of acto-myosin dynamics at the Golgi apparatus 
 
Another network of Golgi regulation appears to revolve around actin dynamics. A 
condensed Golgi phenotype was induced by depletion of the protein kinase 
ROCK1 and also, to a lesser extent, of ROCK2 (Figure 3-10A). Consistently, 
expression of an active form of ROCK1 was previously reported to induce Golgi 
fragmentation [373]. In non-muscle cells, ROCKs regulate actomyosin 
contractility in two ways: phosphorylation of the regulatory myosin light chain 
(MLC) of motor protein myosin II and phosphorylation and activation of the 
LIMK1 and LIMK2 kinases that, in turn, phosphorylate and inhibit the actin 
depolymerising protein cofilin (CFL1). Interestingly, all these effectors have been 
localized at the Golgi complex [374]. It was reported recently that myosin II 
regulates the fission of transport carriers at the Golgi [375]. Regulation of actin 
dynamics by cofilin was also reported to regulate Golgi organisation and export 
from the TGN [376] [377] [378]. Treatment by Latrunculin and other drugs able 
to block actin polymerization have been reported to induce a compaction of the 
Golgi apparatus [379].  
 
Surprisingly, I also found that depletion of PAK1 induces a marked fragmented 
phenotype (Figure 3-10A). This is consistent with previous reports of PAK1 
inhibition of actomyosin contractility by inactivation of MLCK [380] and by 
phosphorylation and inactivation of myosin II heavy chain (MHC) [381]. 
Treatment of cells with IPA3, a PAK1 inhibitor [382], also induced fragmentation 
of the Golgi (Figure 3-10B) after six hours of treatment. The effect was dose 
dependent. In agreement with the model of opposite action of ROCK1 and PAK1 
at the Golgi, IPA3 could rescue at least partially the effect of ROCK1 knockdown 
while having no effect on PAK1 depleted cells (Figure 3-10B). 
 
Together these data suggest that ROCK1 and PAK1 exert antagonistic forces on 
the structure of the Golgi apparatus through actomyosin processes. These 
processes are proposed to be required for the generation of transport carriers at the 
Golgi [375]. Consistent with this model, depletion of ROCK1 induces a 
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significant reduction of constitutive secretion as measured by a secreted Metridia 





Figure 3-10: Regulators of the actomyosin machinery control Golgi 
organisation. (A) ROCK1 depletion resulted in a compact Golgi while PAK1 
depletion resulted in a fragmented Golgi, suggesting antagonistic effects on the 
Golgi structure through actomyosin processes. Red arrows indicate 
phosphorylation. Dashed lines indicate recruitment. (B) Treatment of cells with 
10μM of PAK inhibitor IPA3 for six hours recapitulated the fragmented Golgi 
phenotype in PAK1 depletion. ROCK1 depleted cells treated with IPA3 reverted 
the condensed Golgi phenotype to normal.   
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3.2.6.3 A link between cell cycle regulators and the TGN 
 
Depletion of the mitotic checkpoint kinase BUB1 resulted in a strong diffuse 
morphology affecting more specifically the trans Golgi marker. A previous report 
indicated that BUB1 interacts with the β chains of the 4 heterotrimeric adaptor 
complexes AP1, AP2, AP3 and AP4 [383]. AP complexes, except AP2, act at the 
TGN to promote sorting of cargo proteins into clathrin coated transport carriers 
[384]. Phosphorylation of AP complexes has been proposed to regulate their 
interaction with clathrin coat and/or sorting signals on cargo proteins [385]. 
Consistently, the yeast homologue of BUB1, Bub1p, has been found to interact 
with the human Nexin-1 homolog, Vps5, that is required for trafficking from the 
prevacuolar/late endosomal compartments back to the Golgi apparatus [386].  
 
Consistent with a direct role of BUB1 at the TGN, two BUB1 interactors [387], 
the CLIP-associated protein (CLASP) and microtubule associated protein 
(MAPRE1) are Golgi associated proteins, and have roles in nucleation and 
stabilization of a subset of microtubules that originate from the TGN [72]. These 
TGN-derived microtubules are required for maintaining Golgi structure, 
directional post-Golgi trafficking and cell migration [68]. 
 
Another key mitotic kinase, CDC2, alias Cdk1, known to regulate BUB1 [388], 
also results in a marked perturbation of the TGN. It was therefore hypothesized 
that both kinases may function together at the TGN. Cdk1 has previously been 
reported to phosphorylate GRASP65 during mitosis [389]. However, it is not 
clear whether this is related to the phenotype that was observed in my screen, as 
GRASP65 is not known to localize at the TGN.  
 
Overall, this sub-network suggests an intriguing link between cell cycle kinases 
and post-Golgi traffic (Figure 3-11) that may have to do with the dramatic 
changes in cell morphology and surface-to-volume ratio observed at the onset of 
mitosis. Whether or not this link is related to the Golgi fragmentation observed 
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during mitosis is hard to establish at present: judging by their DNA, the cells are 
not arrested in mitosis and their Golgi phenotype appears different from a mitotic 
Golgi, which would be clearly fragmented: for BUB1 the phenotype is mostly 
diffuse cis and trans and for CDC2 it is a mixture of diffuse and fragmented 





Figure 3-11: A possible link between cell-cycle kinases and trans Golgi-
plasma membrane trafficking. Knockdown of mitotic checkpoint kinase BUB1 
and cell-cycle control kinase CDC2 resulted in a specifically trans diffuse Golgi. 
Purple lines indicate confirmed protein–protein interaction curated in HPRD 
database. Red arrows indicate phosphorylation. Black lines indicate protein–






3.2.6.4 Different MAPKs cascades affect Golgi organisation 
 
The Mitogen Activated Protein Kinases (MAPK) family include more than 30 
different protein kinases that respond to various stimuli [390]. MAPK cascade 
involves, typically in mammalian cells, three or four levels going from MAP4K to 
MAPK [391]. My screen results indicate a significant enrichment in the MAPK 
signaling pathway based on the KEGG pathway database (Enrichment= 9.43, p- 
value= 3.7 x 10-10) This is consistent with the results of two recent screens 
looking at ER exit sites in mammalian cells and Golgi morphology in Drosophila 
S2 cells [392, 393].  
 
Eight MAPK family kinases and thirteen closely related genes were identified, 
including four dual specificity phosphatases (DUSP) (Figure 3-12). DUSP are 
proposed negative regulators of MAPK pathways. I verified that depletion of 
DUSP2, 6 and especially 8 resulted in up regulated phosphorylation of ERK1/2 
based on immunoblotting with phospho-ERK specific antibody. This suggests that 
fragmentation of the Golgi apparatus results from the activation of ERK. Indeed, 
treatment of the DUSP2, 6 or 8 depleted cells with the ERK inhibitor FR180204 
reverted the Golgi phenotype (Figure 3-13A and B). ERK has been shown to 
phosphorylate the Golgi structural protein GRASP65 during the orientation of the 
Golgi towards the leading edge [394]. This phosphorylation event could be one of 
the underlying mechanisms of the observed Golgi fragmentation.  
 
At present, four main MAPK cascades have been described, the classical 
pathway, which respond to mitogenic stimulation, the p38 and JNK cascades that 
tend to be activated by environmental stress and the lesser known ERK5 cascade. 
Based on results from my screen and previous RNAi screens [392], it appears that 








Figure 3-12: MAPKs from all four signaling cascades regulate Golgi 
organization. Multiple players from different tiers of the MAP kinase signaling 
pathway appear as hits in my screen and the screen by [392], highlighting the 
importance of MAP kinases in the regulation of the secretory system. Tiers of the 
MAP kinase pathway are indicated on the left and the four main MAP kinase 
pathways are indicated at the top. Dark green nodes and light green nodes 
represent phosphorylated Golgi proteins and Golgi proteins, respectively. Orange 
nodes represent hit genes from [392]. Grey nodes represent non-hit genes in both 







Figure 3-13: Golgi fragmentation by depletion of DUSPs requires ERK1/2 
activation. (A) Treatment of DUSP-depleted cells with 100μM ERK1/2 inhibitor 
FR180204 for six hours rescue the fragmented Golgi phenotype. Scale bar: 10 
μm. (B) Quantification of medial Golgi fragmentation in cells with (red bars) and 
without (blue bars) drug treatments indicate the reversion to normal Golgi by 
ERK inhibition. Values on graphs indicate the mean ± SEM. **p<0.0001, 







Indeed, one of my screen hits, MECOM, aka Evi1, has been proposed to 
negatively regulate the JNK by direct binding [392]. JNK has been linked to 
Golgi associated proteins, such as AKRL1/2 [395] or vesicular trafficking 
proteins such as JIP1/2/3 [396]. Consistent with the effect of Evi1 depletion being 
mediated by JNK, I found that treatment of the Evi1 depleted cells with the JNK 
inhibitor SP600125 reverted the Golgi condensed phenotype (Figure 3-14A and 
B). 
 
The Golgi proteins that could be mediating these changes of morphology remain 
relatively few at present. In addition to GRASP65, recent screens have 
demonstrated that the classical MAPK ERK1/2 and the atypical ERK7 
phosphorylates the ER exit site component Sec16 to regulate export from the ER 
[392]. Given the variability of phenotypes and the number of kinases involved in 





Figure 3-14: Condensed Golgi from MECOM depletion is likely due to JNK 
activation. (A) The condensed Golgi phenotype in MECOM depleted cells is 
reverted back to normal after treatment with 50μM of JNK inhibitor SP600125 for 
sixs hours. Scale bar: 30µm. (B) Quantification of medial Golgi fragmentation in 
cells with (red bars) and without (blue bars) drug treatment substantiates that JNK 
inhibition rescued the condensed Golgi in in EVI1 knockdown. Values on graphs 
117 
 
indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-tailed unpaired t-test, 
relative to untreated control cells.  
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3.2.8 Growth factors and cell surface receptors signal to the Golgi apparatus 
 
Among the confirmed gene depletion affecting most significantly Golgi 
morphology, several cell surface receptors were identified. FGFR2 and IGF1R 
displayed opposite phenotypes, fragmented and condensed respectively, 
suggesting that different signaling cascades can balance each other’s effects on 
the Golgi apparatus (Figure 3-15A and B). These Golgi phenotypes imply that 
cells modulate the secretory pathway in response to ligand binding to these 
receptors.  
 
To test this, I stimulated cells with Insulin-like Growth Factor 1 (IGF-1) or the 
Transforming Growth Factor B1 (TGF-B1). Stimulation of serum-starved HeLa 
cells with 100ng/ml of IGF-1 or 2ng/ml TGF-B1 induced significant 
fragmentation of the Golgi apparatus as early as one hour and for as long as four 
hours (Figure 3-15C and D). This relatively short time-course suggests that these 
cell surface receptors could regulate the secretory pathway relatively directly. 
This is further supported by the rapidity of response to the IGF1R inhibitor 
AG1024, which recapitulates IGF1R depletion (condensed Golgi apparatus) as 







Figure 3-15: Cell surface receptors control Golgi organisation. (A) Correlation 
plot of cis fragmented against cis condensed phenotypic scores from the depletion 
of signaling genes. (B) Golgi staining of different compartments in the depletion 
of cell surface receptors IGF1R and TGFBR1 reveals a typical condensed Golgi 
phenotype. Scale bar: 30µm. (C) Golgi staining after cell stimulation with 
100ng/ml IGF1R ligand IGF-1 for two hours (top) and 2ng/ml TGFBR1 ligand 
TGF-B1 (bottom) for four hours or treatment with the IGF1R inhibitor AG1024 
for one hour (middle). Images were acquired at x60 magnification. Scale bar: 
10µm. (D) Quantification for Golgi fragmentation in IGF-1 (left) and TGF-B1 
stimulation (right) reveal increasing Golgi fragmentation over time of stimulation. 
Values on graphs indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-tailed 






3.2.9 110 Golgi organisation regulators also affect general secretion 
 
The Golgi apparatus plays essential roles in protein sorting. To test whether the 
Golgi regulators that were identified also affect general protein secretion, I have 
generated a HeLa cell line stably expressing secreted Metridia luciferase (Met-
Luc) and the subsequent secretion screens were performed with Dr. Germaine 
Goh. To test this reporter system, the cell line was subjected to RNAi by the pilot 
library of membrane trafficking regulators and the drugs known to affect Golgi 
organisation. Total secretion levels of Met-Luc in the well were measured in the 
supernatant four hours after media change. To normalize Met-Luc secretion 
according to the number of cells, the number of cells was counted from imaging 
nuclei staining.  
 
Not surprisingly, BFA treatment and depletion of several membrane trafficking 
proteins involved in secretion significantly reduced Met-Luc secretion (Figure 3-
16A) which validated our assay. For instance, SAR1A is a GTPase for assembly 
of COPII coats for ER to Golgi transport [397] while v-SNARE VAMP3 is 
involved in post- Golgi trafficking for constitutive secretion [398, 399]. SNAP47, 
that is involved general intracellular membrane trafficking [400], could also 
regulate secretion by mediating intra-Golgi traffic. On the contrary, we identified 
loss of several other SNAREs induced an increase in Met-Luc secretion (Figure 3-
16A). This relatively surprising result was highly reproducible among replicates 
of different wells in the same plate and on different plates, verifying that it was 
not due to experimental variations. A possible explanation is that Met-Luc, being 
an exogenous substrate, is not secreted at full efficiency but is partially diverted to 
intracellular compartments such as lysosomes. A defect in the normal sorting 
machinery would then result in the observed increase in secretion. In support of 
this hypothesis, Syntaxin 16 depletion resulted in Met-Luc hypersecretion (Figure 
3-16A). Syntaxin 16 (STX16) is known to regulate mostly retrograde trafficking 
from the endosomes to the TGN [401, 402]. Its knockdown could therefore be 
expected to perturb sorting from Golgi to lysosomes. Hence, we found various 
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proteins that are involved in different trafficking events to be important for 
constitutive secretion. 
 
Next, the signaling hits were screened for Met-Luc secretion. Both hypo and 
hyper secretion phenotypes were again observed and the amplitude of phenotype 
was comparable to the pilot library results (Figure 3-16B). We found that 62 of 
the gene depletions caused a significant decrease in Met-Luc secretion, while 58 
resulted in increased secretion (Table 3.2). Notably, phosphatidylinositol 4-
kinases PIK4CA (and less prominently, PIK4CB) knockdown led to significant 
inhibition of Met-Luc secretion (Figure 3-16B). This is consistent with their 
critical role in maintaining functional Golgi membranes through PIP4 production 
as mentioned in Section 3.2.7.1. Indeed, the phosphatidylinositol 4-kinases have 
been shown to regulate secretion in cells [138, 403-405]. No clear correlation 
between morphological phenotype and secretion phenotype could be found, 








Figure 3-16: 110 Golgi organisation regulators also regulate constitutive 
secretion. Met-Luc secretion (log of luciferin signal per cell and normalized to 
the average score of transfection reagent-treated control (TR) wells) of (A) genes 
in the pilot membrane trafficking screen and (B) the primary Golgi morphology 
hit genes. Control wells are indicated as in the legend. Some genes on the 







I then further verified the secretion defect for nine hits, that perturb the cis marker 
specifically when depleted, using the well-established VSVG-tsO45G transport 
assay [406]. Briefly, VSVG-tsO45G is a transmembrane protein that contains a 
mutation that leads to its reversible folding and retention in the ER at 40ºC and 
upon temperature reduction to 32ºC, it folds properly and is exported out of the 
ER and proceeds in the secretory pathway. I have generated HeLa cells stably 
expressing VSVG-tsO45G-mcherry and MannII-GFP and tested the kinetics of 
the VSVG release. VSVG was found to accumulate strongly at the Golgi after 15 
to 20 minutes of release from the restrictive temperature of 40ºC. By probing the 
colocalisation of VSVG-tsO45G with the Golgi marker MannII-GFP at 15 
minutes after release from the restrictive temperature, I was able to assess more 
specifically and quantitatively the ER to Golgi trafficking step. In agreement with 
the Met-Luc secretion data, depletion of six genes induced a significant reduction 






Figure 3-17: Most Met-Luc secretion hits also affect ER to Golgi trafficking 
of VSVG-tsO45G protein. (A) ER to Golgi trafficking of VSVG-tsO45-mcherry 
is impaired in the depletion of most genes that display both cis diffuse Golgi and 
reduced Met-Luc secretion phenotypes. (B) Pearson’s correlation coefficient of 
Golgi marker MannII-GFP and VSVG at 0 minutes (blue bars) and 15 minutes 
(red bars) after change to permissive temperature at 32ºC. Cells were analysed 
using Metaexpress Translocation-Enhanced analysis module. Values on graphs 
indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-tailed unpaired t-test, 






3.2.10 146 Golgi organisation regulators also affect glycan biosynthesis 
 
I, in collaboration with Dr. Germaine Goh, sought to evaluate whether the 
perturbations in Golgi organisation resulted in changes in cell surface glycan 
patterns. Cell surface glycans were studied because they are the final products 
after the passage through the Golgi. Hence, they would reflect glycosylation 
defects along the biosynthetic pathway. An increase in premature glycan 
structures and a decrease in end-capping glycans on the cell surface would 
indicate defects in the early glycan synthesis. The prominent glycans in most cell 
types are N-glycans and O-GalNAc glycans. Therefore, we selected eight 
fluorescent lectins with different specificities that are known to bind the main N- 
and O-glycan structures (Figure 3-18A). We included the intracellular staining 
intensities of HPL that was used in the primary screen in this analysis.   
 
To evaluate the range of lectin staining variation that could be expected and to test 
the specificities of the lectins, various enzymes and/ or sugar transporters were 
knocked down and lectin fluorescence signals were quantified. For each lectin, we 
could obtain significant changes in staining upon depletion of enzymes or 
transporters involved in the specific glycosylation processes, consistent with their 
expected specificity (Figure 3-18B and further elaborations are found in Materials 
section of Chapter 2). For example, depletion of the Golgi-localized UDP-
GlcNAc transporter SLC35A3 reduced staining by ECA, which binds mostly the 
common disaccharide Gal-GlcNAc. Alternatively, knockdown of the 
fucosyltransferase 8 (FUT8) reduced staining with LCA, a fucosyl-specific lectin 
(Figure 3-18C). These genes, hence, serve as positive controls for our secondary 







Figure 3-18: Eight fluorescent lectins that display different glycan 
specificities were chosen probe N- and O-glycan expression patterns. (A) A 
schematic of the main glycan structures recognised by the lectins used in the 
secondary screening. (B) Overview of the validation of lectin specificities 
(elaborations found in Material section in Chapter 2). (C) Erythrina cristagalli 
lectin (ECA) and Lens culinaris agglutinin-A (LCA) lectin staining were 
dramatically reduced in cells depleted of Golgi UDP-GlcNAc transporter 
SLC35A3 and fucosyltransferase FUT8 respectively. Cells were imaged under 




We next proceeded with the secondary screen for the identified 181 primary Golgi 
morphology hits using the seven lectins on non-permeabilized fixed cells (Table 
3.2). For most lectins, we noted a trend of slightly higher staining intensity values 
per cell in wells with lower cell number (Figure 3-19A). By fitting this systematic 
shift into a standard curve, followed by measuring the deviation of lectin 
intensities of each gene depletion from the curve, we derived a “normalized lectin 
signal” for each gene. This, thus, would eliminate the variability of lectin signals 
due to cell number (Further elaborated in methods section in Chapter 2). 
 
We found the lectin fluorescence staining highly reproducible in our experimental 
conditions demonstrated by the tight distribution of the multiple control wells 
comprising of untransfected cells (Figure 3-19B). High reproducibility between 
experimental replicates for each lectin staining was also observed (not depicted). 
Based on the distribution of lectin staining in the control wells, we defined the 
thresholds of significance as a normalized lectin signal of >4 or <-4 (Figure 3-19B 
and C). The former indicates significantly increased lectin staining while the latter 
indicates significantly decreased lectin staining. Strikingly, most (146/159) of the 
validated Golgi morphology hits resulted in a significant change of intensity for at 
least one lectin (Figure 3-19D). Interestingly, siRNA knockdown of several 
signaling genes resulted in lectin staining changes similar to or more pronounced 
than the respective positive controls. For example, while knockdown of UDP- 
GlcNAc transporter SLC35A3 induced a ~35% reduction of ECA staining, 
FGFR1 depletion showed ~40% reduction and DGKZ targeting resulted, 









Figure 3-19: Most signaling proteins regulate Golgi morphology and glycans 
expression. (A)  DSL lectin intensity per cell (arbitrary units) against cell count 
for each of the hit genes (red) and control wells (black). Each data set is fit to a 
log equation and the resulting fits (solid lines) represent the expected intensity 
under unperturbed conditions. A normalized lectin signal for each gene is then 
calculated in relation to the mean absolute deviation of control wells, as a measure 
of extent of perturbation (see Methods section in Chapter 2 for further 
elaborations). (B) Normalized lectin signals of control wells (black) in 
comparison with signaling genes (colored), for all lectins tested. Dotted lines 
indicate hit cutoff values of <4 and >4. (C) Complete zoomed out plot of (B), with 
some extreme genes labeled. Yellow filled circles represent the normalized lectin 
signal for control genes (indicated below lectin names). (D) Overview of the 
distribution of the number of lectin hits per gene. The corresponding numbers of 







Figure 3-20:  A high diversity of glycophenotypes could be observed in 
signaling gene depletions. (A) Plots of pairwise comparisons between the 
normalized lectin signals for the eight different lectins. Squares on the bottom left 
of the diagonal are scatter plots of lectin intensities of the primary hits while 
squares on the top right of the diagonal contain the Pearson’s correlation 
coefficients between the paired lectins. (B) Principal Component Analysis plot of 
the seven lectin scores (excluding HPL) for each hit gene. Genes are color coded 
according to the six Golgi morphology groups as indicated. Inset: Eigen vectors 
with the respective lectins labeled. 
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Surprisingly, results for most of the lectins across the whole screen did not 
correlate significantly with each other (Figure 3-20A). Yet, the effects were 
highly reproducible between replicates. Furthermore, two lectins, DSL and PHA-
L, which are both proposed to bind tri and tetra-antennary glycans did correlate 
well with each other (Figure 3-20A). This indicates that the lack of correlation 
between lectin staining reflects a real biological phenomenon. It suggests that 
different signaling genes affect different glycosylation pathways.  
 
This complexity is apparent in the PCA of the lectin staining data (Figure 3-20B). 
PCA demonstrates consistency with the biology of glycans. Indeed, the Eigen 
vectors organizing the PCA (black arrows in Figure 3-20B) are aligned in two 
groups, oriented at 90 degrees from each other. One corresponds roughly to short 
glycan structures, i.e. ConA, PNA, ECA and LCA lectins and the other to 
elongated glycan structures, i.e. MAL, PHA-L and DSL lectins. However, in 
contrast with the PCA of the morphological signatures (Figure 3-5E), the lack of 
clear groups formed by the signaling genes illustrates that their effects on glycan 
expression are quite diverse.  
 
 
3.2.11 A complex interaction between signaling genes and the regulation of 
glycosylation 
 
Glycan synthesis in the Golgi apparatus comprises several pathway functioning in 
parallel, mainly but not exclusively N- and O-GalNAc glycosylation [407]. Even 
within the N-glycosylation pathway, it is unclear whether different glycosylation 
reactions such as fucosylation or sialylation are coordinated. Our results indicate 
that changes in the efficiency of glycosylation reactions can occur relatively 
independently of each other’s.  
 
This variability of effects on glycan expression prompted us to define a glycan 
profile for each gene by incorporating the data for the eight lectins in one plot, 
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similar to the Golgi morphology signature (Figure 3-21). Not surprisingly given 
the diversity of the glyco- and morpho-phenotypes, glycan profiles did not 
correlate tightly with specific Golgi morphological parameters. However, some 
general trends surfaced: the glycan profile tends to show a general decrease in 
lectin intensities when the Golgi adopts a condensed morphology whereas 
fragmentation tends to yield generally increased lectin intensities (Figure 3-20B).  
 
The variety of glycan profiles is illustrated by some examples with one lectin 
staining and the overall glycophenotype displayed (Figure 3-21) and the results 





Figure 3-21: The variety of glycophenotypes of the Golgi hits is illustrated by 
glycan profiles. Glycan profiles (top), lectin staining (middle) and the targeted 
glycan structures (bottom) of representative hit genes. Axis values indicate 
normalized lectin signals and solid lines delineate cutoff values (-4 or 4) on 
glycan profiles.  
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Table 3.2. 181 primary hits with nine Golgi morphology scores and 
corresponding phenotypic signature pictogram, deconvolution validation 
status, 8 lectin-binding scores and corresponding glycan profile pictogram, 





































































Cells colored in yellow or pink indicate score above or below positive and 






My screen results reflect the morphological plasticity of the mammalian Golgi 
apparatus, as illustrated by the great variety of phenotypes observed. Golgi 
plasticity was initially revealed through the effect of drugs such as Brefeldin A, 
which induces a dramatic dispersion of Golgi membranes in a short amount of 
time [408]. This phenomenon is linked to the highly dynamic nature of this 
organelle, which is constantly receiving and dispatching membrane material 
[409]. 
 
As shown in the pilot screen, transient depletion of membrane trafficking-related 
proteins such as SNAREs can drive significant Golgi morphological 
modifications, presumably through the impairment of specific trafficking events. 
Indeed, it is known that the Golgi integrity is inextricably linked to the steady 
state balance of membrane trafficking events and perturbing the rates of 
trafficking has profound effects on its structure [410]. Although the precise 
mechanistic links between these protein depletions and the observed phenotypes 
are not entirely clear at present, some observations were made: proteins acting in 
specific Golgi trafficking pathways tend to show Golgi compartmental-specific 
effects and proteins that participate in common pathways often yield similar 
phenotypes. For instance, depletions of VAMP7 and AP-1 complex that act in 
trans Golgi trafficking result in trans Golgi specific perturbations. In contrast, 
knockdown of syntaxin 5 that is involved in ER to Golgi traffic affects 
predominantly the cis-Golgi. Similar phenotypes were also observed with GS27 
and Sec22b that work with syntaxin 5, implying that the observed cis-Golgi 
effects could be due to an impairment of ER to Golgi traffic. However, it was not 
obvious for most other SNAREs, presumably because of the promiscuous activity 
of the SNAREs [411, 412]. It could also be due in part to the difficulty in 
interpreting Golgi phenotypes. For example, fragmented Golgi phenotypes could 
reflect changes in the links between stacks and/or their interaction with the 
underlying cytoskeleton. Yet, it is clear that there are various types of fragmented 
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phenotypes, which can be detected by a trained human eye. Fragmented 
phenotypes are also associated with various effects on constitutive secretion and 
glycan synthesis, suggesting different molecular perturbations at the Golgi level. 
 
Nevertheless, Golgi morphological perturbations can help reveal the genetic 
regulation of this organelle. The signaling genes screen uncovered that 159 
signaling genes, or 20% of the tested set, are implicated in the regulation of the 
Golgi apparatus. This proportion may appear surprisingly high, however, other 
evidence support this result. First, in public databases, over 850 different 
phosphoproteins are associated with Golgi membranes. Second, numerous 
signaling proteins have been localized on Golgi membranes, and their importance 
for this organelle is starting to be revealed through various screening approaches 
[127, 392, 413, 414]. Third, several of my hits or their close homologs are 
validated by the previous literature. For example, SCYL3 display a clear diffuse 
trans Golgi phenotype in my screen, suggesting a possible redistribution of 
TGN46 to the ER. In recent years, it has been well established that a close 
homolog, SCYL1, binds the COPI coat and regulates both retrograde traffic and 
Golgi morphology [415, 416]. SCYL2, alias CVAK104, has been proposed to 
mediate clathrin-coated vesicles formation at the TGN [417]. Together, these data 
suggest that the SCY-1-like family of catalytically inactive protein kinases have 
similar roles in regulating membrane traffic. To note, neither SCYL2 nor SCYL3 
contains the COPI binding site identified in SCYL1 [416]. 
The Golgi apparatus is a complex but coordinated structure, which can be 
conceived as built up of various modules interacting with each other’s [418]. The 
kinases, phosphatases, associated proteins and phosphoproteins that I identified 
are likely to regulate some of these modules and function to coordinate them. As 
the Golgi apparatus is relatively constant in shape and function in a given cell 
population, these signaling molecules acting on the Golgi can be conceived as a 
large interconnected regulatory network. For the most part, how this network is 
regulated and what it regulates remains mostly unknown.  
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An exception is the regulation of the phosphoinositide PIP4 and related lipids in 
Golgi membranes. PIP4 is known to have multiple effectors in Golgi membranes, 
its regulation is therefore critical for Golgi physiology [419]. Another exception is 
the regulation of acto-myosin dynamics, shown to be critical for the formation of 
transport intermediates both at the TGN and at the CGN [420]. 
Some of the lipid and protein kinases and phosphatases present in these two 
subnetworks are known to respond to extracellular stimulations, which could 
therefore regulate Golgi physiology. Consistently, I also found that several cell 
surface receptors such as IGFR, TGFBIIR, EGFR or FGFR and their cognate 
ligands affect strongly Golgi organisation. Cells appear, therefore, to respond to 
various stimuli by modulating membrane trafficking events at the Golgi level. 
Cells also respond to endogenous signals to maintain homeostasis. Endogenous 
signaling in the secretory pathway has been well described for the unfolded 
protein response for example [421]. Protein cargo load could also constitute a 
signal for transport carrier formation that could engage kinases such as PKD [137] 
or Src [422]. Therefore, it is likely that the large regulatory network that was 
uncovered from my screen is responsible both for the maintenance of Golgi 
homeostasis and for adapting Golgi functions to changing extracellular 
conditions. It has been shown recently that the flux of protein trafficking in the 
secretory pathway is under the control of a MAPK cascade at the level of the ER 
exit sites [361, 392, 413]. Additional layers of regulation of secretion probably 
function at the Golgi level as was shown recently in pancreatic B cells for insulin 
secretion [423]. This Golgi-localized regulation could possibly act through the 
modulation of sorting events, as suggested by the hyper-secretion of the Met-Luc 
reporter. An attractive hypothesis is that not all cargo will be similarly regulated, 
explaining perhaps partially the complexity of this regulatory network. 
In addition, the results suggest that glycosylation is a major target of regulation by 
signaling networks. Although the precise mechanisms are not known at present, 
the extensive co-occurrence of perturbations in Golgi morphology and glycan 
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expression argues that depletion of signaling genes affects glycan expression 
through Golgi organisation modifications. 
Golgi glycosylation is a complex process and signaling could affect multiple 
mechanisms [424]. For example, lumenal pH could be modulated; it has been 
shown to affect strongly some glycosylation reactions [289]. Alternatively, the 
organisation of the Golgi stacks in a network could have a critical role in 
glycosylation, for example by regulating the kinetics of transport and therefore the 
interaction between substrates and enzymes [50]. Another hypothesis is that 
glycosylation is regulated through the cisternal distribution of glycosylation 
enzymes. Indeed, our analysis did detect obvious changes in cisternal 
organisation. This is exemplified by the dissociation of GalNAc-Ts from 
Mannosidase II (HPL and MannII-GFP markers) observed in various gene 
depletions leading to strong cis diffuse but normal medial Golgi.  
As shown recently, GalNAc-Ts’ activity can be regulated by affecting their 
intracellular distribution through inducible and specific COPI-dependent transport 
[193]. By extension, it is possible that other Golgi proteins such as sugar 
transporters, anion channels or glycosylation enzymes are packaged and 
redistributed in a specific manner. In favor of this hypothesis, emerging evidence 
show that Golgi enzymes can be associated with specific adaptors to direct their 
trafficking [213]. Furthermore, the cytoplasmic tails of different Golgi enzymes 
have been shown to interact with different cytosolic proteins [425-428], 
suggesting that they could be differentially trafficked. 
The modulation of glycosylation enzymes expression is arguably the favored 
mechanism so far to explain changes in glycan expression [283, 429]. Golgi 
remodeling would represent an alternative, faster mechanism. It could explain the 
fast changes in glycan expression observed for example during stem cell 
differentiation programs [430]. Golgi reorganisation would also be an efficient 
and transient way to regulate cell-cell and cell-matrix adhesion as glycans have 
been shown to mediate these processes [159]. Furthermore, the cell surface glycan 
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changes required for apoptotic phases are likely to stem from the Golgi 
fragmentation that occurs early in apoptosis [431].   
As signaling pathways are often modified in cancer cells, our results may help 
explain some of the abnormal Golgi morphologies commonly observed in cancer 
cell lines [432]. Alterations in signaling pathways could also potentially explain 
some of the numerous perturbations of glycoprotein profiles observed in cancer 
and studied as biomarkers [433, 434]. Overall, our data suggest a complex web of 
interaction between signaling cascades and the product of Golgi biosynthetic 
activity, the glycans. There is likely an exquisite regulation of Golgi organisation 
by different signaling pathways leading to a diversity of glycan expression 
patterns, each having a unique, distinct role in mediating cellular biology (Figure 
3-22). The glycosylation of cell surface receptors is known to affect their stability 
and signaling potential [435]. Therefore, it is likely that the regulation of glycan 
expression will, in turn, impact signaling cascades (Figure 3-22). 
The cells from complex organisms such as mammals have evolved a capacity to 
integrate multiple extracellular signal inputs into their physiology, allowing for 
the coherent behavior of cellular assemblies. Cellular interactions are mainly 
controlled by cell surface glycoproteins, which are modified and sorted at the 
Golgi apparatus. Our study highlights that signaling cascades control Golgi 





Figure 3-22: A model of Golgi organisation and glycosylation regulation. 
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GalNAc type O-linked glycans are polysaccharides present on secreted and 
membrane inserted proteins [242]. Traditionally associated with mucins and 
mucin-like proteins, recent advances in mass spectrometric analysis have revealed 
hundreds of different proteins, many do not exhibit mucin-like features, bearing 
O-glycans [436]. The function of O-glycosylation for most of these proteins is 
poorly understood but recent results have highlighted examples of its critical role 
in functional regulation. For instance, O-glycosylation of the growth factor 
FGF23 regulates its secretion [248, 437] and processing of the lipid homeostatic 
factor ANGPTL2 is dependent on its glycosylation status [249]. 
 
O-glycans are synthesized through the step-wise action of various glycosylation 
enzymes at the Golgi. Among these are the UDP-N-Acetyl-Alpha-D 
Galactosamine: Polypeptide N-Acetylgalactosaminyltransferases (GalNAc-Ts, a 
large family of twenty different isoforms, that catalyzes the initiating sugar 
residue known as N-Acetylgalactosamine (GalNAc) onto serine and threonine 
residues of O-glycosylated proteins [241].  
 
GalNAc addition on proteins, in its terminal form, generates the Tn antigen. 
Earlier work demonstrated that Tn antigen is highly expressed in carcinomas. The 
high prevalence and specificity of this cancer glycophenotype are remarkable, 
with corresponding normal tissues and benign tumors expressing much lower 
levels. Tn increases were also found to correlate with metastatic potential and 





The Tn antigen is specifically detected by antibodies and lectins such as Helix 
pomatia (HPL) and Vicia Villosa Lectin (VVL) which have been commonly used 
to detect Tn levels in carcinoma samples [438, 439]. Antigenicity to Tn is lost 
upon the addition of further sugar residues, hence, explaining the low Tn levels in 
normal tissues where GalNAc is rapidly modified by downstream O- GalNAc 
modifying enzymes. 
 
It has been proposed that increase in Tn levels stem from a block or reduction in 
the activity of the main O-GalNAc–modifying enzyme, the Core 1 Galactosyl-
Transferase (C1GalT) [216, 264, 266, 424]. Loss of C1GalT in the high Tn-
expressing T cell leukaemia Jurkat cell line has indeed been reported [267]. 
 
Another mechanism was found recently to underlie high Tn levels in cancers. In 
breast carcinoma and various cancer cell lines, high Tn levels are largely due to 
the massive relocation of GalNAc-Ts from the Golgi to the endoplasmic 
reticulum (ER) with Tn staining largely located in the ER [194]. O-glycosylation 
initiation in the ER in some cancer cells had also been reported earlier by others 
[440].  
 
Trafficking of GalNAc-Ts to the ER can be stimulated by growth factors such as 
epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) [193]. 
GalNAc-Ts are specifically relocated as other glycosylating enzymes are not 
affected. These enzymes are active in the ER and GalNAc incorporation in 
proteins increases after relocation [193]. Glycosylation of ER-resident proteins 
likely explains the observed increase in Tn staining, as several of these proteins 
bear O-GalNAc in mass spectrometric analyses [436]. 
 
Although it is still unclear which specific proteins are modified and how their 
function might be affected, O-glycosylation in the ER has a marked stimulating 
effect on cell adhesion and cell migration [194]. This suggests that ER O-
glycosylation promotes the invasiveness and metastatic potential of malignant 
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tumor cells. Tn levels are consistently higher in higher grade, more aggressive 
breast tumors. Conversely, ER-specific inhibition of O-glycosylation reduced 
drastically lung metastasis in a mice model [194]. Thus, the precise subcellular 
location of GalNAc-Ts has important physiological effects.  
 
GalNAc-T transport is stimulated by the Src tyrosine kinases and mediated by 
COPI- dependent trafficking [193]. COPI transport carrier formation requires the 
assembly of the COPI coat which is a multimeric protein complex that functions 
in the retrograde traffic between the Golgi and the ER [441, 442]. The assembly 
of coat components is regulated by small GTPases of the Arf family and their 
regulator, the GTP Exchange Factor, GBF1. However, the regulation of COPI-
coated carrier formation in response to extracellular signals and how signaling 
proteins might act to regulate COPI carrier formation are poorly understood. In 
addition, apart from Src, what are the other signaling proteins regulating Tn 
expression are not known.   
 
Given that signaling proteins are often modified in cancer, I further explored the 
role of signaling regulation on Tn expression. In this chapter, I describe the use of 
RNAi screening to identify signaling regulators of Tn expression. This would help 
to gain mechanistic insights to Tn expression in cancer and provides potential 
therapeutic targets for Tn-related cancer therapy.   
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4.2 RESULTS: RNAi screening identifies ERK8 as a negative regulator of O- 
GalNAc glycosylation and cell migration. 
 
 
4.2.1 RNAi screening identifies 12 signaling genes negatively regulating Tn 
levels. 
 
Tn can be detected by glycan binding proteins such as the Helix Pomatia Lectin 
(HPL) [439]. The levels of Tn expression can, hence, be measured from the 
amount of HPL binding. As described in Chapter 3, I utilized a fluorophore 
conjugated HPL to mark the Golgi in the primary RNAi screen. Using the same 
dataset, I quantified the total HPL intensities and the nuclei number to obtain the 
levels of Tn expression per cell. The automated image analysis module 
(Transfluor HT) on the MetaXpress software (Molecular Devices) was employed 
for intensity quantification. The analysis involved setting an intensity threshold to 
classify the region of measurement for HPL and nuclei staining and the intensity 
of each pixel within the masking was quantified (Figure 4-1A). The pilot screen 
with 63 membrane trafficking regulators revealed that knockdown of Syntaxin 5 
(STX5) induced a six- to seven-fold increase in HPL intensities relative to a non-
targeting control (GFP siRNA) (Figure 4-1A). STX5 and GFP siRNAs were 
included as controls in the primary screen of 948 signaling genes. In this study, I 
used them as positive and negative controls respectively to evaluate effects on O-
glycosylation. Out of the 948 siRNA pools, 134 that reduced cell number below 
20% of average cell number in non-targeting control wells were first excluded 
from further analysis (Figure 4-1B).  
 
Interestingly, knockdown of several signaling genes was observed to increase 
HPL levels significantly more than STX5 (Figure 4-1C). The increases were 
highly reproducible between the two independent replicates, verifying that the 
phenotypes were not due to experimental variations (not depicted). Staining 
intensities of the multiple wells of STX5 knockdown were tightly distributed; 
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further demonstrating reproducibility of the lectin staining and between replicates 
(Figure 4-1C). The trend was mostly independent of the analysis algorithm used. 
Quantification by both the MetaXpress software and the HCS analysis algorithm 
(described in Chapter 3) were highly correlated (R2= 0.93), indicating that the 
results were consistent across different analysis softwares. The effects observed 
were not specific to the detection method as a highly consistent pattern could be 
observed in the staining with VVL, a different lectin specific to Tn antigen (not 
depicted). 
 
To focus my analysis, I applied a stringent cut-off of nine-fold increase in HPL 
intensity, significantly above that of STX5 depletion, to select for 19 primary hits 
(Figure 4-1B and C). To exclude the possibility of off-target effects in these 
primary hits, I repeated the screen using the four independent siRNAs that were 
used in the original pools in the primary screen. With the criteria of having 
significant HPL increases in at least two independent siRNAs, 12 genes were 








Figure 4-1: RNAi screening revealed 12 negative regulators of Tn expression.          
HeLa cells stained with Helix pomatia lectin (HPL) and nuclei (Hoechst) were 
quantified for HPL intensities using “Transfluor HT” module of MetaXpress 
software (Molecular Devices). A mask was generated for both HPL and nuclei 
staining by setting an intensity threshold to classify the regions of measurement 
(lower panels). Shown here, knockdown of the positive control STX5 (STX5 KD) 
resulted in seven-fold increase in HPL intensities compared to the non-targeting 
control. Scale bar: 30µm. (B) A schematic overview of the screening process. 
HPL and nuclei stained images from the RNAi screen in [443] were quantified for 
HPL intensities. (C) Plot of fold changes of HPL intensities normalized to non-
targeting (NT) siRNA treatment (green). A number of genes showed significantly 
higher HPL increases compared to positive control STX5 (orange). 19 primary 
hits were selected based on a threshold of nine-fold increase (red dashed line) and 
the 12 deconvoluted siRNA validated genes are labeled red. 
 
 
Among the validated hits, I found that depletion of atypical Ser/Thr kinase 
Mitogen-Activated Protein Kinase 15 (MAPK15, alias ERK8) [444] induced a 
particularly marked increase in Tn levels (Figure 4-2A). The phenotype was not 
likely due to an siRNA off-target effect as knockdown with three out of the four 
single siRNAs (deconvoluted siRNA) from the pool as well as other RNAi 
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reagents such as short hairpin RNA (shRNA) and microRNA (miR RNA) 





Figure 4-2: Depletion of ERK8 results in dramatic increase in Tn levels. (A) 
HPL staining intensities in ERK8 depleted HeLa cells showed pronounced 
upregulation. The staining appeared diffuse-looking and was not confined to the 
perinuclear localization observed in untransfected control cells. The general Golgi 
structure as reflected by Mannosidase II (MannII-GFP) was not affected. Scale 
bar: 30μm. (B) Knockdown with three out of four single siRNAs (deconvoluted 
siRNA: dERK8-1 to -4) of the pool or depletion with alternative RNAi methods 
such as microRNA (BLOCK-iT miR RNAi from Invitrogen) (Illustrated in C) and 
short hairpin RNA (shRNA) reproduced significant Tn increases, substantiating 
that the ERK8 depletion phenotype was not likely an off-target effect. Values on 
graphs indicate mean±SEM.  **p<0.0001, *p<0.05 by two-tailed unpaired t-test, 
relative to NT siRNA-treated cells. (C) Transfection of GFP tagged miR RNAi 
ERK8 vector (miR-ERK8 bottom panels) induced appreciable Tn increases in 
cells while those transfected with the empty miR RNA vector (miR-Vector; top 




Tn increase was also apparent when ERK8 was depleted in the ovarian cell line 
Skov3. Loss of ERK8 led to a diffused, cytoplasmic HPL staining as compared to 
the predominantly perinuclear staining in untransfected control or non-target 
siRNA treated cells (Figure 4-3A). Appreciable increase in Tn levels was also 
observed when most of the hits were depleted in Skov3 cells (Figure 4-3B), 






Figure 4-3: Upregulation of Tn in ERK8 depletion and most hits is conserved 
across cell lines. (A) ERK8 knockdown in Skov3 cells induced a similar 
phenotype as that in HeLa cells. HPL staining in ERK8 knockdown cells 
appeared diffuse- looking and cytoplasmic with multiple punctuate structures. The 
Golgi (MannII-GFP) showed some signs of fragmentation in some cells. (B) Tn 
levels were significantly elevated when most of the hits were depleted, validating 
that the phenotype is not cell-type specific. Values on graphs indicate 




In addition, to further validate that the genes control the GalNAc O-glycosylation 
of proteins, I next sought to downregulate the responsible enzymes. Although 
GalNAc-Ts represent a large family of enzymes, the -T1 and -T2 isoforms are by 
far the most prevalent and represent most of the activity in HeLa cells [241]. This 
is apparent in the almost completely abolished Tn levels when GalNAc-T1 and -
T2 are depleted (Figure 4-4A and B). Not surprisingly, co-depletion of the two 
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enzymes also reduced significantly the Tn increase from the knockdown of ERK8 
as well as the other Tn regulators (Figure 4-4A and B). This effect was not due to 
inefficient protein knockdown as ERK8 levels were still significantly reduced in 
the triple knockdown configuration (Figure 4-4C).  
 
Overall, the screen revealed a number of negative regulators of Tn levels which 
highlighted that the O-GalNAc glycosylation process appears to be tightly 







Figure 4-4: Tn increases are predominantly due to GalNAc-T1 and –T2 
activity. (A) Co-knockdown with GalNAc-T1 and –T2 significantly reduced the 
increased Tn levels from ERK8 depletion. Scale bar: 30μm. (B) Co-knockdown of 
each of the 12 Tn regulators with GalNAc-T1 and –T2 resulted in substantial 
rescues of Tn expression. (C) SDS-PAGE analysis of ERK8 expression levels in 
single and co-knockdown with GalNAc-T1 and –T2 validated the efficiencies in a 
triple knockdown configuration. Values on graphs indicate mean±SEM.  







4.2.2 Negative regulators of Tn expression are not required for O-glycan 
extension. 
 
I next sought to establish the mechanism by which signaling genes control O-
GalNAc glycosylation. As mentioned in Section 4.1, two mechanisms are known 
to increase Tn levels: inhibition of O-GalNAc glycan chain extension [266, 267] 
or relocation of GalNAc-Ts from the Golgi apparatus to the ER [193]. However, 
different phenotypes were found to arise from the two mechanisms: for instance, 
loss of expression of C1GalT or its molecular chaperone Cosmc resulted in failure 
to generate the subsequent Core 1 glycan structure, also known as the Thomsen- 
Friedenreich (TF antigen), which can be detected with the PNA lectin  [445]. By 
contrast, our group has previously reported that relocation of GalNAc-Ts from the 
Golgi to ER induces a modest but measurable increase in PNA staining [194]. 
 
To distinguish between the two possibilities responsible for Tn expression, I first 
tested if C1GalT activity is perturbed. Each of the 12 Tn regulators were depleted 
and the fluorescence staining intensity of PNA in the cells was quantified. I also 
measured the PNA staining in Cosmc knockout cells, which lack C1GalT activity, 
as the positive control. As expected, loss of Cosmc almost completely abolished 
PNA staining (Figure 4-5A). On the other hand, there was either no significant 
decrease or some increases in PNA staining levels when each of the 12 Tn 
regulators were depleted (Figure 4-5A). Similar trends were observed when the 
genes were depleted with single siRNAs from the pooled version shown in Figure 
4-5A, verifying the phenotype observed (not depicted). Increase in PNA levels 
seemed to correlate with Tn increases and was one of the most significant with 
ERK8 knockdown. Staining intensities of PNA on the cell surfaces of ERK8 
depleted cells (non-permeabilised) paralleled the increases in intracellular 
staining, suggesting that a large proportion of O-glycan chains remain unextended 
during their passage through the Golgi (Figure 4-5B). Supporting this, ERK8 
depleted cells displayed pronounced reduction in extended O-glycan structures as 
marked by the Datura stramonium lectin (DSL) that was shown in the previous 
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chapter (Table 3.2). Finally, my results indicate that none of the Tn regulating 





Figure 4-5: The identified Tn regulators do not control O-glycan extension. 
(A) Knockdown of each of the 12 Tn regulators did not reduce PNA lectin 
staining intensities significantly as shown with Cosmc knockout cells. This 
suggests that C1GalT activity was not affected when the genes were depleted, 
hence Tn increases were not due to lack of core 1 forming activity. Values on 
graphs indicate mean± SEM.  **p<0.0001, *p<0.05 by two-tailed unpaired t-test, 
relative to non- targeting siRNA treated cells.  (B) ERK8 depleted cells displayed 
increases in intracellular and cell surface peanut agglutinin lectin ( PNA) staining. 
Scale bar: 30μm. 
 
 
4.2.3 Tn levels depend on GalNAc-Ts subcellular localization. 
 
The other phenotypic difference between the two regulatory mechanisms is the 
intracellular distribution of the Tn antigen. In cases of C1GalT activity loss, Tn is 
mostly localized at the cell surface and Golgi, and not the ER, whereas it is 
mostly in the ER when GalNAc-Ts are relocated [194]. I next probed if the 
increase in Tn expression was due to the latter case by evaluating the subcellular 
distribution of GalNAc-Ts using specific antibodies for immunofluorescence 
staining. In control cells, GalNAc-T1 localised exclusively in the perinuclear 
region and co-localizes with Golgi marker MannII (Figure 4-6A). Upon ERK8 
depletion, GalNAc-T1 localisation was shifted from a perinuclear location to a 
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diffuse distribution, which co-localizes with ER marker Calreticulin (Figure 4-
6A). This was also observed in GalNAc-T2 staining (not depicted). By contrast, 
the medial Golgi N-glycosylation enzyme MannII-GFP remained mostly 
perinuclear, suggesting that the relocation event was specific to GalNAc-Ts in 
ERK8 depletion. MannII-GFP positive structures appeared more fragmented than 
in untreated cells, reminiscent of the effects of Src activation. Indeed, active Src 
induces GalNAc-Ts relocation to the ER with limited fragmentation of the rest of 
the Golgi [193]. Depletion of another major regulator of Tn, the 
phosphatidylinositol (PI) 4-kinase (PIK4CA), also resulted in redistribution of 
GalNAc-Ts from a perinuclear localization (Figure 4-6A). Hence, high Tn levels 
appear to derive from the ER relocation of the GalNAc-T enzymes in these two 
cases. However, in contrast with ERK8, MannII-GFP appeared to also redistribute 
to a cytoplasmic pattern upon PIK4CA depletion (Figure 4-6A). In fact, the entire 
content of the Golgi apparatus was redistributed to the ER in PIK4CA knockdown 
as a similar pattern was observed with trans Golgi marker TGN46 and general 
protein secretion was blocked (Table 3.2). 
 
I extended the analysis to the other Tn regulating genes using a quantitative 
approach. To measure the extent of ER relocation, the colocalisation between 
GalNAc-T1 and Calreticulin staining was measured. Mean Pearson’s correlation 
coefficient (MPCC) between the two markers was significantly increased in the 
knockdown of each of the 12 genes (Figure 4-6B). Similar trends were observed 
in the depletions with single siRNAs from the siRNA pools used in Figure 4-6B, 
further verifying the phenotype observed (not depicted). Most gene depletions 
exhibited similar MPCC levels as Brefeldin A (BFA) treatment which have been 
shown to redistribute Golgi proteins to the ER [446]. In contrast, GalNAc-T1 
localisation in the Cosmc knockout cell appeared similar to non-targeting siRNA 
treated cells (Figure 4-6B). Similar trends were also observed for GalNAc-T2 
staining (Figure 4-6C). In addition, high Tn levels in each of the gene depletions 
was not due to increased expression levels of GalNAc-Ts. This is based on the 
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quantification of total cellular GalNAc-T1 and –T2 staining intensities in each 
gene knockdowns (data not shown). 
 
 
Next, I determined if GalNAc-Ts are specifically relocated in the knockdown of 
the other Tn regulators ie. if the phenotype is similar to ERK8 depletion. I probed 
for the integrity of the MannII-GFP staining by measuring the co-localization 
between MannII-GFP and Calreticulin. As expected from visual observations in 
Figure 4-6A, PIK4CA depletion resulted in significant co-localisation between the 
two markers, similar to, if not stronger than, BFA treatment (Figure 4-6D). In 
contrast, depletion of the other Tn regulators did not affect MannII-GFP 
localisation as dramatically as PIK4CA.  
 
Collectively, the results suggest that GalNAc-Ts subcellular distribution plays a 
central role in how signaling cascades can influence Tn staining levels. Other 
factors may also be at play, but the down-regulation of C1GalT activity does not 
appear to be a major hub regulated by the identified signaling genes. Finally, it 
appears that most genes that were identified, with the exception of PIK4CA, 







Figure 4-6: Tn regulators control Tn expression through GalNAc-T 
subcellular localisation. (A) Immunofluorescence staining for endogenous 
GalNAc-T1 with Golgi (MannII-GFP) and ER (Calreticulin) markers revealed 
that the enzyme appeared to localise at the ER in ERK8- and PIK4CA-depleted 
cells. Medial Golgi MannII enzyme remained predominantly at the perinuclear 
region when ERK8 is depleted while it was diffused and appeared more 
cytoplasmic in PIK4CA knockdown. Scale bar: 10 μm. (B) Colocalisation 
between the GalNAc-T1 and Calreticulin was measured using Mean Pearson’s 
correlation coefficient (MPCC) of the staining intensities of the two staining. 
Cells were analysed using MetaXpress Translocation-Enhanced analysis module. 
(C) Quantification of MPCC between GalNAc-T2 and Calreticulin staining 
revealed significant increases in GalNAc-T2 co-localisation with ER marker upon 
depletion of each of the 12 genes. (D) Quantification of MPCC between MannII 
and Calreticulin staining revealed that MannII localisation in cells depleted with 
each of the hit genes were not as perturbed as PIK4CA depletion, suggesting that 
ER relocation was specific to the GalNAc-Ts in these gene knockdowns. Values 
on graphs indicate the mean±SEM. **p<0.0001, *p<0.05 by two-tailed unpaired 





4.2.4 Bioinformatics analyses reveal a putative complex network of Tn 
regulators acting at the Golgi apparatus. 
 
To explore how the identified genes might be functioning, I retrieved data 
pertaining to their subcellular localisation and protein-protein interactions from 
Protein Atlas, GeneCards and STRING [447-452]. Three proteins—PIK4CA, 
PKMYT1 and MAP4K2—have previously been reported to be localized at least 
partially at the Golgi apparatus [453-455]. While the role of MAP4K2 at the 
Golgi is not completely understood, PIK4CA has been proposed to generate 
phosphoinositol-4-phosphate (PI4P) at the Golgi (Figure 3-9). PI4P is essential 
for recruiting membrane trafficking effectors to the Golgi [144], including 
Vps74/GOLPH3 that is required to retain various glycosyltransferases at the 
Golgi through retrograde trafficking [456]. Although GalNAc-Ts have not been 
known to be regulated by Vps74/GOLPH3, it represents a potential mechanism 
for their retention at the Golgi.  PKMYT1, on the other hand, is required for the 
reassembly of the Golgi during telophase [457, 458]. In addition, ERK8 has been 
reported to localize perinuclearly in A431 cells by the Protein Atlas database 
[449], suggesting potential Golgi localisation. 
 
Four other kinases, HIPK3, TTK, MARK2 and DUSP7, have been found to 
interact with Golgi associated proteins through genetic and large scale proteomics 
studies with yeast two-hybrid or anti-tag co-immunoprecipitation assays [459-
463]. Though extensive protein interaction mapping of human signaling proteins, 
HIPK3 was found to interact with Golgin GRASP65, Golgi localised LIM kinase 
and ERK8 interactor TGFB1l1 [460]. HIPK3 was also found interact with 
PKMYT1 [464].  
 
The MARK2 protein controls microtubule stability through phosphorylation of 
microtubule- associated proteins [465] and its interaction with microtubule 
tracking protein CLASP2 [462] suggests CLASP2 as a potential substrate. 
CLASP2 is involved in microtubule nucleation at the Golgi for post Golgi 
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trafficking [68] and also forms a distinct microtubule subsets at the cis Golgi [74]. 
In addition, Golgi to ER retrograde traffic is known to depend on microtubules 
tracks [466, 467] suggesting that GalNAc-T relocation could depend on CLASP2 
associated microtubules. 
 
Two proteins ERK8 and TGFBR2 have been shown to interact with Src, a 
positive Tn regulator [444, 468]. ERK8 activity was reported to increase in the 
presence of active Src [444] and TGFBR2 is phosphorylated by Src [468], 
suggesting roles in pathways involving Src. In addition, MAP4K2, IKBKE and 
PPP6C are linked to the canonical NFkB pathway, suggesting that this pathway 
might control GalNAc-T localisation [469-472]. Finally, several other 
interactions, either direct or with one intermediate, were found between the Tn 
regulating genes.  
 
Altogether, this analysis suggests that the Tn-regulating genes are acting at the 
Golgi level, perhaps part of a regulatory network controlling the subcellular 
localization of GalNAc-Ts (Figure 4-7). Further experiments are required to 





Figure 4-7: A potential regulatory network of signaling proteins regulating 




4.2.5 ERK8 kinase activity is required for O-glycosylation regulation. 
 
I next sought to better understand the mechanistic basis of the regulation of Tn 
levels and focused my efforts on the top hit, ERK8. In contrast with the classical 
MAP kinases ERK1/2, ERK8 displays high basal activity in resting cells and is 
not stimulated by growth factor stimulation [444, 473]. Although ERK8 possesses 
a typical Thr-X-Tyr (T-E-Y) activation motif at residues 175 to 177, it does not 
appear to be activated by the classical, three-tiered MAP kinase cascade as the 
other MAP kinases. Conversely, activation of ERK8 occurs by auto-
phosphorylation on the TEY motif. These properties suggest that its constitutive 
kinase activity could be important for ERK8 to function as a constant brake on 
GalNAc-Ts trafficking in the cell. 
 
To test this notion, I selected the siRNA dERK8-4 for its potency and knockdown 
efficiency (Figure 4-2B) and designed an siRNA resistant ERK8 construct tagged 
with GFP (GFP-ERK8siR). A kinase inactive version mutated at the TEY 
activation motif (GFP-ERK8-siR-T175A-Y177F/ ERK8-siR-mutant) was 
generated in parallel to test the importance of its kinase activity on GalNAc-T 
trafficking. Gene replacement with either wild type or kinase mutant ERK8 was 
performed by transfecting each construct into ERK8 depleted cells at 48 hours 
after dERK8-4 siRNA treatment (Figure 4-8A). The HPL intensity was quantified 
for transfected (GFP expressing) and non-transfected (non-GFP expressing) cell 
populations, each comprising hundreds of cells. While the ERK8 depleted cells 
that were not transfected (non-GFP expressing) displayed a marked increase in 
HPL staining, there was significantly lower HPL staining in cells transfected with 
wild type GFP-ERK8siR construct (Figure 4-8B).  
 
More importantly, HPL intensities remained almost similar to non-GFP 
expressing cells when transfected with the kinase inactive mutant (GFP-ERK8-
siR-T175A-Y177F/ ERK8-siR-mutant) (Figure 4-8B). This suggests that the 







Figure 4-8: Kinase activity of ERK8 is required to block Tn expression. (A) 
Gene replacement by expressing of siRNA resistant wild-type ERK8 (ERK8-siR) 
in ERK8 depleted (dERK8-4 siRNA treated) cells resulted in a significant rescue 
of HPL intensity levels (top panels) while expression of the kinase inactive 
mutant (ERK8-siR-mutant) showed little effect (bottom panels). Scale bar: 30µm. 
(B) Tn levels of NT siRNA treated and ERK8 depleted cells that were 
untransfected (red), transfected with wild type ERK8 (blue bars) or kinase 
inactive mutant ERK8 (orange). Values on graph indicate the mean ± SEM. 
**p<0.0001, *p<0.05 by two-tailed unpaired t- test, relative to untransfected or 
ERK8 wildtype transfected cells. 
 
 
4.2.6 ERK8 inhibitor induces a rapid and reversible increase in Tn levels. 
 
Indoyl bismaleimide Ro-31-8220 has been reported to inhibit the kinase activity 
of ERK8 by blocking its auto-phosphorylation [473]. The compound has been 
active only on ERK8 and not other MAP kinases such as ERK2, JNK1 or p38 
isoforms. I next seek to determine if this compound could recapitulate ERK8 
depletion and to evaluate its kinetics of action by treating cells with 5µM Ro-31-
8220 for various durations before fixing and staining for Tn levels. 5µM Ro-31-
8220 was found to effectively abolish ERK8 phosphorylation levels within one 
hour of treatment [473]. Strikingly, a significant increase in Tn level was also 
observed as early as one hour and peaked at eight- to ten-folds from basal levels 
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after 3.5 hours of Ro-31-8220 treatment (Figure 4-9A and B). Consistent with the 
levels of phosphorylated ERK8 [473], treatment with a lower concentration of 
Ro-31-8220 at 1µM resulted in slower increases in Tn levels, rising to only three-
fold after four to five hours of treatment (not depicted). Similar to ERK8 
depletion, visual observations revealed that cells treated with Ro-31-8220 also 
displayed a diffused HPL staining. Tn levels were observed to decrease after 3.5 
hours of treatment, which was likely due to the effect on cell mortality. In 
addition, the effects of ERK8 inhibition were rapidly reversible. Inhibitor washout 
after three hours of treatment began to rescue the Tn levels as early as one hour 
and significantly by 40% and 65% after two and four hours respectively (Figure 
4-9C and D). 
 
Thus, these evidences substantiate that the kinase activity of ERK8 is important 
for negative regulation of O-glycosylation initiation whereby its constitutive 
activity provides a continual brake to GalNAc-T relocation. Rescue of Tn 
expression upon the inhibitor washout demonstrated that reactivation of ERK8 
was able to rapidly block GalNAc-T redistribution to the ER, which was most 
likely relocated back to the Golgi by anterograde traffic, thus accounting for the 
rescue in Tn expression. Given the rapidity of changes in Tn levels, ERK8 







Figure 4-9:  ERK8 inhibition led to rapid and reversible changes in Tn 
expression. (A) Treatment with 5 µM ERK8 inhibitor Ro-31-8220 (iERK8) 
induced increases in Tn staining over time compared to the vehicle control 
(water). The diffused HPL staining recapitulated the phenotype observed in ERK8 
depletion and was more apparent with time. (B) Quantification of Tn expression 
dynamics of 5 µM iERK8 over time revealed significant increases within one 
hour of treatment. (C) Compound washout of 5µM iERK8 Ro-31-8220 over 
various durations revealed the reversibility of Tn expression levels. (D) 
Quantification of Tn expression dynamics upon iERK8 treatment followed by 
compound washout highlighted the short duration required for Tn levels to reduce 
significantly. Values on graphs indicate the mean±SEM. **p<0.0001, *p<0.05 by 
two-tailed unpaired t- test, relative to vehicle treated cells unless indicated by a 
line above the bars of the compared treatments.  
 
 
The rapid increase in Tn levels also suggests that accumulation of O-GalNAc 
glycosylated proteins can be achieved in a few hours and it is not likely to be due 
to expression changes of these O-glycoproteins or the O-glycosylation machinery. 
Indeed, co-treatment of Ro-31-8220 with transcriptional inhibitor α-armanitin 
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[474] did not reduce Tn levels over time (Figure 4-10A). Protein levels of the O-
glycosylation enzymes and molecular chaperones were also found to be 





Figure 4-10:  Tn increase in ERK8 inhibition was not due to expression 
changes in the O-glycoproteins and O-glycosylation machinery. (A) Co-
treatment of cells 10µg/ml transcription inhibitor α-armanitin and 5µM iERK8 
Ro-31-8220 for three and five hours did not reduce high Tn levels brought by 
iERK8, indicating that Tn increases was not due to transcriptional upregulation. 
(B) SDS-PAGE analysis of protein expression levels of O-glycosylation initiating 
enzymes and molecular chaperones in ERK8 depleted cells appeared unchanged 
compared to control. siRNA knockdown of these O-glycosylation proteins also 
verified the specificities of the antibodies. Values on graphs indicate the mean ± 
SEM. **p<0.0001, *p<0.05 by two-tailed unpaired t-test, relative iERK8 treated 
cells for three hours. 
 
 
4.2.7 O-glycosylation is initiated in the ER and several proteins are hyper 
glycosylated when ERK8 is inhibited. 
 
Staining of GalNAc-T1 and –T2 strongly suggested their relocation to the ER 
upon ERK8 depletion (Figure 4-6A). In addition, the dramatic increases in Tn 
levels suggested that the enzymes are more active in the ER (Figure 4-2 and 4-9). 
To further confirm this, I used an ER-specific glycosylation reporter (GFP-Muc-
PTS) (Figure 4-11A). This reporter construct is specifically targeted to the ER and 
contains a proline, threonine, serine (PTS)–rich sequence that is prone to O-
glycosylation whereby it contains up to 15 sites of GalNAc addition [193]. The 
182 
 
glycosylation status of the reporter was evaluated by immunoprecipitation with 
HPL-conjugated beads. This confirmed a significant increase in ER-localized O-
glycosylation upon ERK8 inhibition with Ro-31-8220 for 3.5 hours (Figure 4-
11B). ER localization of GalNAc-Ts was further verified using an ER-trapped 
GalNAc-T inhibitor (ER-2Lec) that is stably and homogenously expressed in 
HeLa cells [194]. ER-2Lec contains two lectin domains from GalNAc-T2 in 
tandem fused together with an ER-targeting sequence and GFP at the N-terminus 
and a KDEL sequence at the C-terminus. Both ER-targeting and KDEL sequences 
ensure inhibitor targeting and retention in the ER. Normally, the lectin domain of 
GalNAc-Ts would recognize O-GalNAc on glycoproteins and add more GalNAc 
to adjacent sites, increasing the density of GalNAc addition. Presence of ER-2Lec 
would compete with endogenous GalNAc-Ts by binding to the O-glycosylated 
substrates in the ER, hence reducing GalNAc density (Figure 4-11C). In line with 
the results from the Muc-PTS reporter, expression of this inhibitor reduced 
significantly the increase in Tn levels observed upon ERK8 knockdown (Figure 
4-11D), substantiating ER localised activity. 
It has recently been proposed that several ER resident proteins are O-glycosylated 
[436]. To test the extent of modification of the proteome upon ERK8 depletion, I 
metabolically labeled cells with FLAG-GalNAz, a GalNAc sugar analogue that is 
covalently conjugated with a FLAG epitope [475]. After 24 hours of 
incorporation, cells depleted of ERK8 or inhibited with Ro-31-8220 exhibited 
substantial increases in GalNAz incorporation in several bands as revealed by 
SDS-PAGE analysis (Figure 4-11E). This suggests that ERK8 controls the O-







Figure 4-11: ERK8 inhibited cells displayed increased ER- localized O-
glycosylation. (A) A schematic of ER-trapped Muc-PTS GalNAc-T activity 
reporter. The reporter contains a secretion signal sequence (SS) fused with GFP at 
the N-terminus and a KDEL motif at the C-terminus to ensure delivery and 
retention in the ER. Orange dots represent sites for O-GalNAc addition. (B) SDS-
PAGE analysis of Muc-PTS expressed in HEK293T cells treated with vehicle or 
with 5µM iERK8 Ro-31-8220 for 3.5 hours. Muc-PTS was immunoprecipitated 
using HPL-conjugated agarose. (C) A schematic of the effect of the ER-specific 
GalNAc-T inhibitor (ER-2Lec). ER-2Lec comprise of two isolated GalNAc-T 
lectin domains in tandem tagged with GFP for visualization. ER-2Lec would 
compete with the lectin domain of endogenous GalNAc-Ts and prevents further 
addition of GalNAc to substrates. (D) Tn level of ERK8 depleted cells was 
significantly lower in cells expressing ER localised 2Lec (ER-2Lec) compared to 
wild type HeLa cells. (E) SDS-PAGE analysis of control, ERK8 depleted and 
inhibitor (iERK8) treated cell lysate metabolically labeled using GalNAz-FLAG 
revealed increased GalNAz addition to multiple proteins in ERK8 depleted or 
inhibited cells [476]. 
 
 
4.2.8 ERK8 localizes at the Golgi and is displaced upon growth factor 
stimulation. 
 
GalNAc-Ts have been proposed to regularly cycle between the ER and the Golgi 
apparatus [477]. Thus, the relocation of these enzymes to the ER upon ERK8 
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depletion could result either from an enhanced export from the Golgi or an 
inhibition of exit from the ER. To address this alternative, I first analyzed the 
subcellular localization of ERK8 protein. Regular immunofluorescence staining 
of ERK8 in wild type HeLa cells produced a predominantly cytosolic staining 
pattern. However, prolonged permeabilization with 0.2% triton-X detergent for 
two hours revealed an obvious Golgi staining, suggesting that a fraction of ERK8 
is associated with this organelle (Figure 4-12). This is consistent with the 





Figure 4-12: Endogenous ERK8 is enriched at the Golgi. Image was acquired 
on 100x magnification. Scale bar: 10μm. 
 
 
To test how dynamic is this pattern and to understand how ERK8 is regulated 
when GalNAc-Ts are induced to relocate, HeLa cells were stimulated with 50 
ng/µl of growth factor platelet- derived growth factor (PDGF) for various 
durations. Reported previously, stimulation with PDGF induced significant 
increases of HPL staining intensity between 30 minutes and two hours [193]. 
Interestingly, I found that during this period, there was a constant decrease of 
ERK8 at the Golgi apparatus (Figure 4-13A). The mean Pearson Correlation 
coefficient of ERK8 and Golgi marker TGN46 staining was quantified to assess 
localisation of ERK8. Consistent with the visual observations, it revealed 
significant reductions of the Golgi fraction of ERK8 within 30 minutes and about 




Tyrosine kinase Src is a key signal transducer that relays growth factor 
stimulation (PDGF and EGF) at the cell surface to regulate GalNAc-Ts traffic at 
the Golgi [193] . An inactivated mutant construct of Src (Src-8A7F) has been 
shown to be inducible by small molecule imidazole [478]. This provided a useful 
tool to measure the kinetic effects of Src activation. I have generated a HeLa cell 
line stably expressing Src-8A7F-mcherry and another expressing Src-6N7F-
mcherry, a catalytically defective mutant that is insensitive to imidazole. 
Induction with 5mM imidazole resulted in a gradual decrease of ERK8 at the 
Golgi, similar to PDGF stimulation (Figure 4-13C and D). Akin to the 
constitutively active Src expression observed previously [193], longer durations 
of imidazole treatment also resulted in a fragmented Golgi with multiple 
punctuate structures. Conversely, as a negative control, cells expressing Src- 
6N7F had little effect after two hours of imidazole addition (Figure 4-13E). This 
data suggests that Src activity regulates ERK8 localization at the Golgi.  
 
Overall, the data suggests that ERK8 is dynamically localized at the Golgi 







Figure 4-13: ERK8 is dynamically localized at the Golgi. (A) The Golgi 
fraction of ERK8 was displaced over PDGF (50ng/ml) stimulation time. Scale 
bar: 10μm. (B) Mean Pearson’s correlation coefficient (MPCC) between ERK8 
and Golgi marker TGN46 in cells treated with PDGF for the indicated times. (C) 
The Golgi fraction of ERK8 was displaced over the duration of induction of Src-
8A7F activation with 5mM imidazole treatment. Scale bar: 10μm. (D) MPCC 
between ERK8 and Golgi marker Giantin in Src-8A7F expressing cells treated 
with imidazole for the indicated times. (E) The Golgi fraction of ERK8 remained 
unperturbed after two hours of imidazole treatment in cells expressing kinase 
inactive mutant Src-6N7F. Scale bar: 10μm. Images were acquired on 100x 
magnification. More than 30 cells were quantified in each treatment duration. 
Values on graphs indicate the mean±SEM. **p<0.0001, *p<0.05 by two-tailed 






4.2.8 ERK8 regulates COPI-dependent GalNAc-Ts traffic. 
 
Upon Src activation, export of GalNAc-Ts to the ER is dependent on the COPI 
coatomer and the Arf small GTPases family [193]. The activity of these Arf 
GTPases is regulated by GTP exchange factors which replace GDP to GTP. The 
key GTP exchange factor that is essential for the Golgi to ER retrograde traffic is 
GBF1 which is likely to regulate COPI mediated GalNAc-T relocation to the ER 
[442, 479]. 
 
To test if the relocation of GalNAc-Ts upon ERK8 depletion relies on the COPI 
machinery, wild type Arf1 and the dominant negative mutant Arf1(Q71L) were 
separately expressed in ERK8 depleted cells. Arf1(Q71L) is unable to hydrolyze 
bound GTP (Dascher and Balch, 1994). Similar to Src activation [193], Tn levels 
in Arf (Q71L) expressing ERK8 depleted cells appeared significantly reduced 
compared to the neighbouring untransfected cells and those expressing wild type 
Arf1 (Figure 4-14A). I also tested if GBF1 is required for GalNAc-T traffic by 
treating ERK8 depleted cells with 50nM GBF1 inhibitor Golgicide [480] over 
various durations. Quantification of Tn levels revealed significant rescue of more 
than 50% after two hours and 80% by six hours (Figure 4-14B). These results 
imply that both Arf1 GTPase and its GTP exchange factor GBF1 and hence, 
COPI-dependent retrograde traffic is required for GalNAc-T trafficking to the ER. 
 
To further establish the specificity of these results, ERK8 was co-depleted with 
the various COPI regulators to evaluate the effects on Tn levels. The combined 
knockdown of ERK8 and GBF1 almost completely reversed high HPL staining 
from ERK8 depletion, further indicating that GBF1 is required for relocation of 
GalNAc-Ts from Golgi to ER (Figure 4-14C). Co-knockdown of GBF1 with 
ERK8 reduced HPL staining intensity by about 80% whereas a non-targeting 
siRNA had almost no effect (Figure 4-14D). Interestingly, co-knockdown of 
ERK8 with Arf1, the primary Arf involved in Golgi to ER trafficking [481], did 
not reduce Tn levels as dramatically as GBF1 co-knockdown but produced about 
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60% reduction (Figure 4-14C and D). Similar decreases were observed in co-
knockdown with other Arfs, Arf3, -4 and -5, all potential regulators of COPI at 
the Golgi [482], suggesting functional redundancy amongst the Arf proteins. By 
contrast, co-knockdown with Arf6, which is not involved in COPI vesicle 
formation but regulates endosomal traffic at the plasma membrane, did not affect 
Tn levels (Figure 4-14D). Consistently, combined double or triple knockdowns of 
the Arf GTPases in ERK8 depleted cells resulted in more extensive rescue, with 
the exception of Arf6 inclusion (Figure 4-14D). For instance, co-knockdown with 
Arf1 and 3 (Arf1+3) or Arf1, 3 and 4 (Arf1+3+4) with ERK8 led to 71% and 84% 
decrease in Tn levels respectively. These reductions in HPL levels were not due to 
reduced knockdown efficiencies of ERK8, as similar effects were observed with 
increasing amounts of NT siRNA added to the transfection mix (not depicted). 
The efficiency and specificity was also verified by assaying protein expression of 
each gene (not depicted). Collectively, these data indicate that the COPI 
trafficking machinery is essential for the ER relocation of GalNAc-Ts and suggest 
that ERK8 represses constitutively the activity of this transport system.  
 
A key activation step for the COPI coatomer is the exchange of GDP for GTP of 
the Arf1 family small GTPases [442, 479, 483]. Therefore, I assessed Arf1-GTP 
loading after ERK8 inhibition using Ro-31-8220. This is by the specific pulldown 
of Arf1-GTP in cell lysates using the binding domain of an Arf1 effector coupled 
to agarose beads [484]. ERK8 inhibition over various time points revealed 
activation of Arf1 as early as 15 minutes after treatment and sustained for over 







Figure 4-14: COPI machinery is required for GalNAc-T relocation in ERK8 
depleted cells. (A) Rescue of Tn levels was observed in ERK8 depleted cells 
expressing dominant negative mutant Arf1 (Q71L) but not in wildtype Arf1 
expressing cells. Scale bar: 10 μm. (B) Quantification of Tn expression dynamics 
upon 50nM GBF1 inhibitor Golgicide treatment. (C) Co-knockdown of ERK8 
with small GTPase Arf1 or its GEF GBF1, but not NT siRNA, rescued increased 
Tn levels from ERK8 depletion. Scale bar: 30μm. (D) Quantification of Tn 
expression upon ERK8 co-knockdown with the Arf proteins and GBF1. (E) SDS-
PAGE analysis of total Arf1 and actin, as well as, immunoprecipitated Arf1-GTP 
from lysate of cells treated with 5 µM of iERK8 Ro-31-8220  at the indicated 
times. Values on graphs indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-
tailed unpaired t-test, relative to vehicle treated cells in (B) and NT siRNA-treated 
cells in (D), unless indicated by a line above the bars of the compared treatments.  
 
 
To evaluate the effect of ERK8 depletion on COPI, I next stained cells for the 
Golgi marker GM130 and the COPI subunit beta-COP (COPB). As observed 
previously with MannII-GFP, GM130 staining revealed significant Golgi 
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fragmentation after ERK8 depletion. Interestingly, COPB staining was 
significantly more affected and found on small structures in the cytoplasm, 
suggesting enrichment on transport intermediates (Figure 4-15A). Using a 
granularity measurement algorithm, I found a nearly four-fold increase in 
distribution for COPB but only slightly more than two-fold increase for GM130 
(Figure 4-15B), suggesting that depletion of ERK8 induces the activation of COPI 
transport carriers that export GalNAc-Ts from the Golgi apparatus. This data 
suggests that depletion of ERK8 induces the activation of COPI transport carriers 
that export GalNAc-Ts from the Golgi apparatus.  
 
To visualize this process, cells were treated with the ERK8 inhibitor Ro-31-8220 
for 15 minutes then fixed and processed for staining. In inhibitor-treated cells 
specifically, numerous COPI positive vesicular structures could be detected near 
the Golgi apparatus (Figure 4-15C). Some of these structures were also clearly 
stained with an antibody against GalNAc-T1 (Figure 4-15C), supporting my 
hypothesis. Interestingly, in several instances, I could detect tubular structures 
emanating from the Golgi apparatus and stained for GalNAc-T1 (Figure 4-15C 
bottom panel). These structures were also stained for COPB, although usually not 
as homogenously on their whole length as for GalNAc-T1 (Figure 4-15C bottom 
panel).  
 
Taken together, these results strongly support the notion that ERK8 specifically 
inhibits the formation of COPI transport intermediates at the Golgi apparatus, thus 







Figure 4-15: ERK8 regulates the formation of COPI transport carriers. (A) 
Staining of beta-COP (COPB) revealed significant increase in COPI transport 
carriers in ERK8-depleted compared to NT siRNA treated cells. The Golgi 
marked by GM130 also appeared significantly fragmented in ERK8 depletion but 
not as strongly perturbed as COPB staining. Scale bar: 10μm. (B) Quantification 
of the relative numbers of COPI transport carriers (red bars) and number of Golgi 
fragments in GM130 staining (blue bars) using granularity measurement module 
in MetaXpress software in NT and ERK8 siRNA treated cells. Cells were imaged 
under 100x magnification and more than 30 cells were quantified for each 
treatment. Values on graphs indicate the mean ± SEM. **p<0.0001, *p<0.05 by 
two-tailed unpaired t- test, relative to NT siRNA treated cells. (C) Co-staining of 
COPB and GalNAc-T1 in cells treated with 5 µM iERK8 Ro-31-8220 for 15 
minutes revealed that a number of COPI transport intermediates co-localize with 
GalNAc-T1. Transient tubular structures were observed in GalNAc-T1 and less 
homogenously COPI staining in some cells. Scale bars: 10 μm. 
 
 
4.2.9 ER relocation of GalNAc-Ts in ERK8 depletion is dependent on 
tyrosine phosphorylation of Golgi proteins. 
 
Redistribution of GalNAc-Ts to the ER was previously reported to be induced by 
Src activation [193]. To test if ER relocation of GalNAc-Ts in ERK8 depletion is 
dependent on Src activity, HeLa cells knockdown with ERK8 were treated with 
10μM Src family kinase (SFK) inhibitor PP2 for 16 hours. Interestingly, PP2 
addition resulted in a dramatic reduction of HPL staining intensity by 70% 
(Figure 4-16A and B). However, none of the members of the SFK family 
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dramatically rescued Tn levels with ERK8 depletion (Figure 4-16C), suggesting 
that there is likely to be redundancy among the SFKs or PP2-inhibited tyrosine 
kinase are involved in regulating GalNAc-T trafficking, given that the drug has 
some effects on other tyrosine kinases [485]. 
 
I further investigated if GalNAc-T trafficking was dependent on the activity of 
SFKs or other tyrosine kinases by immunofluorescence staining of 
phosphotyrosine in ERK8 depleted cells. Interestingly, the general cellular 
phosphotyrosine intensities appeared to increase slightly only by about 1.2-fold in 
ERK8 depleted cells (Figure 4-16D). This was also validated by western blotting 
of total phosphotyrosine levels of cell lysates (data not shown). However, 
strikingly, while phosphotyrosine staining in non-targeting siRNA treated cells 
was predominantly at the cytoplasm and cell membrane, there was a significant 
upregulation of phosphotyrosine levels at the perinuclear region in ERK8 depleted 
cells (Figure 4-16E). This perinuclear pool of phosphotyrosine proteins was 
observed to colocalise with Golgi marker Giantin. Indeed, when I quantified the 
mean Pearson’s correlation coefficient between PY20 and Giantin staining, there 
was about four-fold increase in phospho-tyrosine levels at the Golgi region 
(Figure 4-16F) This suggested that a pool of Golgi localised proteins that are 
tyrosine phosphorylated. The effect is specific to ERK8 as the expression of 
siRNA-resistant ERK8 construct reduced the high perinuclear phosphotyrosine 
staining to a cytoplasmic staining, similar to NT-siRNA treated cells (Figure 4-
16G). Addition of PP2 also abolished the perinuclear phospho-tyrosine staining 
(Figure 4-16H), suggesting that SFKs or PP2-inhibited tyrosine kinases are the 
primary mediators of the tyrosine phosphorylation.  
 
Collectively, the results have shown that ERK8 controls tyrosine phosphorylation 
of a pool of Golgi or Golgi-associated proteins. Tyrosine phosphorylation is likely 
to depend on the activities of several SFKs or PP2-inhibited tyrosine kinase. 





Figure 4-16: ERK8 regulates Golgi-localized phosphotyrosine levels. (A) 
Treatment with 10μM Src inhibitor PP2 for 16 hours rescued Tn levels in ERK8 
depleted cells significantly. Scale bar: 30µm. (B) Quantification of Tn levels of 
NT-siRNA treated or ERK8 depleted cells treated with PP2 or vehicle over 16 
hours. (C) Quantification of Tn expression upon ERK8 co-knockdown with 
several members of SFK family revealed that none of the SFKs was specifically 
involved in GalNAc-T relocation in ERK8 depleted cells. (D) Quantification of 
total phospho-tyrosine immunofluorescence staining intensities revealed mild 
overall increase in phospho-tyrosine levels in ERK8 depletion. (E) 
Immunofluoresence staining with phospho-tyrosine specific antibody (PY20) 
revealed spatial upregulation of phospho-tyrosine levels at Golgi regions when 
ERK8 is depleted. Images acquired at 60x magnification. Scale bar: 10µm. (F) 
MPCC between PY20 and Golgi marker Giantin staining in NT siRNA-treated 
and ERK8 depleted cells. (G) Expression of siRNA resistant ERK8 (ERK8-siR-
mcherry) reduced the upregulated PY20 staining in ERK8 depleted cells. Scale 
bar: 10µm. (H) Treatment of ERK8 depleted cells with 10μM Src inhibitor PP2 
for 16 hours abolished phospho-tyrosine levels at the Golgi region. Scale bar: 
10µm. Values on graphs indicate the mean ± SEM. **p<0.0001, *p<0.05 by two-




4.2.10 ERK8 regulates cell migratory ability through control of O-
glycosylation. 
 
I previously reported that O-glycosylation in the ER stimulates cell adhesion and 
cell migration and tends to induce spindle-shaped cell morphology [194]. 
Interestingly, this morphology was also apparent in ERK8 depleted HeLa cells 
under phase contrast microscopy (Figure 4-17A) and after staining for the actin 





Figure 4-17: Loss of ERK8 result in spindle- shaped cells. (A) Phase contrast 
images and (B) actin and tubulin staining of NT siRNA- treated (NT control) and 
ERK8- depleted (ERK8 KD) cells. Scale bar: 100 μm in (A) and 10 μm in (B). 
 
 
I next tested if ERK8 depleted cells also display enhanced cell motility. When 
tested on fibronectin-coated plates in a scratch-wound healing assay, ERK8 
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depleted cells migrated about two-fold faster into the denuded area compared with 
NT siRNA-treated cells (Figure 4-18A). This faster rate was constant over seven 
hours (Figure 4-18B), indicating that the faster wound closure is caused by faster 
cell migration and not enhanced reactivity to the initial wound. ERK8 knockdown 
also led to a dramatically higher cell surface Tn staining, with numerous Tn-
positive protrusion structures (Figure 4-18C). These Tn-bearing glycoproteins are 
likely to promote increased cell adhesion, as shown previously [194].  
 
However, ERK8 has also been implicated in various other cellular processes. To 
verify that the increased cell motility was due to enhanced O-glycosylation, the 
scratch-wound healing assay was repeated in ERK8 and GalNAc-T1 and -T2 
knocked down cells (ERK8+GalNAcT1&2 KD). I found that these cells migrated 
significantly slower than ERK8 and ERK8+NT knockdown cells and were in fact 
similar to NT control cells (Figure 4-18B and D). To further confirm the 
importance of ER O-glycosylation, I used the ER-localised GalNAc-T inhibitor, 
Lec2GFP. Cell migration rates induced by ERK8 depletion in Lec2GFP cells 
were significantly reduced compared with cells expressing only GFP (NGFP 
cells) (Figure 4-18B) and again rather similar to non- targeting control cell 
migration. It is important to note that the Lec2GFP construct itself did not 
significantly slow cell migration in the absence of ERK8 depletion.  
 
Thus, collectively, these results indicate that ERK8 is a negative regulator of cell 







Figure 4-18: ERK8 regulates cell migration through ER O-glycosylation. (A) 
Migration assay using scratch wound of cellular monolayer on fibronectin coated 
plates revealed significantly faster migratory rates of ERK8-depleted cells 
compared to NT siRNA treated cells. Scale bars: 100 μm. (B) Rate of wound 
closure (area) measured over seven hours (n = 4 experiments). Values on graphs 
indicate mean ± SEM.  **p<0.001, *p<0.05 by two-tailed unpaired t-test. Red 
asterisk indicates t-test between NT siRNA-treated and ERK8-depleted cells. 
Green asterisk indicates t-test between cells co-knockdown with ERK8 and 
GalNAc-T1 and -T2 (ERK8+GalNac-T1 & -T2 KD) and cells co-knockdown 
with ERK8 and NT siRNA (ERK8+NT control KD). Blue asterisk indicates t-test 
between ERK8 knockdown in NGFP-expressing and ER-localised GalNAc-T 
inhibitor Lec2GFP cells. NS, not significant (black vertical lines). (C) Cell surface 
staining using a specific Tn antibody (green) and Helix Pomatia Lectin (HPL) 
(red) on non-permeabilised cells revealed a dramatic upregulation in Tn levels in 
ERK8-depleted cells with localised increases in multiple protrusion structures. 
Scale bar: 10 μm. (D) Cells co-knockdown with ERK8 and GalNAc-T1 and -T2 
(ERK8+GalNAcT1 & T2) migrated dramatically slower than cells co-knockdown 
with ERK8 and non-targeting (NT) siRNA (ERK8+NT). Scale bars: 100 μm.  
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4.2.11 ERK8 expression is frequently downregulated in breast and lung 
carcinoma. 
 
Tn levels were found to be frequently upregulated in tumours of multiple tissue 
types [438] and my initial goal was to elucidate mechanisms for this frequent 
increase. Interestingly, on the other hand, ERK8 protein levels was reported to be 
fairly constant in normal breast tissue and benign tumours but decline 
significantly in malignant tumours, with a loss in about 50, 80 and 100% of grade 
1, 2 and 3 tumours, respectively [486]. The authors proposed that ERK8 
stimulates the degradation of Oestrogen Receptor-alpha, suggesting a possible 
selective advantage for the loss of this MAPK [486].  Interestingly, this trend is 
also consistent with the increased frequency and intensity of Tn staining as our 
group had previously reported in breast carcinomas [194]. 
 
To further examine the relationship between ERK8 and Tn levels in breast cancer, 
both ERK8 and Tn (stained with VVL) were co-labelled in a panel of 39 human 
frozen tissue arrays comprising five normal breast tissues and 34 invasive ductal 
breast carcinoma (Figure 4-19A-C). Visually, recapitulating previous reports, 
VVL staining in the normal cores was observed to be significantly lower than the 
tumour cores. Conversely, ERK8 levels appeared higher in the normal cores. 
Hence, to compare their expression levels, ERK8 and VVL levels of each tissue 
core were quantified by measuring the area of the tissue core with staining 
intensity above a fixed threshold and normalised to the total area of the core 
represented by nuclei staining (DAPI) (Figure 4-19D). The thresholds for ERK8 
and VVL staining were selected based on the masking of the brightest and 
dimmest core, such that the masking on the brightest core covered the entire core 








Figure 4-19: Quantification of ERK8 and Tn expression levels in human 
breast carcinomas. (A) Hematoxylin and eosin stain (H&E) staining of 40 
human breast biopsies on BRF404 slides purchased from US Biomax, Inc. Image 
is from Biomax website (http://www.biomax.us/). (B) ERK8 and (C) Vicia 
Villosa Lectin (VVL) were co-stained on the breast tissue arrays. Red boxes 
indicate the positions of normal breast tissue cores. Note: Core E6 was absent on 
the slide, hence only 39 of the original 40 biopsies were included in the analysis. 
(D) Method of quantification of ERK8 and VVL staining in the tissue cores. The 
area of tissue core with intensity above a fixed threshold, highlighted by the 
masking (red), was measured. This was then normalised to the total core area 
represented by the nuclei (DAPI) staining. The fold change of ERK8 and VVL 
staining area with respect to (wrt) the average of all normal cores is presented on 






Although the levels varied considerably, more than half of the carcinoma cores 
(18/34) showed at least 50% reduction of ERK8 (Figure 4-20A). In line with 
previous reports, Tn levels also varied significantly in the carcinoma cores but in 
the large majority of samples, they were significantly upregulated compared to the 
normal tissue cores (Figure 4-20B). The subcellular pattern of VVL staining in 
many carcinoma cores also displayed an ER pattern, verifying that Tn expression 
in these carcinomas are likely due to ER relocation of GalNAc-Ts (Figure 4-20C). 
When I compared both ERK8 and Tn levels, their levels appeared to show 
opposing trends in most cores, suggesting that loss of ERK8 could partially drive 
high Tn expression. Several cores displayed increased Tn levels, yet high ERK8 
levels, indicating that Tn expression in these cores are likely due to other 
mechanisms. Hence, there was no clear correlation between the levels of both 






Figure 4-20: ERK8 is downregulated in human breast carcinomas. (A) 
Quantification of ERK8 staining in 39 human breast biopsies reveals significantly 
reduced levels in carcinomas compared normal tissues. Each point represents the 
staining of one tissue core and normalised to the average staining of the normal 
tissue cores. (B) Quantification of Tn (VVL) staining in human breast biopsies 
illustrates upregulated Tn levels in carcinomas. *p<0.05, **p<0.01, by two-tailed 
unpaired t-test. (C) Co-staining VVL and ER marker Calnexin revealed extensive 
ER localisation of Tn in two different malignant breast carcinoma samples. Scale 
bar: 20 μm. 
 
 
High Tn has also been reported in other tumour types, where Oestrogen regulation 
is not thought to be critical. As ERK8 was previously found to be highly 
expressed in the lung [444], I explored the link between ERK8 and Tn levels in 
lung cancer with 23 lung biopsies containing two normal lung tissues, 14 




Visually, ERK8 staining appeared clearly detectable in normal tissues but 
markedly reduced in all lung carcinomas (Figure 4-21A). On the other hand, Tn 
staining appeared upregulated a number of carcinoma cores (Figure 4-21B). 
Strikingly, when I quantified ERK8 levels, the reduction was ~80% on average 
with a range of 40 to 90% reduction (Figure 4-21C). No specific trend in regards 
to cancer type was noticed. Quantification of Tn levels revealed a significant 
increase in a majority of samples, with on average more than four-fold increase. 
This increase ranged from two- to ten-fold, with 18 cores (86%) displayed higher 
than normal levels of Tn (Figure 4-21D).  
 
I also investigated if high Tn was linked to ER O-glycosylation as observed in 
breast carcinomas. Indeed, Tn staining co-localised extensively with the ER 
marker calnexin in lung carcinoma samples. By contrast, Tn staining in the 
normal lung tissue was clearly more punctuate and reminiscent of a Golgi 
localization (Figure 4-21E). 
 
Thus, in most lung carcinoma tumours, ERK8 expression is downregulated while 
Tn levels are increased. However, similar to the breast carcinomas, anti-
correlation between ERK8 and Tn levels was not observed in the lung 
carcinomas. Interestingly, I noticed an anti-correlation between ERK8 and Tn 
staining in samples with heterogeneous staining for Tn (Figure 4-21F). 
 
The lack of direct correlation indicates that, in human lung and breast tumours, 
ERK8 levels do not strictly control the levels of Tn. Given the number of Tn 
regulators that have been identified in the screen (Figure 4-1) and in previous 
studies, this is not very surprising. Notwithstanding, our analysis indicates that 
ERK8 is frequently downregulated in lung and breast carcinomas, which probably 
facilitates the relocation of GalNAc-Ts to the ER when other biochemical or 










Figure 4-21: ERK8 is downregulated in human lung carcinomas. (A) ERK8 
and (B) VVL staining of 23 lung biopsies on FBN406a and FMC407 slides 
purchased from US Biomax, Inc. Note: Core B1 of FMC407 was absent on the 
slide, hence only 23 of the original 24 biopsies were included in the analysis. (C) 
Quantification of ERK8 staining in human lung biopsies. (D) Quantification of Tn 
staining in human lung biopsies. *p<0.05, **p<0.01, ***p<0.0001 by two-tailed 
unpaired t-test. (E) Co-staining VVL and ER marker Calnexin revealed extensive 
ER co-localisation of Tn in lung carcinoma (FMC407: Core B3) while Tn 
appeared as punctuate structures in the normal lung (FBN406: Core C1). Scale 
bar: 20μm. (F) Top panel: ERK8 and Tn staining appear anti-correlated in some 
regions of a lung adenocarcinoma core (FMC407: Core B8). Scale bar: 200μm. 







Several hallmarks of neoplastic transformation in cells, including metastatic 
potential, have been linked with the expression tumour-associated carbohydrate 
antigens (TACA). Hence, multiple studies attempted to understand the molecular 
basis of their expression, with the aim of generating antitumor therapy [487-490]. 
Among the most common TACAs is the Tn antigen, that is expressed in more 
than 80% of human carcinomas of multiple tissue origins [252, 254, 491]. In 
contrast, the corresponding normal tissues exhibit little or no expression. Given 
the dramatic variations of Tn levels in cancer cells, it suggests that O-
glycosylation initiation and/or elongation is highly regulated. Indeed, through an 
RNAi screen on signalling and related proteins, I identified 12 proteins that exert 
significant control over O-glycosylation initiation. In addition to the Src tyrosine 
kinase which our group have previously reported [492], the identification of novel 
regulators helps in expanding the current limited knowledge on the molecular 
mechanisms involved in Tn expression in cancer. 
 
The mechanisms of linking Tn antigen to cancer progression are just beginning to 
be understood. High Tn levels were initially found to arise from a loss or 
inhibition of the elongation of the O-GalNAc and was attributed primarily 
through loss of activity of the elongating enzyme, C1GalT or its specific 
chaperone, Cosmc. Consequently, this has been proposed to underlie the high Tn 
cancer phenotype [251, 267]. However, the loss of C1GalT activity has only been 
in a limited set of cancer cell lines and human tumors [216, 251, 267]. In recent 
years, our group have reported that O-glycosylation initiation can be regulated 
through trafficking of the GalNAc-Ts between the ER and the Golgi [492] and 
that marked ER localisation of these enzymes explains the high Tn phenotype of 
at least 60% of human breast tumours [194].  
 
In our secondary screens, it appears that most, if not all, signalling proteins 
affecting Tn levels regulate the subcellular localisation of GalNAc-Ts and not the 
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expression levels of the enzymes or the O-GalNAc elongation process. This 
obviously does not preclude C1GalT or Cosmc from being regulated in some 
conditions but a significant inhibition of the activity of these proteins was not 
observed in our screen conditions.  
 
By contrast, the subcellular localisation of GalNAc-Ts appears to be a nodal point 
of control in a complex signalling network. Indeed, at least 12 independent 
negative regulators that were identified and at least as many positive regulators, 
including the Src family tyrosine kinases, are likely to be involved. This 
regulatory complexity suggests that perhaps signals of different origins are being 
integrated at the level of GalNAc-Ts traffic. 
 
ERK8 is one of the most potent regulators that was identified in the screen. The 
extent of Tn expression and GalNAc-T relocation with ERK8 depletion and the 
spontaneous Tn increases upon drug inhibition provided an initial hint to its 
directness on regulating GalNAc-T localisation. This is further substantiated by 
the findings that a fraction of ERK8 localises to the Golgi region in resting cells, 
suggesting that ERK8 is constantly present to control the rate of GalNAc-T 
trafficking. How ERK8 localises to the Golgi is a question worth to pursue and 
would further clarify its regulatory mechanisms. Several MAPKs have been 
shown to localise at the Golgi where they spatially direct specific signals [493]. 
For instance, ERK and MEK are tethered to Golgi membranes by scaffold 
proteins interleukin-17 receptor D (Sef) [155] or peptidyl-tRNA hydrolase 2 
(BIT1) [329]. ERK3, on the other hand, localises to Golgi membranes by its C-
terminal residues that are reminiscent to the dilysine (KKXX) motif for targeting 
to early secretory apparatus [494]. It is possible ERK8 could adopt any of these 
mechanisms for its Golgi localisation, although a C-terminal dilysine motif could 
not be observed in ERK8 sequence. Yet, there are other possibilities including 
post-translational myristoylation [495] or palmitoylation [496] that are involved 




Furthermore, I showed for the first time that the localisation of ERK8 at the Golgi 
is dynamic and appears to be controlled by growth factor (PDGF) and Src-
mediated signalling. These findings present a regulatory mechanism for ERK8 
activity at the Golgi. Since ERK8 is constitutively active by autophosphorylation 
in the cell [444], spatially limiting access to Golgi substrates would make sense to 
regulate its activity. In line with this, classical MAP kinases ERK1/2 also display 
dynamic localisation upon stimulation and they act on different sets of substrates 
at different locations. For instance, in resting cells, ERK1/2 is localised in the 
cytoplasm where it phosphorylates multiple cytoplasmic targets. Upon mitogen 
stimulation, it translocates to the nucleus and acts on nuclear proteins [497]. 
ERK1/2 was also found to accumulate at the Golgi during G2/M phase of the cell 
cycle and was proposed to act on golgi proteins to induce Golgi fragmentation 
during mitosis [135, 498, 499]. In addition, what could be the underlying 
mechanisms that coordinate ERK8 translocation from the Golgi during growth 
factor stimulation/Src activation? Changes in subcellular localisation of ERK1/2 
have been known to be mediated by various mechanisms such as phosphorylation 
in and outside the activation motif [497, 500] and distorting scaffold interactions 
[501]. ERK8 could also be controlled by similar mechanisms and the process is 
likely to be mediated by Src signalling. Nevertheless, the findings highlight the 
dynamicity of the system in controlling GalNAc-T trafficking whereby the 
“brake” by ERK8 can be spontaneously regulated by extracellular signals. 
 
Various lines of evidence indicate that ERK8 control GalNAc-T localisation by 
inhibiting the formation of GalNAc-Ts containing COPI vesicles and this is a 
signalling-dependent mechanism. While it is found that some kinases that localise 
at the secretory pathway have non-signalling roles [502], my findings that activity 
of ERK8 is essential to block GalNAc-T relocation supports that it is a signalling 
event (Figure 4-8). However, one of the important questions that remained open 
in this study is what could be the downstream substrate(s) of ERK8 involved in 
GalNAc-T trafficking? Given the fact that ERK8 was only discovered a decade 
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ago [444], direct substrates of ERK8 are still not identified while it is only known 
to exhibit distinct substrate specificities from the classical ERK1/2 [473].  
 
The observations that loss of ERK8 promotes Golgi localised upregulation of 
phosphotyrosine levels, and not general cellular levels, indicates that ERK8 
specifically inhibits tyrosine phosphorylation at the Golgi. As demonstrated by 
our previous results that Src activity at the Golgi regulates GalNAc-T trafficking 
[193], it substantiates that tyrosine phosphorylation of a pool of Golgi proteins is 
important for GalNAc-T ER relocation. Supporting this, ERK8 was found to 
directly interact with Src by binding to its SH3 domains [444], implying that both 
proteins could carry out similar biological functions, although direct 
phosphorylation between both proteins is not known. Thus, the rescue of 
GalNAc-T ER relocation with Src inhibitor PP2 initially supports the view that 
ERK8 could act by inhibiting Src which mediates tyrosine phosphorylation of the 
pool of Golgi proteins involved in GalNAc-T trafficking. However, the 
assumption is refuted by the lack of rescue of HPL intensities when ERK8 is co-
depleted with Src or other SFKs. In addition, it is known that PP2 is not specific 
to Src but affects the activities of other members of SFK, particularly Lck and 
Hck. More recently, it was also found to affect several other tyrosine kinases 
[485]. Taken together, the results imply that tyrosine phosphorylation of Golgi 
proteins for GalNAc-T traffic could involve multiple SFKs or a PP2-inhibited 
non-SFK tyrosine kinase. It is possible that there is functional redundancy among 
the SFKs in regulating GalNAc-T traffic as several members of the SFKs have 
been found to localise and act at the Golgi [129]. ERK8 could interact and act 
with other SFKs/non-SFK tyrosine kinase through their SH3 domains like Src. 
However, whether there is any direct phosphorylation and activity inhibition 
between ERK8 and other SFKs/non-SFK tyrosine kinase is not known.  
 
Given the current results, three scenarios could be postulated. Firstly, in normal 
cells, ERK8 directly acts and inhibits the hyperactivation of SFKs or non-SFK 
tyrosine kinase (PP2-inhibited) that phosphorylates Golgi proteins involved in 
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GalNAc-T traffic (Figure 4-22). Secondly, ERK8 acts on a phosphotyrosine 
phosphatase that dephosphorylates tyrosines on the SFKs or Golgi protein(s) 
involved in GalNAc-T trafficking. Thirdly, ERK8 could directly act on 
phosphorylated Golgi proteins involved in COPI biogenesis and block their 
activities. For instance, several Golgi proteins involved in ER-Golgi traffic have 
been found to be phosphorylated for regulation of membrane traffic [392, 484, 
503, 504]. However, with the lack of information of ERK8 substrates, the 
mechanisms of this signalling event such as the order of ERK8 and SFKs/non-
SFK tyrosine kinase remains elusive. It can only be concluded at this point that 
both ERK8 and SFK or tyrosine kinase act in antagonistic pathways on GalNAc-T 
trafficking. Hence, my findings demonstrate that ERK8 acts by specifically 
inhibiting tyrosine phosphorylation of a pool of Golgi proteins involved in 
targeting GalNAc-Ts for Golgi to ER trafficking. Future studies should 
encompass the elucidation of the precise signalling events that regulate GalNAc-T 
traffic and the identification of ERK8 substrates at the Golgi should shed more 
light to this aspect. Identification of the subset of tyrosine phosphorylated Golgi 
proteins would also uncover how GalNAc-Ts are specifically targeted to COPI 
carriers.  
 
Based on the genetic interaction profile, the other negative regulators appear to 
act at the same level as ERK8. Consistently, two of these proteins, PKMYT1 and 
MAP4K2, are also reported to localize at the Golgi [454, 455], and several other 
regulators interact with Golgi localized proteins. Together, this suggest that the 
incorporation of GalNAc-Ts in COPI vesicles is the key point of regulation of this 
potential regulatory network.  
 
The trafficking of GalNAc-Ts to the ER results in the glycosylation of multiple 
different substrates, as indicated by the metabolic labelling results. The precise 
identity of these substrates, as well as the functional effects of their glycosylation, 
remains to be established. Notwithstanding, the outcome of the relocation at the 
cellular level is clearly a significant stimulation of cell migration. Indeed, the 
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stimulatory effect of ERK8 depletion is dependent on ER-localized O-
glycosylation. These results are also consistent with our previous data based on 
the expression of an exogenous, ER-targeted form of GalNAc-T2 [194]. Thus, an 
interesting hypothesis is that the intensity of packaging of GalNAc-Ts into Golgi-
derived COPI-coated vesicles could be a signalling integration point that sets the 
“motility potential” of cells. 
 
In breast and lung cancer cells, this set-point appears constitutively high, as the 
relocation of GalNAc-Ts is extensive and frequent. The promotion of cell motility 
associated with ER-localized O-glycosylation appeared to favour the formation of 
lung metastases in a tail-vein injection-based assay [194]. Thus, how GalNAc-T 
relocation is stimulated in cancer cells probably has important medical 
implications. 
 
My analyses suggest that multiple mechanisms are possible, including a decrease 
in ERK8 protein levels. However, the actual level of decrease required to 
stimulate relocation is not known and is anyway probably dependent on other 
cellular parameters. Additionally, Tn levels are not likely to depend only on the 
intracellular distribution of GalNAc-Ts. For instance, normal tissues with high 
levels of mucin expression, such as stomach, colon or kidney, tend to have higher 
endogenous Tn levels without clear evidence for relocation. This complexity 
probably contributes to the lack of direct correlation between ERK8 and Tn 
levels.  
 
In addition to promoting O-glycosylation, ERK8 depletion could also have other 
beneficial advantages for cancer cells. Indeed, ERK8 has been implicated in 
multiple, apparently unrelated, molecular processes, such as maintenance of 
genomic integrity [505], regulation of telomerase activity [506],  autophagy [507] 
and inhibition of nuclear receptor activity [486, 508, 509]. Recently, the 
Drosophila homolog ERK7 and human ERK8 were also shown to participate in 
the regulation of protein secretion during starvation through disassembly of ER 
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exit sites [413]. Whether these different processes are somewhat linked through 
ERK8 or whether ERK8 is simply moonlighting in different, independent 
functions constitute an interesting challenge for the future.  
 
In sum, my results suggest that initiation of O-glycosylation in the ER is under an 
elaborate regulatory control system of which ERK8 is a key player. This 
regulation sets the level of cellular motility and is frequently perturbed in cancer 






Figure 4-22: A model illustrating signaling regulation of O-glycosylation 
initiation at the Golgi that influences cellular motility and cancer 
invasiveness. Golgi to ER relocation of GalNAc-T is dependent on tyrosine 
phosphorylation of a pool of Golgi proteins. ERK8 could regulate tyrosine 
phosphorylation in three potential scenarios: inhibiting activation of 
SFKs/tyrosine kinases, activating an unidentified phosphotyrosine phosphatase or 
inhibiting the activity of tyrosine phosphorylated Golgi protein(s) involve in 
GalNAc-T traffic. Src represents multiple SFKs and non-SFK tyrosine kinase. Ph 



















5.1 RNAI SCREENING REVEALS A LARGE SIGNALING NETWORK 
CONTROLLING THE GOLGI APPARATUS IN HUMAN CELLS 
 
5.1.1 Main conclusions  
 
To investigate the mechanisms that regulate Golgi architecture, I utilised RNAi 
screening coupled with high-throughput imaging and quantitative image analysis 
to identify its molecular regulators in an unbiased fashion. Golgi organization was 
probed with three markers specific for different Golgi compartments to assess 
cisternal specific effects. A pilot screen on membrane traffic regulators revealed 
three visually observable Golgi morphologies in human cells. Based on these 
reference Golgi phenotypes, a support vector machine was successfully developed 
to automatically classify and quantify the three different Golgi morphologies. The 
screen on 948 kinases and phosphatases uncovered 159 signalling genes, which 
constitutes nearly 20% of genes assayed. The signalling gene depletions induced 
strong and varied Golgi morphological perturbations that were comparable, if not 
stronger, than that of the membrane trafficking regulators. Using bioinformatics 
data, a large regulatory network on Golgi morphology could be constructed. 
Specific sub-networks involving phosphoinositides regulation, acto-myosin 
dynamics, and MAPK signalling provided further understanding to Golgi 
regulatory mechanisms. Depletions of most Golgi organization regulators also 
affected Golgi functions of secretion and glycan biosynthesis, suggesting that 
signalling cascades can control these processes directly at the Golgi level. 
Collectively, our data provides a genetic overview of the signalling pathways that 
control the Golgi physiology in human cells. 
 
5.1.2 Future directions: towards better Golgi morphological classification  
 
Our RNAi screen identified numerous signalling proteins, both known and novel, 
regulating Golgi organization and its secretory and glycosylation functions. The 
data was further supported by our bioinformatics study which found an 
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unexpectedly large number of phosphoproteins associated with the Golgi whereby 
many interact with the identified hits, suggesting the direct impact of the 
signalling proteins on the Golgi. However, for most of these signalling regulators, 
what regulates them, as well as how and when they are activated are still not 
completely known. It is not known if the connections in the large regulatory 
network that we derived are direct phosphorylation events, given that the direct 
substrates of these signalling proteins are mostly not clear. Furthermore, the 
precise functional and physiological meaning of this signalling regulation to the 
cell and organism are not well-understood.  
 
The functions are only beginning be elucidated for a few of them. For instance, 
ERK phosphorylates GRASP65 to remodel and re-orientate the Golgi towards the 
leading edge for cell migration [116] and MEK1 and several signalling proteins 
phosphorylate GRASP65 to unlink the Golgi ribbon for mitosis which also serves 
as a mitotic checkpoint [124, 125, 510, 511]. Our secondary screens demonstrated 
that most of our hits also strongly affected Golgi functions, particularly glycan 
synthesis. The functional implications of most of this glycan regulation are not 
known, apart from the regulation of cell adhesion and motility by O-glycans as 
shown in Chapter 4. Given the vast number of glycosylated proteins in the 
proteome (more than 50% of the proteome), it suggests the critical importance of 
glycans to cell and organism physiology and hence, understanding the regulation 
of glycan biosynthesis is essential. Based on our data, it can be speculated that the 
downstream functions of the identified signaling regulators could also be executed 
from changes in glycan expression. For example, the ERK-regulated remodelling 
of the Golgi during cell migration [116] could also lead to changes in glycan 
structures of adhesive and migratory factors transported to the cell leading edge.  
 
Thus, future efforts should be placed on elucidating the mechanistic basis and 
physiological relevance of Golgi organisation and glycan regulation by the 
identified signalling regulators. This will advance our understanding on the long-
standing questions of how the Golgi maintains and changes its structure under 
215 
 
different conditions. It will also aid comprehension on the role of this organelle in 
various cellular processes and ultimately, its importance in organism physiology 
and pathology. In recent years, various human diseases are increasingly linked to 
the Golgi and its associated proteins, suggesting its critical role in organism 
homeostasis [308]. For instance, mutations and loss of the vesicle tethering COG 
complex leads to defects in Golgi organization and glycosylation and result in 
genetic diseases known as the congenital disorders of glycosylation (CDG) [301]. 
Loss of ubiquitin-protein ligase UBE3A results in altered Golgi morphology and 
protein sialylation, causing the neurodisorder known as Angelman syndrome 
[512]. However, the molecular origins of most disease etiology remain to be 
established. Hence, the study of the molecular basis of Golgi regulation provides 
more complete knowledge of the disease-causing mechanisms and ultimately, aid 
in the development of appropriate therapies. 
 
The study of Golgi regulatory mechanisms can be initiated by more in-depth 
classification of Golgi morphologies. Although the current screen methodology is 
efficient in identifying and distinguishing between the three visually observable 
Golgi perturbations, the approach is constrained by the limits of human vision. 
There are actually different shades of perturbations within each phenotypic 
category and they may arise from very different underlying mechanisms. For 
instance, a fragmented Golgi may or may not involve the loss of perinuclear 
positioning of the Golgi mini-stacks. The latter could arise from loss of lateral 
linking of the Golgi ribbon and the former from perturbations of the microtubule 
cytoskeleton. Therefore, by establishing a more refined classification of Golgi 
phenotypes from our hit gene depletions, it would further distinguish gene 
depletions with similar phenotypes which are most likely acting in common 
pathways and functions. This can be executed through computer-based 
classification and clustering algorithms that are independent of human vision 
[513]. The refined Golgi classification method would greatly improve the 
detection, classification and deciphering of genetic networks in Golgi regulation. 
Subsequent expansion to a genome-wide screen could also reveal putative Golgi 
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targets of the signalling proteins. Signalling proteins that give similar phenotypes 
to known Golgi proteins could represent potential signalling cascades. This could 
generate hypotheses and verified by experimental testing to uncover novel 
regulatory mechanisms on the Golgi 
 
5.2 ERK8 IS A NEGATIVE REGULATOR OF O-GALNAC 
GLYCOSYLATION AND CELL MIGRATION 
 
5.2.1 Main conclusions 
 
The Tn antigen is an O-GalNAc glycan that is frequently up-regulated in tumors 
and its expression correlates with metastasis and poor prognosis. Tn is generated 
during O-glycosylation initiation of secreted and cell surface proteins. Our group 
has previously reported that O-glycosylation initiation can be up-regulated by the 
redistribution of GalNAc-Ts to the ER. The process markedly increases cell 
motility and was found to be activated in more than 60% of human breast 
carcinomas. To better understand the mechanistic basis of Tn expression in 
cancer, I screened 948 signaling and related genes using RNAi and imaging that 
revealed 12 negative regulators of Tn expression. All 12 regulators do not appear 
to regulate Tn levels through inhibition of O-GalNAc elongation but through the 
subcellular localisation of the GalNAc-Ts. Based on their genetic interaction and 
cellular localisation profiles, most of them act at the Golgi level and constitute a 
regulatory network controlling GalNAc-T subcellular localisation. Among the 
most potent regulators was atypical MAP kinase ERK8 whose depletion induced 
dramatic increases in Tn levels. ERK8 partially localise at the Golgi where its 
constitutive kinase activity is required to inhibit COPI-dependent GalNAc-T 
trafficking to the ER. Drug inhibition with Ro-31-8220 induced rapid and 
reversible increases in Tn levels, further demonstrating the directness of ERK8 on 
the process. ERK8 spatially inhibits tyrosine phosphorylation at the Golgi that 
controls GalNAc-T traffic. Growth factor stimulation spontaneously perturbs the 
Golgi fraction of ERK8, thus presenting a dynamic mechanism for the system to 
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control GalNAc-T trafficking according to extracellular signals. Regulation of 
ERK8 on O-GalNAc glycosylation, in turn, inhibits cell motility. In human breast 
and lung carcinomas, ERK8 expression is frequently downregulated while O-
glycosylation initiation is hyperactivated. In sum, my results demonstrate a novel 
role of ERK8 as a constitutive brake on GalNAc-T relocation and loss of its 
expression could drive cancer aggressivity through increased cell motility. 
 
5.2.2 Future directions: more in-depth studies of the regulatory mechanisms 
of GalNAc-T localisation 
 
The focused study on the regulation of Tn expression revealed negative regulators 
that all control GalNAc-T subcellular localisation. Bioinformatics analysis 
indicate that they are likely to act at the level of the Golgi and form a potential 
regulatory network controlling GalNAc-T trafficking. Further experiments will be 
required to confirm this network and its connectivity. In-depth characterization of 
how each of the Tn regulators and their associated pathways regulate GalNAc-T 
trafficking would gain further insights to the mechanisms of signaling control on 
the process. In addition, determining the physiological changes in vivo upon loss/ 
mutations of these proteins will enrich our understanding of mechanisms involved 
in the progression of Tn-related cancers. Extensions of these studies can lead to 
potential therapeutic opportunities.  
 
Among the Tn regulators, my findings highlighted that ERK8 is an important 
node with implications in cancer metastasis. Future efforts should be placed on 
identifying the molecular mechanism of how ERK8 inhibit GalNAc-T relocation. 
Investigations on how and what modulates ERK8 at the Golgi will further enrich 
our understanding on how the system coordinates this brake on GalNAc-T 
relocation. This could be first addressed by identifying ERK8 interactors and 
substrates which could be approached by proteomic techniques such as 
SILAC/mass spectrometry [514] or genetically engineered kinase mutants that 
utilize ATP analogs [515].  The list can be filtered using bioinformatics analyses 
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for Golgi-associated proteins which could constitute the potential upstream 
regulators and substrates involved in GalNAc-T trafficking. Subsequent 
molecular and biochemical validations will be required to confirm the protein-
protein relationships.  
 
The mechanisms involved in the specific targeting GalNAc-T into COPI carriers 
to the ER also require further study. Like most glycosyltransferases, GalNAc-Ts 
are type II integral membrane proteins with a short cytoplasmic tail, 
transmembrane domain and luminal stem, catalytic and lectin domain [241]. 
Localisation signals of most glycosyltransferases mainly reside in the N-terminal 
cytoplasmic tail, transmembrane and stem regions [516-519]. Mechanisms that 
influence the localisation of Golgi glycosyltransferases include direct or indirect 
links through adaptor proteins with the COPI coat [213, 520]. While the 
mechanisms are well-studied in several glycosyltransferases, it is not elucidated 
for GalNAc-Ts. Hence, future efforts should be placed on how GalNAc-Ts 
maintain their Golgi localisation and targeting into COPI carriers. This can be 
addressed by generating substitution and/or chimeric mutants of GalNAc-T to 
determine the essential COPI targeting domains. Immunoprecipitation studies 
with COPI components would verify if they directly interact with the coatomer. 
These experiments should be performed in cells when the ER relocation pathway 
is activated, such as an ERK8-depleted cell line. Identification of the players that 
target GalNAc-Ts to COPI carriers will also aid in the mechanistic study which 
could be addressed by an RNAi screen for genes that promote GalNAc-T 
trafficking to the ER, for instance, by co-RNAi screening with ERK8 depletion 




5.3 THE GOLGI: A HIGHLY REGULATED SORTING AND 
PROCESSING MACHINE  
 
Central in the secretory pathway, the Golgi is a dynamic organelle that constantly 
exchanges proteins and lipids with other organelles and cell surface. This together 
with its role as the primary protein and lipid processing station in the cell indicate 
that its structure and functions must be correctly coordinated and tightly 
controlled under different physiological contexts for cellular growth, survival, 
communication and homeostasis. Dysregulation of these processes can initiate 
pathological conditions. 
 
In recent years, various signaling components that are involved in key cellular 
processes are increasingly discovered to reside at the Golgi and regulate its 
functional organization according to intracellular and extracellular cues [127-
129]. The Golgi was found to be highly responsive to endogenous and exogenous 
stimuli and its functional organization is deeply integrated to various signaling 
events in order to accommodate cellular requirements and modulate homeostasis.  
 
Mitosis regulates Golgi and Golgi regulates mitosis 
 
Perhaps the best studied to date is its critical involvement in mitosis. During 
mitosis, the Golgi ribbon progressively fragments into dispersed elements to 
allow correct partitioning into the two daughter cells. Several signaling players 
including CDK1, RAF/MEK1/ERK1c, Plk1 and Plk3 [130-135] have been found 
to be involved and they phosphorylate Golgi proteins including GRASPs and 
golgins to mediate Golgi fragmentation. Unexpectedly, Golgi fragmentation at the 
G2 phase is also required for mitotic entry, suggesting the existence of a novel 
‘Golgi mitotic checkpoint’ that links the state of Golgi disassembly to mitotic 
progression (Figure 5-1). Failure of Golgi fragmentation would arrest the cell 
cycle at the G2 stage [124, 125, 325]. The exact mechanisms of this checkpoint 
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remain elusive currently but it suggests that the Golgi at G2 phase might initiate 





Figure 5-1. Schematic of the involvement of the Golgi apparatus in mitosis. 
Stimulus for mitosis (orange box represents stimulus) promotes intracellular 
signaling pathways (e.g. phosphorylation of GRASP65 by MEK) (green box 
represents signaling event) which lead to Golgi structural remodeling and 
subsequent breakdown (blue box represents effects on the Golgi). Golgi 
fragmentation at G2 phase also serves as a mitotic checkpoint. Upon Golgi 
fragmentation, mitosis results (yellow box represents cellular process). 
 
 
Golgi re-orientation and cell migration 
 
Another well-established example revolves around directional cell migration in 
response to chemoattractants. The process requires reorientation and structural 
remodeling of the Golgi to the leading edge of the migrating cell [121] so as to 
establish cell polarity and ensure delivery of new membrane and secretory cargo 
to the leading cell periphery. Mechanisms for Golgi remodeling and orientation 
are starting to be elucidated whereby ERK phosphorylation of GRASP65 at serine 
residue 277 have been shown to be crucial (Figure 5-2) [116]. The mechanisms 
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involved in the downstream events in cell polarity and specific trafficking to the 
leading edge of the cell are still unknown, but the current knowledge implies that 
these events could also depend on signaling-based regulation. 
 
The Golgi also generates signaling for its own reorientation during cell migration. 
Binding of germinal-centre kinases III (GCKIII), MST4 and YSK1, to GM130 
recruits them to the Golgi and leads to their activation. This, in turn, 
phosphorylates 14-3-3ζ that might recruit the Par complex for cell polarity and 
migration (Figure 5-2) [117, 148, 326]. This could represent an additional 
regulatory mechanism to the ERK-GRASP65 signaling to ensure alignment of the 





Figure 5-2: Schematic of the involvement of the Golgi apparatus in cell 
migration. Cell migration stimulus by chemoattractants activates intracellular 
signaling pathways involving ERK phosphorylation on GRASP65. GRASP65 
phosphorylation leads to Golgi remodeling and re-orientation to the leading edge 
of the migrating cell. Recruitment and binding of GM130 activates GCKIII 
kinases which participate in establishing Golgi polarity and re-enforces the 





Regulation of cargo flow and regulation of Golgi by cargo 
 
Signaling regulation is also important for controlling general secretion at the 
Golgi level. Golgi PIP4 regulation by protein kinase D (PKD) and p38 MAPK 
[138-141] and protein kinase A (PKA) activation [142, 143] were found to 
remodel the Golgi structure and facilitate cargo flux from the TGN (Figure 5-3A). 
Although the physiological stimuli of these signaling events are still unknown, 
they highlight the involvement of signaling cascades in Golgi functional 
regulation.  
 
One of the most interesting instances of regulation of cargo flow is the initiation 
of signaling by the Golgi to modulate its functional organization. This is 
highlighted by the local activation of the SFKs by the Golgi in response to 
variable cargo load (Figure 5-3B) [145]. This local SFK activation is mediated by 
KDEL receptor binding to the incoming luminal chaperones which enter the 
Golgi with the cargo wave [145]. SFK activation promotes secretion and 
facilitates intra-Golgi trafficking, likely through Golgi organisation remodeling. 
The functional significance of this regulatory mechanism is proposed to maintain 
Golgi homeostasis so as to prevent functional and structural disruption and  









Figure 5-3: Schematic of the regulatory mechanisms of secretion at the Golgi. 
(A) Stimuli for secretion such as activation of G-protein coupled receptor (GPCR) 
promote signaling pathways involving PKD, p38 MAPK and PKA which remodel 
the Golgi and supports post-Golgi trafficking to increase cargo secretion. (B) In 
contrast, increased cargo wave from the ER activates SFKs at the Golgi which 
regulates intra-Golgi trafficking and promotes secretion. 
 
 
Regulation of Golgi glycosylation 
 
These various examples imply that the complex structure and functions of the 
Golgi are under the control of multiple signaling regulations. Current studies 
mainly examine the effects of one or a few genes but this could only provide 
partial information on the complex regulation of the Golgi given the highly 
integrated and dynamic nature of the mammalian Golgi. Moreover, different 
studies vary in experimental setups and biological models used. These 
shortcomings highlighted the importance of studying Golgi regulation in a more 
coordinated and large-scale fashion and this can be resolved by RNAi screening. 
Pioneering RNAi screens have been used to study various aspects of secretory 
pathway regulation such as endocytosis [521, 522], secretion [523, 524] and ER-
Golgi trafficking [392]. To date, a comprehensive study on Golgi morphological 
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regulation has not been attempted. In this study, shown in Chapter 3, I reported 
the utilization of RNAi screening to uncover signaling genes involved in Golgi 
regulation in an unbiased fashion.  
 
The screen results demonstrate significant importance of signaling cascades on 
Golgi organisation regulation with a relatively large proportion (20%) of signaling 
proteins involved. In addition to identifying several known regulators of Golgi 
organisation that validated our approach, the screen also yielded multiple novel 
Golgi regulators which deserve further characterization for their roles at the Golgi 
in the future. The morphological diversity and the extensive morphological 
perturbations from the various gene knockdowns imply that multiple regulatory 
mechanisms are involved. This supported by the unexpectedly high proportion of 
Golgi associated phosphoproteins (413 out of 854) and many interact with the 
signaling hits, forming a large interconnected regulatory network. However, at the 
moment, it remains unknown if the signaling protein-Golgi phosphoprotein 
interaction represents a direct phosphorylation event as the network is built on 
protein-protein interaction information. How this network is regulated, what it 
regulates and its physiological functions in the cell and organism also remain 
mostly unknown, although it has been uncovered for some of the subnetworks 
that I found i.e. PIP4, actomyosin and MAPK subnetworks. Future studies will be 
required to further understand the exact regulatory mechanisms involved and their 
functional implications. Nevertheless, the data obtained from this screen study 
present a global overview of the genetic regulation of signaling regulation on the 
intricate morphology of the mammalian Golgi and hence, provided a rich dataset 
to further explore this question.  
 
On top of the previous examples of functional regulation by signaling cascades, 
our findings propose an additional instance of regulation, which is the regulation 
of Golgi cargo glycosylation, and perhaps also encompassing general cargo 
processing events. We show that a large proportion of signaling proteins affect 
glycan synthesis strongly and variably, indicating that there might be many 
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different glycosylation pathways that are being regulated, presumably by different 
signaling pathways. The massive co-occurrence of glycan and Golgi 
morphological changes implies that the glycosylation perturbations occur through 
Golgi organisational modifications (Figure 5-4A). Overall, it suggests an 
exquisite regulation by the different signaling pathways impacting on the Golgi 
that finely modulates its organization, under different physiological contexts, to 
generate the diversity of glycans patterns expressed.  
 
Each of these glycan patterns has a unique and specific role in mediating cellular 
processes. For instance, the ephrin receptors (e.g. EPHB1) are activated by 
membrane-associated ligands expressed on neighboring cells [525] and cell-cell 
contact promotes ephrin signaling. As reflected by our screen results that EPHB1 
depletion perturbs the Golgi and dramatically influences the expression of the 
truncated Core 1 O-glycan, it indicates that ephrin signaling would regulate Golgi 
structure and O-glycan expression. These effects on glycan synthesis could, in 
turn, control various biological processes downstream of ephrin signaling (Figure 
5-4B). Similarly, growth factor stimulation of the FGF and IGF receptors remodel 
the Golgi and affects glycosylation which could ultimately, influence the plethora 
of physiological processes that are regulated by these receptors [526-528]. 
Supporting this, our data show that FGF and IGF-1 stimulation affect Golgi 
structure within a short duration, indicating that these signaling pathways can 
rapidly regulate Golgi organization and functions (Figure 5-4B). Furthermore, the 
changes in Golgi organization could affect glycan expression patterns on these 
cell surface receptors and in turn, further impact on signaling cascades and 
cellular physiology. 
 
As opposed to gene expression changes of the glycosylation machinery, Golgi 
remodeling would provide a faster mechanism to modulate glycan changes for 
example during stem cell differentiation [430]. Glycan changes could also occur 
to aid progression of spontaneous cellular events such as cell migration [116] and 
mitosis [319]. For instance, modulation of glycans on the glycoproteins and 
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glycolipids that are transported to the leading edge of the cell during cell 
migration could rapidly mediate cell-matrix adhesion and cell-cell 
communication. Indeed, cell adhesive and migratory factors, such as integrins 
[529] and cadherins [530], are known to be heavily glycosylated proteins and the 





Figure 5-4: Schematics of Golgi organization and glycosylation regulation. 
(A) Multiple signaling cascades involving the identified 159 Golgi organization 
regulators are activated by different stimuli. These different signaling pathways 
regulate the Golgi organization and affect different glycosylation pathway. This 
generates a diversity of glycan expressed and each having a unique, distinct role 
in mediating various physiological processes. (B) Examples of regulation of Golgi 
organization and glycosylation by our hits EPHB1, FGFR2 and IGF1R.  
 
 
Signaling regulation of O-glycosylation initiation 
 
Signaling mechanisms can affect the Golgi glycosylation in multiple ways, such 
as modulating the luminal pH, as well as network and cisternal distribution of 
glycosylation enzymes. The latter mechanism is exemplified by the findings of a 
subset of signaling genes that specifically control the cisternal localisation of O-
glycosylation enzymes GalNAc-Ts, and not mannosidase II. This was examined 
in further detail in Chapter 4. Relocation of GalNAc-Ts from the Golgi to the ER 
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was previously shown to be rapidly induced by growth factor stimulation and Src 
activation [193]. Redistribution to the ER increases O-GalNAc glycosylation on 
multiple glycoproteins, leading to an increased expression of the Tn antigen, a 
tumor-associated glycan structure. Tn expression increases cell motility and 
invasiveness of cancer cells and ER O-glycosylation occurs in at least 60% of 
breast carcinomas [194]. My screen identified the molecular players that 
negatively regulate this glycosylation pathway (Figure 5-5). Most of them were 
found to act at the Golgi level, thus validating the dataset. It suggests that many 
signals from various origins impinge at the Golgi to regulate GalNAc-T traffic. 
The precise mechanisms for each of these regulators would require further study 
to gain insights to the progression of Tn-related cancers and aid future 





Figure 5-5: Schematic of the regulation of O-glycosylation initiation. Various 
stimuli impact on multiple signaling cascades involving the 12 Tn regulators 
which control GalNAc-T trafficking at the Golgi. This, in turn, modulates 





Regulation of ER O-glycosylation initiation by ERK8 
 
I have examined the atypical MAPK ERK8 in greater detail. ERK8 was 
previously found to interact with Src through its SH3 domains [444], suggesting 
that it could act in Src regulated pathways. Inhibition of ERK8 resulted in rapid 
increases in O-glycosylation of multiple proteins, suggesting that the kinase acts 
relatively directly on the pathway. This was reconciled by the fact that ERK8 
partially localizes at the Golgi, further indicating that it inhibits trafficking at the 
Golgi (Golgi-to-ER retrograde trafficking) and not at the ER (blocking 
anterograde trafficking to the Golgi). The notion was further substantiated by the 
acute increases in COPI transport carriers containing GalNAc-Ts upon ERK8 
inhibition. How ERK8 selectively inhibits the GalNAc-T COPI trafficking to the 
ER is an interesting aspect to pursue in the future and this can be addressed by 
identifying its Golgi substrates. 
 
Unlike the classical MAPKs that require multiple tiers of activation, ERK8 is a 
constitutively active kinase by autophosphorylation. Rescue experiments with an 
inactive ERK8 mutant demonstrated that the inhibition of GalNAc-T trafficking is 
a kinase activity-dependent event. It indicates that ERK8 phosphorylation on an 
unknown Golgi substrate(s) provides a constant “brake” to this trafficking 
pathway in normal resting cells. In line with this, ERK8 activity is reduced in at 
least two breast cancer cell lines: MCF-7 and T47D [505] which we have also 
found upregulated ER O-glycosylation [194]. This further substantiates that 
ERK8 kinase activity required to inhibit this pathway.  
 
Surprisingly, the ERK8 “brake” is dynamically regulated and is released in times 
when GalNAc-Ts are induced to relocate as observed by the loss of Golgi 
localisation upon growth factor stimulation. Indeed, it makes sense to spatially 
regulate ERK8 given its constitutive kinase activity. Supporting this, the classical 
MAPKs are also dynamically localised to different subcellular locations upon 
stimulation where they act on different substrates [497]. This could also be the 
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case for ERK8. Hence, the underlying mechanisms involved in regulating ERK8 
localisation at the Golgi and its activity when it is relocated should be established 
in the future to gain further insights on ERK8’s functions in the cell. Taken 
together, these results suggest that the ER O-glycosylation pathway is under 
constant, yet dynamic, repression by a constitutively active kinase.  
 
This model presents an interesting alternative mechanism to our current 
knowledge of signaling cascades. Signal transduction pathways are typically 
conceived to be “switch on” by upstream molecule activating a downstream 
effector or by inactivating an inhibitory molecule through phosphorylation events. 
The former being the central dogma of signal transduction pathways, is 
commonly occurring as in the classical MAPK pathway [531], PI3K-Akt [532] 
pathway, and many others. On the other hand, the latter can be observed in the 
NFkB pathway where NFkB is constantly sequestered and inhibited in the 
cytoplasm by the IkB proteins. Phosphorylation of IkB proteins by the IKK 
complex releases NFkB into the nucleus for transcriptional activation,  thus 
activating the pathway [533]. Our findings, hence, presents a novel alternative 
regulatory mechanism of a signaling event. Finally, our findings have increased 
the current knowledge on the poorly characterized functions of ERK8. 
 
5.4 FINAL REMARKS 
 
Protein glycosylation is an essential post-translational modification process for 
numerous different proteins in the cell. The process has profound effects on 
protein functions and controls numerous biological processes, and ultimately cell 
and organism physiology. Most glycosylation reactions occur at the Golgi 
apparatus and depend on its intricate and compartmentalized organization for 
proper glycan synthesis. In recent years, the complex Golgi organization was 
found to be controlled by an increasing number of signaling proteins. For a few of 
them, their effects on Golgi functions and implications in cell physiology are only 
beginning to be elucidated. The regulation of glycosylation at the Golgi and how 
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it relates to health and disease have not been well-studied. Therefore, the findings 
reported in this dissertation had contributed to further understanding to this 







1. Lopez-Garcia P, M.D. (1999). "Metabolic symbiosis at the origin of eukaryotes." 
Trends in biochemical sciences 24(3): 88-93. 
2. Kirschner M, G.J. (1998). "Evolvability." Proceedings of the National Academy 
of Sciences of the United States of America 95(15): 8420-8427. 
3. Warren, G. (1990). "Intracellular transport. Vesicular consumption." Nature 
345(6274): 382-383. 
4. Pryer, N.K., L.J. Wuestehube, et al. (1992). "Vesicle-mediated protein sorting." 
Annual Review of Biochemistry 61: 471-516. 
5. Golgi, C. (1898). "Sur la structure des cellules nerveuses des ganglions spinaux." 
Arch Ital Biologie 30: 278-286. 
6. Klumperman, J. (2011). "Architecture of the Mammalian Golgi." Cold Spring 
Harbor perspectives in biology 3(7): a005181-a005181. 
7. Gillin, F.D., D.S. Reiner, et al. (1996). "Cell biology of the primitive eukaryote 
Giardia lamblia." Annual review of microbiology 50: 679-705. 
8. Preuss, D., J. Mulholland, et al. (1992). "Characterization of the Saccharomyces 
Golgi complex through the cell cycle by immunoelectron microscopy." Mol Biol Cell 
3(7): 789-803. 
9. Rambourg, A., C.L. Jackson, et al. (2001). "Three dimensional configuration of 
the secretory pathway and segregation of secretion granules in the yeast Saccharomyces 
cerevisiae." J Cell Sci 114(Pt 12): 2231-2239. 
10. Pelletier, L., C.A. Stern, et al. (2002). "Golgi biogenesis in Toxoplasma gondii." 
Nature 418(6897): 548-552. 
11. Rabouille, C., T. Misteli, et al. (1995). "Reassembly of Golgi stacks from mitotic 
Golgi fragments in a cell-free system." The Journal of Cell Biology 129(3): 605-618. 
12. Ladinsky, M.S., D.N. Mastronarde, et al. (1999). "Golgi structure in three 
dimensions: functional insights from the normal rat kidney cell." The Journal of Cell 
Biology 144(6): 1135-1149. 
13. Glick, B.S. and A. Nakano (2009). "Membrane traffic within the Golgi 
apparatus." Annual review of cell and developmental biology 25: 113-132. 
14. Rambourg A, C.Y. (1997). "Three-dimensional structure of the Golgi apparatus 
in mammalian cells." In The Golgi Apparatus (ed. E.G. Berger, J. Roth) Birkhauser 
Verlag, Basel.: 37–61. 
15. Mollenhauer, H.H. (1974). "Distribution of microtubules in the golgi apparatus 
of Euglena gracilis." Journal of Cell Science 15(1): 89-97. 
16. Rambourg, A. and Y. Clermont (1990). "Three-dimensional electron microscopy: 
structure of the Golgi apparatus." Eur J Cell Biol 51(2): 189-200. 
17. Glick, B.S. and A. Luini (2011). "Models for Golgi Traffic: A Critical 
Assessment." Cold Spring Harbor perspectives in biology 3(11): a005215-a005215. 
18. Goldfischer, S., E. Essner, et al. (1964). "The Localization of Phosphatase 
Activities at the Level of Ultrastructure." The journal of histochemistry and 
cytochemistry : official journal of the Histochemistry Society 12: 72-95. 
19. Novikoff, P.M., A.B. Novikoff, et al. (1971). "Golgi apparatus, GERL, and 
lysosomes of neurons in rat dorsal root ganglia, studied by thick section and thin section 
cytochemistry." The Journal of Cell Biology 50(3): 859-886. 
20. Grove, S.N., C.E. Bracker, et al. (1968). "Cytomembrane differentiation in the 
endoplasmic reticulum-Golgi apparatus-vesicle complex." Science 161(3837): 171-173. 
232 
 
21. Sprong, H., P. van der Sluijs, et al. (2001). "How proteins move lipids and lipids 
move proteins." Nat Rev Mol Cell Biol 2(7): 504-513. 
22. Orci, L., R. Montesano, et al. (1981). "Heterogeneous distribution of filipin--
cholesterol complexes across the cisternae of the Golgi apparatus." Proceedings of the 
National Academy of Sciences of the United States of America 78(1): 293-297. 
23. Cluett, E.B., E. Kuismanen, et al. (1997). "Heterogeneous distribution of the 
unusual phospholipid semilysobisphosphatidic acid through the Golgi complex." 
Molecular Biology of the Cell 8(11): 2233-2240. 
24. Mobius, W., E. van Donselaar, et al. (2003). "Recycling compartments and the 
internal vesicles of multivesicular bodies harbor most of the cholesterol found in the 
endocytic pathway." Traffic 4(4): 222-231. 
25. Banfield, D.K. (2011). "Mechanisms of Protein Retention in the Golgi." Cold 
Spring Harbor perspectives in biology 3(8): a005264-a005264. 
26. Paroutis, P., N. Touret, et al. (2004). "The pH of the secretory pathway: 
measurement, determinants, and regulation." Physiology (Bethesda) 19: 207-215. 
27. Carnell, L. and H.P. Moore (1994). "Transport via the regulated secretory 
pathway in semi-intact PC12 cells: role of intra-cisternal calcium and pH in the transport 
and sorting of secretogranin II." The Journal of Cell Biology 127(3): 693-705. 
28. Chanat, E. and W.B. Huttner (1991). "Milieu-induced, selective aggregation of 
regulated secretory proteins in the trans-Golgi network." The Journal of Cell Biology 
115(6): 1505-1519. 
29. Chapman, R.E. and S. Munro (1994). "Retrieval of TGN proteins from the cell 
surface requires endosomal acidification." The EMBO journal 13(10): 2305-2312. 
30. Dunphy, W.G., E. Fries, et al. (1981). "Early and late functions associated with 
the Golgi apparatus reside in distinct compartments." Proc Natl Acad Sci U S A 78(12): 
7453-7457. 
31. Farquhar, M.G. and H.P. Hauri (1997). Protein sorting and vesicular traffic in the 
Golgi apparatus. Birkhauser, Basel, Switzerland. 
32. Wang, Y., J.-H. Wei, et al. (2008). "Golgi cisternal unstacking stimulates COPI 
vesicle budding and protein transport." PloS one 3(2): e1647. 
33. Mowbrey K, D.J. (2009). "Evolution and diversity of the Golgi body." FEBS 
Letters 583(23): 3738-3745. 
34. Lees, J.A., C.K. Yip, et al. (2010). "Molecular organization of the COG vesicle 
tethering complex." Nature structural & molecular biology 17(11): 1292-1297. 
35. Marsh, B.J., N. Volkmann, et al. (2004). "Direct continuities between cisternae at 
different levels of the Golgi complex in glucose-stimulated mouse islet beta cells." 
Proceedings of the National Academy of Sciences of the United States of America 
101(15): 5565-5570. 
36. Trucco, A., R.S. Polishchuk, et al. (2004). "Secretory traffic triggers the 
formation of tubular continuities across Golgi sub-compartments." NATURE CELL 
BIOLOGY 6(11): 1071-1081. 
37. Boevink, P., K. Oparka, et al. (1998). "Stacks on tracks: the plant Golgi 
apparatus traffics on an actin/ER network." The Plant journal : for cell and molecular 
biology 15(3): 441-447. 
38. Nebenfuhr, A., L.A. Gallagher, et al. (1999). "Stop-and-go movements of plant 
Golgi stacks are mediated by the acto-myosin system." Plant physiology 121(4): 1127-
1142. 
39. Kondylis, V. and C. Rabouille (2009). "The Golgi apparatus: lessons from 
Drosophila." FEBS Lett 583(23): 3827-3838. 
233 
 
40. Brigance, W.T., C. Barlowe, et al. (2000). "Organization of the yeast Golgi 
complex into at least four functionally distinct compartments." Molecular Biology of the 
Cell 11(1): 171-182. 
41. Dacks, J.B., L.A. Davis, et al. (2003). "Evidence for Golgi bodies in proposed 
'Golgi-lacking' lineages." Proceedings. Biological sciences / The Royal Society 270 
Suppl 2: S168-171. 
42. Mollenhauer, H.H. (1965). "An Intercisternal Structure in the Golgi Apparatus." J 
Cell Biol 24(3): 504-511. 
43. Franke, W.W., J. Kartenbeck, et al. (1972). "Inter- and intracisternal elements of 
the Golgi apparatus. A system of membrane-to-membrane cross-links." Z Zellforsch 
Mikrosk Anat 132(3): 365-380. 
44. Cluett, E.B. and W.J. Brown (1992). "Adhesion of Golgi cisternae by 
proteinaceous interactions: intercisternal bridges as putative adhesive structures." J Cell 
Sci 103 ( Pt 3): 773-784. 
45. Slusarewicz, P., T. Nilsson, et al. (1994). "Isolation of a matrix that binds medial 
Golgi enzymes." J Cell Biol 124(4): 405-413. 
46. Xiang, Y. and Y. Wang (2011). "New components of the Golgi matrix." Cell 
Tissue Res 344(3): 365-379. 
47. Barr, F.A., M. Puype, et al. (1997). "GRASP65, a protein involved in the 
stacking of Golgi cisternae." Cell 91(2): 253-262. 
48. Shorter, J., R. Watson, et al. (1999). "GRASP55, a second mammalian GRASP 
protein involved in the stacking of Golgi cisternae in a cell-free system." EMBO J 
18(18): 4949-4960. 
49. Sutterlin, C., R. Polishchuk, et al. (2005). "The Golgi-associated protein 
GRASP65 regulates spindle dynamics and is essential for cell division." Mol Biol Cell 
16(7): 3211-3222. 
50. Puthenveedu, M.A., C. Bachert, et al. (2006). "GM130 and GRASP65-dependent 
lateral cisternal fusion allows uniform Golgi-enzyme distribution." Nat Cell Biol 8(3): 
238-248. 
51. Feinstein, T.N. and A.D. Linstedt (2008). "GRASP55 regulates Golgi ribbon 
formation." Molecular Biology of the Cell 19(7): 2696-2707. 
52. Xiang, Y. and Y. Wang (2010). "GRASP55 and GRASP65 play complementary 
and essential roles in Golgi cisternal stacking." J Cell Biol 188(2): 237-251. 
53. Kondylis, V., K.M. Spoorendonk, et al. (2005). "dGRASP localization and 
function in the early exocytic pathway in Drosophila S2 cells." Mol Biol Cell 16(9): 
4061-4072. 
54. Levi, S.K., D. Bhattacharyya, et al. (2010). "The yeast GRASP Grh1 colocalizes 
with COPII and is dispensable for organizing the secretory pathway." Traffic 11(9): 
1168-1179. 
55. Behnia, R., F.A. Barr, et al. (2007). "The yeast orthologue of GRASP65 forms a 
complex with a coiled-coil protein that contributes to ER to Golgi traffic." J Cell Biol 
176(3): 255-261. 
56. Schotman, H., L. Karhinen, et al. (2008). "dGRASP-mediated noncanonical 
integrin secretion is required for Drosophila epithelial remodeling." Dev Cell 14(2): 171-
182. 
57. Staehelin, L.A. and B.H. Kang (2008). "Nanoscale architecture of endoplasmic 
reticulum export sites and of Golgi membranes as determined by electron tomography." 
Plant physiology 147(4): 1454-1468. 
58. Faso, C., A. Boulaflous, et al. (2009). "The plant Golgi apparatus: last 10 years of 
answered and open questions." FEBS Lett 583(23): 3752-3757. 
234 
 
59. Sengupta, D., S. Truschel, et al. (2009). "Organelle tethering by a homotypic 
PDZ interaction underlies formation of the Golgi membrane network." J Cell Biol 186(1): 
41-55. 
60. Tang, D., H. Yuan, et al. (2010). "The role of GRASP65 in Golgi cisternal 
stacking and cell cycle progression." Traffic 11(6): 827-842. 
61. Vinke, F.P., A.G. Grieve, et al. (2011). "The multiple facets of the Golgi 
reassembly stacking proteins." Biochem J 433(3): 423-433. 
62. Barr, F.A., N. Nakamura, et al. (1998). "Mapping the interaction between 
GRASP65 and GM130, components of a protein complex involved in the stacking of 
Golgi cisternae." EMBO J 17(12): 3258-3268. 
63. Short, B., C. Preisinger, et al. (2001). "A GRASP55-rab2 effector complex 
linking Golgi structure to membrane traffic." J Cell Biol 155(6): 877-883. 
64. Lowe, M. (2011). "Structural organization of the Golgi apparatus." Current 
Opinion in Cell Biology 23(1): 85-93. 
65. Ramirez, I.B. and M. Lowe (2009). "Golgins and GRASPs: holding the Golgi 
together." Seminars in cell & developmental biology 20(7): 770-779. 
66. Shorter, J. and G. Warren (1999). "A role for the vesicle tethering protein, p115, 
in the post-mitotic stacking of reassembling Golgi cisternae in a cell-free system." J Cell 
Biol 146(1): 57-70. 
67. Rambourg, A., Y. Clermont, et al. (1987). "Tridimensional structure of the Golgi 
apparatus of nonciliated epithelial cells of the ductuli efferentes in rat: an electron 
microscope stereoscopic study." Biology of the cell / under the auspices of the European 
Cell Biology Organization 60(2): 103-115. 
68. Miller, P.M., A.W. Folkmann, et al. (2009). "Golgi-derived CLASP-dependent 
microtubules control Golgi organization and polarized trafficking in motile cells." Nat 
Cell Biol 11(9): 1069-1080. 
69. Wei, J.H. and J. Seemann (2009). "The mitotic spindle mediates inheritance of 
the Golgi ribbon structure." J Cell Biol 184(3): 391-397. 
70. Pelletier, L., E. Jokitalo, et al. (2000). "The effect of Golgi depletion on exocytic 
transport." Nat Cell Biol 2(11): 840-846. 
71. Chabin-Brion, K., J. Marceiller, et al. (2001). "The Golgi complex is a 
microtubule-organizing organelle." Mol Biol Cell 12(7): 2047-2060. 
72. Efimov, A., A. Kharitonov, et al. (2007). "Asymmetric CLASP-dependent 
nucleation of noncentrosomal microtubules at the trans-Golgi network." Developmental 
cell 12(6): 917-930. 
73. Rios, R.M., A. Sanchis, et al. (2004). "GMAP-210 recruits gamma-tubulin 
complexes to cis-Golgi membranes and is required for Golgi ribbon formation." Cell 
118(3): 323-335. 
74. Rivero, S., J. Cardenas, et al. (2009). "Microtubule nucleation at the cis-side of 
the Golgi apparatus requires AKAP450 and GM130." The EMBO journal 28(8): 1016-
1028. 
75. Cole, N.B., N. Sciaky, et al. (1996). "Golgi dispersal during microtubule 
disruption: regeneration of Golgi stacks at peripheral endoplasmic reticulum exit sites." 
Mol Biol Cell 7(4): 631-650. 
76. Wehland, J., M. Henkart, et al. (1983). "Role of microtubules in the distribution 
of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies." 
Proc Natl Acad Sci U S A 80(14): 4286-4290. 
77. Burkhardt, J.K., C.J. Echeverri, et al. (1997). "Overexpression of the dynamitin 
(p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of 
membrane organelle distribution." J Cell Biol 139(2): 469-484. 
235 
 
78. Liang, Y., W. Yu, et al. (2004). "Nudel functions in membrane traffic mainly 
through association with Lis1 and cytoplasmic dynein." J Cell Biol 164(4): 557-566. 
79. Corthesy-Theulaz, I., A. Pauloin, et al. (1992). "Cytoplasmic dynein participates 
in the centrosomal localization of the Golgi complex." J Cell Biol 118(6): 1333-1345. 
80. Hurtado, L., C. Caballero, et al. (2011). "Disconnecting the Golgi ribbon from 
the centrosome prevents directional cell migration and ciliogenesis." J Cell Biol 193(5): 
917-933. 
81. Vinogradova, T., R. Paul, et al. (2012). "Concerted effort of centrosomal and 
Golgi-derived microtubules is required for proper Golgi complex assembly but not for 
maintenance." Mol Biol Cell 23(5): 820-833. 
82. Goldfischer, S., Y. Kress, et al. (1981). "Primary fixation in osmium-potassium 
ferrocyanide: the staining of glycogen, glycoproteins, elastin, an intranuclear reticular 
structure, and intercisternal trabeculae." J Histochem Cytochem 29(9): 1105-1111. 
83. Duran, J.M., M. Kinseth, et al. (2008). "The role of GRASP55 in Golgi 
fragmentation and entry of cells into mitosis." Molecular Biology of the Cell 19(6): 2579-
2587. 
84. Wang, Y., J. Seemann, et al. (2003). "A direct role for GRASP65 as a mitotically 
regulated Golgi stacking factor." The EMBO journal 22(13): 3279-3290. 
85. Nilsson, T., M.H. Hoe, et al. (1994). "Kin recognition between medial Golgi 
enzymes in HeLa cells." EMBO J 13(3): 562-574. 
86. Yadav, S., S. Puri, et al. (2009). "A primary role for Golgi positioning in directed 
secretion, cell polarity, and wound healing." Molecular Biology of the Cell 20(6): 1728-
1736. 
87. Sutterlin, A., M. Sutterlin, et al. (2005). "Normalization of a severely abnormal 
ductus venosus Doppler flow velocity waveform in the presence of normal arterial flow 
parameters." J Perinat Med 33(1): 83-86. 
88. Schoenenberger, C.A., S. Buchmeier, et al. (2005). "Conformation-specific 
antibodies reveal distinct actin structures in the nucleus and the cytoplasm." J Struct Biol 
152(3): 157-168. 
89. Honig, A., L. Rieger, et al. (2005). "Brain metastases in breast cancer--an in vitro 
study to evaluate new systemic chemotherapeutic options." Anticancer Res 25(3A): 
1531-1537. 
90. Kristen, P., R. Lorenz, et al. (2005). "Axillary recurrences after sentinel node 
(SLN) biopsy without complete axillary dissection in breast cancer patients." Br J Cancer 
92(5): 981; author reply 982. 
91. Frambach, T., T. Muller, et al. (2005). "Self-limitation of intravenous tocolysis 
with beta2-adrenergic agonists is mediated through receptor G protein uncoupling." J 
Clin Endocrinol Metab 90(5): 2882-2887. 
92. Stroud, W.J., S. Jiang, et al. (2003). "Persistence of Golgi matrix distribution 
exhibits the same dependence on Sar1p activity as a Golgi glycosyltransferase." Traffic 
4(9): 631-641. 
93. Ward, T.H., R.S. Polishchuk, et al. (2001). "Maintenance of Golgi structure and 
function depends on the integrity of ER export." The Journal of Cell Biology 155(4): 
557-570. 
94. Mardones, G.A., C.M. Snyder, et al. (2006). "Cis-Golgi matrix proteins move 
directly to endoplasmic reticulum exit sites by association with tubules." Molecular 
Biology of the Cell 17(1): 525-538. 
95. Altan-Bonnet, N., R. Sougrat, et al. (2006). "Golgi inheritance in mammalian 
cells is mediated through endoplasmic reticulum export activities." Molecular Biology of 
the Cell 17(2): 990-1005. 
236 
 
96. Puri, S., H. Telfer, et al. (2004). "Dispersal of Golgi matrix proteins during 
mitotic Golgi disassembly." Journal of Cell Science 117(Pt 3): 451-456. 
97. Bechler, M.E., P. de Figueiredo, et al. (2012). "A PLA1-2 punch regulates the 
Golgi complex." Trends in Cell Biology 22(2): 116-124. 
98. Schmidt, J.A. and W.J. Brown (2009). "Lysophosphatidic acid acyltransferase 3 
regulates Golgi complex structure and function." J Cell Biol 186(2): 211-218. 
99. Brown, W.J., K. Chambers, et al. (2003). "Phospholipase A2 (PLA2) enzymes in 
membrane trafficking: mediators of membrane shape and function." Traffic 4(4): 214-
221. 
100. Baumgart, T., S.T. Hess, et al. (2003). "Imaging coexisting fluid domains in 
biomembrane models coupling curvature and line tension." Nature 425(6960): 821-824. 
101. Zimmerberg, J. and M.M. Kozlov (2006). "How proteins produce cellular 
membrane curvature." Nature reviews. Molecular cell biology 7(1): 9-19. 
102. Manneville, J.B., J.F. Casella, et al. (2008). "COPI coat assembly occurs on 
liquid-disordered domains and the associated membrane deformations are limited by 
membrane tension." Proceedings of the National Academy of Sciences of the United 
States of America 105(44): 16946-16951. 
103. Bard, F. and V. Malhotra (2006). "The formation of TGN-to-plasma-membrane 
transport carriers." Annual review of cell and developmental biology 22: 439-455. 
104. Ha, K.D., B.A. Clarke, et al. (2012). "Regulation of the Golgi complex by 
phospholipid remodeling enzymes." Biochim Biophys Acta 1821(8): 1078-1088. 
105. Bechler, M.E., A.M. Doody, et al. (2010). "The phospholipase complex PAFAH 
Ib regulates the functional organization of the Golgi complex." J Cell Biol 190(1): 45-53. 
106. Bechler, M.E., A.M. Doody, et al. (2011). "The phospholipase A(2) enzyme 
complex PAFAH Ib mediates endosomal membrane tubule formation and trafficking." 
Mol Biol Cell 22(13): 2348-2359. 
107. San Pietro, E., M. Capestrano, et al. (2009). "Group IV phospholipase A(2)alpha 
controls the formation of inter-cisternal continuities involved in intra-Golgi transport." 
PLoS Biol 7(9): e1000194. 
108. Yang, J.S., C. Valente, et al. (2011). "COPI acts in both vesicular and tubular 
transport." Nat Cell Biol 13(8): 996-1003. 
109. Dorner, C., T. Ciossek, et al. (1998). "Characterization of KIF1C, a new kinesin-
like protein involved in vesicle transport from the Golgi apparatus to the endoplasmic 
reticulum." J Biol Chem 273(32): 20267-20275. 
110. Dippold, H.C., M.M. Ng, et al. (2009). "GOLPH3 bridges phosphatidylinositol-
4- phosphate and actomyosin to stretch and shape the Golgi to promote budding." Cell 
139(2): 337-351. 
111. Zilberman, Y., N.O. Alieva, et al. (2011). "Involvement of the Rho-mDia1 
pathway in the regulation of Golgi complex architecture and dynamics." Mol Biol Cell 
22(16): 2900-2911. 
112. Campellone, K.G., N.J. Webb, et al. (2008). "WHAMM is an Arp2/3 complex 
activator that binds microtubules and functions in ER to Golgi transport." Cell 134(1): 
148-161. 
113. Diao, A., D. Rahman, et al. (2003). "The coiled-coil membrane protein golgin-84 
is a novel rab effector required for Golgi ribbon formation." J Cell Biol 160(2): 201-212. 
114. Cole, N.B., C.L. Smith, et al. (1996). "Diffusional mobility of Golgi proteins in 
membranes of living cells." Science 273(5276): 797-801. 
115. Marra, P., L. Salvatore, et al. (2007). "The biogenesis of the Golgi ribbon: the 
roles of membrane input from the ER and of GM130." Mol Biol Cell 18(5): 1595-1608. 
116. Bisel, B., Y. Wang, et al. (2008). "ERK regulates Golgi and centrosome 
orientation towards the leading edge through GRASP65." J Cell Biol 182(5): 837-843. 
237 
 
117. Preisinger, C. (2004). "YSK1 is activated by the Golgi matrix protein GM130 
and plays a role in cell migration through its substrate 14-3-3 " The Journal of Cell 
Biology 164(7): 1009-1020. 
118. Stinchcombe, J.C., E. Majorovits, et al. (2006). "Centrosome polarization 
delivers secretory granules to the immunological synapse." Nature 443(7110): 462-465. 
119. Jaffe, A.B. and A. Hall (2005). "Rho GTPases: biochemistry and biology." Annu 
Rev Cell Dev Biol 21: 247-269. 
120. Horton, A.C., B. Racz, et al. (2005). "Polarized secretory trafficking directs cargo 
for asymmetric dendrite growth and morphogenesis." Neuron 48(5): 757-771. 
121. Yadav, S., S. Puri, et al. (2009). "A primary role for Golgi positioning in directed 
secretion, cell polarity, and wound healing." Mol Biol Cell 20(6): 1728-1736. 
122. Magdalena, J., T.H. Millard, et al. (2003). "Microtubule involvement in NIH 3T3 
Golgi and MTOC polarity establishment." J Cell Sci 116(Pt 4): 743-756. 
123. Noske, A.B., A.J. Costin, et al. (2008). "Expedited approaches to whole cell 
electron tomography and organelle mark-up in situ in high-pressure frozen pancreatic 
islets." J Struct Biol 161(3): 298-313. 
124. Sutterlin, C., P. Hsu, et al. (2002). "Fragmentation and dispersal of the 
pericentriolar Golgi complex is required for entry into mitosis in mammalian cells." Cell 
109(3): 359-369. 
125. Yoshimura, S., K. Yoshioka, et al. (2005). "Convergence of cell cycle regulation 
and growth factor signals on GRASP65." J Biol Chem 280(24): 23048-23056. 
126. Rabouille, C. and V. Kondylis (2007). "Golgi ribbon unlinking: an organelle-
based G2/M checkpoint." Cell cycle 6(22): 2723-2729. 
127. Farhan, H. and C. Rabouille (2011). "Signalling to and from the secretory 
pathway." J Cell Sci. 124(Pt 2): 171-180. 
128. Cancino, J. and A. Luini (2013). "Signaling circuits on the Golgi complex." 
Traffic 14(2): 121-134. 
129. Mayinger, P. (2011). "Signaling at the Golgi." Cold Spring Harb Perspect Biol 
3(5). 
130. Colanzi, A., C. Suetterlin, et al. (2003). "Cell-cycle-specific Golgi fragmentation: 
how and why?" Curr Opin Cell Biol 15(4): 462-467. 
131. Misteli, T. and G. Warren (1994). "COP-coated vesicles are involved in the 
mitotic fragmentation of Golgi stacks in a cell-free system." J Cell Biol 125(2): 269-282. 
132. Acharya, U., A. Mallabiabarrena, et al. (1998). "Signaling via mitogen-activated 
protein kinase kinase (MEK1) is required for Golgi fragmentation during mitosis." Cell 
92(2): 183-192. 
133. Sutterlin, C., C.Y. Lin, et al. (2001). "Polo-like kinase is required for the 
fragmentation of pericentriolar Golgi stacks during mitosis." Proc Natl Acad Sci U S A 
98(16): 9128-9132. 
134. Xie, S., Q. Wang, et al. (2004). "MEK1-induced Golgi dynamics during cell 
cycle progression is partly mediated by Polo-like kinase-3." Oncogene 23(21): 3822-
3829. 
135. Shaul, Y.D. and R. Seger (2006). "ERK1c regulates Golgi fragmentation during 
mitosis." J Cell Biol 172(6): 885-897. 
136. Colanzi, A., C. Hidalgo Carcedo, et al. (2007). "The Golgi mitotic checkpoint is 
controlled by BARS-dependent fission of the Golgi ribbon into separate stacks in G2." 
EMBO J 26(10): 2465-2476. 
137. Bard, F. and V. Malhotra (2006). "The formation of TGN-to-plasma-membrane 
transport carriers." Annu Rev Cell Dev Biol 22: 439-455. 
238 
 
138. Hausser A, S.P., Märtens S, Link G, Toker A, Pfizenmaier K. (2005). "Protein 
kinase D regulates vesicular transport by phosphorylating and activating 
phosphatidylinositol-4 kinase IIIbeta at the Golgi complex." Nat Cell Biol 7(9): 880-886. 
139. Liljedahl, M., Y. Maeda, et al. (2001). "Protein kinase D regulates the fission of 
cell surface destined transport carriers from the trans-Golgi network." Cell 104(3): 409-
420. 
140. Bossard, C., D. Bresson, et al. (2007). "Dimeric PKD regulates membrane fission 
to form transport carriers at the TGN." J Cell Biol 179(6): 1123-1131. 
141. Blagoveshchenskaya, A., F.Y. Cheong, et al. (2008). "Integration of Golgi 
trafficking and growth factor signaling by the lipid phosphatase SAC1." J Cell Biol 
180(4): 803-812. 
142. Muniz, M., M.E. Martin, et al. (1997). "Protein kinase A activity is required for 
the budding of constitutive transport vesicles from the trans-Golgi network." Proc Natl 
Acad Sci U S A 94(26): 14461-14466. 
143. Mavillard, F., J. Hidalgo, et al. (2010). "PKA-mediated Golgi remodeling during 
cAMP signal transmission." Traffic 11(1): 90-109. 
144. De Matteis, M.A., A. Di Campli, et al. (2005). "The role of the phosphoinositides 
at the Golgi complex." Biochim Biophys Acta 1744(3): 396-405. 
145. Pulvirenti, T., M. Giannotta, et al. (2008). "A traffic-activated Golgi-based 
signalling circuit coordinates the secretory pathway." Nat Cell Biol 10(8): 912-922. 
146. Wang, Y., J. Seemann, et al. (2003). "A direct role for GRASP65 as a mitotically 
regulated Golgi stacking factor." EMBO J 22(13): 3279-3290. 
147. Preisinger, C., B. Short, et al. (2004). "YSK1 is activated by the Golgi matrix 
protein GM130 and plays a role in cell migration through its substrate 14-3-3zeta." J Cell 
Biol 164(7): 1009-1020. 
148. Hurd, T.W., S. Fan, et al. (2003). "Phosphorylation-dependent binding of 14-3-3 
to the polarity protein Par3 regulates cell polarity in mammalian epithelia." Curr Biol 
13(23): 2082-2090. 
149. Kodani, A., I. Kristensen, et al. (2009). "GM130-dependent control of Cdc42 
activity at the Golgi regulates centrosome organization." Mol Biol Cell 20(4): 1192-1200. 
150. Inder, K., A. Harding, et al. (2008). "Activation of the MAPK module from 
different spatial locations generates distinct system outputs." Mol Biol Cell 19(11): 4776-
4784. 
151. Inder, K. and J.F. Hancock (2008). "System output of the MAPK module is 
spatially regulated." Commun Integr Biol 1(2): 178-179. 
152. Choy, E., V.K. Chiu, et al. (1999). "Endomembrane trafficking of ras: the CAAX 
motif targets proteins to the ER and Golgi." Cell 98(1): 69-80. 
153. Matallanas, D., V. Sanz-Moreno, et al. (2006). "Distinct utilization of effectors 
and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid 
rafts and Golgi complex are dispensable for proliferation and transformation." Mol Cell 
Biol 26(1): 100-116. 
154. Chiu, V.K., T. Bivona, et al. (2002). "Ras signalling on the endoplasmic 
reticulum and the Golgi." Nat Cell Biol 4(5): 343-350. 
155. Torii, S., K. Nakayama, et al. (2004). "Regulatory mechanisms and function of 
ERK MAP kinases." Journal of biochemistry 136(5): 557-561. 
156. Kairouz-Wahbe, R., H. Biliran, et al. (2008). "Anoikis effector Bit1 negatively 
regulates Erk activity." Proc Natl Acad Sci U S A 105(5): 1528-1532. 
157. Haltiwanger, R.S. and J.B. Lowe (2004). "Role of glycosylation in 
development." Annu Rev Biochem 73: 491-537. 
158. Paulson, J.C., O. Blixt, et al. (2006). "Sweet spots in functional glycomics." Nat 
Chem Biol 2(5): 238-248. 
239 
 
159. Ohtsubo, K. and J.D. Marth (2006). "Glycosylation in cellular mechanisms of 
health and disease." Cell 126(5): 855-867. 
160. Raman, R., S. Raguram, et al. (2005). "Glycomics: an integrated systems 
approach to structure-function relationships of glycans." Nat Methods 2(11): 817-824. 
161. Nairn, A.V., W.S. York, et al. (2008). "Regulation of glycan structures in animal 
tissues: transcript profiling of glycan-related genes." J Biol Chem 283(25): 17298-17313. 
162. Cummings, R.D. (2009). "The repertoire of glycan determinants in the human 
glycome." Mol Biosyst 5(10): 1087-1104. 
163. Nairn, A.V. and K.W. Moremen "Handbook of Glycomics."  (eds Cummings, R. 
& Pierce, J.M.): 95–136. 
164. Schachter, H. (2000). "The joys of HexNAc. The synthesis and function of N- 
and O-glycan branches." Glycoconj J 17(7-9): 465-483. 
165. Yan, A. and W.J. Lennarz (2005). "Unraveling the mechanism of protein N-
glycosylation." J Biol Chem 280(5): 3121-3124. 
166. Cao, R., Y. Liu, et al. (2010). "Improvement of hydrophobic integral membrane 
protein identification by mild performic acid oxidation-assisted digestion." Analytical 
biochemistry 407(2): 196-204. 
167. Kinoshita, T., K. Ohishi, et al. (1997). "GPI-anchor synthesis in mammalian 
cells: genes, their products, and a deficiency." J Biochem 122(2): 251-257. 
168. Esko, J.D. and S.B. Selleck (2002). "Order out of chaos: assembly of ligand 
binding sites in heparan sulfate." Annu Rev Biochem 71: 435-471. 
169. Maccioni, H.J., C.G. Giraudo, et al. (2002). "Understanding the stepwise 
synthesis of glycolipids." Neurochem Res 27(7-8): 629-636. 
170. Weigel, P.H., V.C. Hascall, et al. (1997). "Hyaluronan synthases." J Biol Chem 
272(22): 13997-14000. 
171. Munro, S. (2001). "What can yeast tell us about N-linked glycosylation in the 
Golgi apparatus?" FEBS Lett 498(2-3): 223-227. 
172. Varki, A., H.H. Freeze, et al. (2009). "Evolution of Glycan Diversity." Essentials 
of Glycobiology. 
173. Moremen, K.W., M. Tiemeyer, et al. (2012). "Vertebrate protein glycosylation: 
diversity, synthesis and function." Nat Rev Mol Cell Biol 13(7): 448-462. 
174. Freeze, H.H. (2006). "Genetic defects in the human glycome." Nat Rev Genet 
7(7): 537-551. 
175. Varki, A. (1995). "Oligosaccharides in vertebrate development." Seminars Dev 
Biol 6: 127–138. 
176. Takeuchi, M., Kobata, A. (1991). "Structures and functional roles of the sugar 
chains of human erythropoietins." Glycobiology 1(4): 337-346. 
177. Marino, K., Bones, J., Kattla, J. J., Rudd, P. M. (2010). "A systematic approach 
to protein glycosylation analysis: a path through the maze." Nat Chem Biol 6(10): 713-
723. 
178. Varki, A. and J.B. Lowe (2009). "Biological Roles of Glycans." Essentials of 
Glycobiology. 
179. Brockhausen, I., H. Schachter, et al. (2009). "O-GalNAc Glycans." Essentials of 
Glycobiology. 
180. Padera, R., G. Venkataraman, et al. (1999). "FGF-2/fibroblast growth factor 
receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 
signaling." FASEB J 13(13): 1677-1687. 
181. Sakata, H., S.J. Stahl, et al. (1997). "Heparin binding and oligomerization of 
hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan 
requirement for Met binding and signaling." J Biol Chem 272(14): 9457-9463. 
240 
 
182. Varki, A. (1993). "Biological roles of oligosaccharides: all of the theories are 
correct." Glycobiology 3(2): 97-130. 
183. Rosen, S.D. (2004). "Ligands for L-selectin: homing, inflammation, and 
beyond." Annu Rev Immunol 22: 129-156. 
184. Shur, B.D., M.A. Ensslin, et al. (2004). "SED1 function during mammalian 
sperm-egg adhesion." Curr Opin Cell Biol 16(5): 477-485. 
185. Surani, M.A. (1979). "Glycoprotein synthesis and inhibition of glycosylation by 
tunicamycin in preimplantation mouse embryos: compaction and trophoblast adhesion." 
Cell 18(1): 217-227. 
186. Akama, T.O., A.K. Misra, et al. (2002). "Enzymatic synthesis in vitro of the 
disulfated disaccharide unit of corneal keratan sulfate." J Biol Chem 277(45): 42505-
42513. 
187. Dennis, J.W., Granovsky, M., Warren, C. E. (1999). "Protein glycosylation in 
development and disease." Bioessays 21(5): 412-421. 
188. Partridge, E.A., C. Le Roy, et al. (2004). "Regulation of cytokine receptors by 
Golgi N-glycan processing and endocytosis." Science 306(5693): 120-124. 
189. Hoseki, J., R. Ushioda, et al. (2010). "Mechanism and components of 
endoplasmic reticulum-associated degradation." J Biochem 147(1): 19-25. 
190. Kollmann, K., S. Pohl, et al. (2010). "Mannose phosphorylation in health and 
disease." Eur J Cell Biol 89(1): 117-123. 
191. Bax, M., J.J. Garcia-Vallejo, et al. (2007). "Dendritic cell maturation results in 
pronounced changes in glycan expression affecting recognition by siglecs and galectins." 
J Immunol 179(12): 8216-8224. 
192. Lau, K.S., E.A. Partridge, et al. (2007). "Complex N-glycan number and degree 
of branching cooperate to regulate cell proliferation and differentiation." Cell 129(1): 
123-134. 
193. Gill, D.J., J. Chia, et al. (2010). "Regulation of O-glycosylation through Golgi-to-
ER relocation of initiation enzymes." J Cell Biol 189(5): 843-858. 
194. Gill, D.J., K.M. Tham, et al. (2013). "Initiation of GalNAc-type O-glycosylation 
in the endoplasmic reticulum promotes cancer cell invasiveness." Proc Natl Acad Sci U S 
A 110(34): E3152-3161. 
195. Ohtsubo, K., S. Takamatsu, et al. (2005). "Dietary and genetic control of glucose 
transporter 2 glycosylation promotes insulin secretion in suppressing diabetes." Cell 
123(7): 1307-1321. 
196. Fuster, M.M., Esko, J. D. (2005). "The sweet and sour of cancer: glycans as 
novel therapeutic targets." Nat Rev Cancer 5(7): 526-542. 
197. Brockhausen, I. (2006). "Mucin-type O-glycans in human colon and breast 
cancer: glycodynamics and functions." EMBO Rep 7(6): 599-604. 
198. Marth, J.D., Grewal, P. K. (2008). "Mammalian glycosylation in immunity." Nat 
Rev Immunol 8(11): 874-887. 
199. Schulz BL, S.A., Robinson LJ, Prasad SS, Lindner RA, Robinson M, Bye PT, 
Nielson DW, Harry JL, Packer NH, Karlsson NG. (2007). "Glycosylation of sputum 
mucins is altered in cystic fibrosis patients." Glycobiology 17(7): 698-712. 
200. Van Beek, W.P., L.A. Smets, et al. (1975). "Changed surface glycoprotein as a 
marker of malignancy in human leukaemic cells." Nature 253: 457–460. 
201. Julien S, A.E., Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, 
Hanisch FG, Delannoy P, Le Bourhis X. (2006). "ST6GalNAc I expression in MDA-MB-
231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their 
tumourigenicity." Glycobiology 16(1): 54-64. 
202. Gabius, H.J. (2011). "Glycobiomarkers by glycoproteomics and glycan profiling 
(glycomics): emergence of functionality." Biochem Soc Trans 39(1): 399-405. 
241 
 
203. Li, M., Song, L., Qin, X. (2010). "Glycan changes: cancer metastasis and anti-
cancer vaccines." J Biosci 35(4): 665-673. 
204. Kang, J.G., Ko, J. H., Kim, Y. S. (2011). "Pros and cons of using aberrant 
glycosylation as companion biomarkers for therapeutics in cancer." BMB Rep 44(12): 
765-771. 
205. Takashima, S. (2008). "Characterization of mouse sialyltransferase genes: their 
evolution and diversity." Biosci Biotechnol Biochem 72(5): 1155-1167. 
206. Koles, K., K.D. Irvine, et al. (2004). "Functional characterization of Drosophila 
sialyltransferase." J Biol Chem 279(6): 4346-4357. 
207. Tian, E. and K.G. Ten Hagen (2009). "Recent insights into the biological roles of 
mucin-type O-glycosylation." Glycoconj J 26(3): 325-334. 
208. Kitazume, S., R. Oka, et al. (2009). "Molecular insights into beta-galactoside 
alpha2,6-sialyltransferase secretion in vivo." Glycobiology 19(5): 479-487. 
209. Shifley, E.T. and S.E. Cole (2008). "Lunatic fringe protein processing by 
proprotein convertases may contribute to the short protein half-life in the segmentation 
clock." Biochim Biophys Acta 1783(12): 2384-2390. 
210. Nilsson, T., P. Slusarewicz, et al. (1993). "Kin recognition. A model for the 
retention of Golgi enzymes." FEBS Lett 330(1): 1-4. 
211. Nilsson, T., C. Rabouille, et al. (1996). "The role of the membrane-spanning 
domain and stalk region of N-acetylglucosaminyltransferase I in retention, kin 
recognition and structural maintenance of the Golgi apparatus in HeLa cells." J Cell Sci 
109 ( Pt 7): 1975-1989. 
212. Opat, A.S., F. Houghton, et al. (2000). "Medial Golgi but not late Golgi 
glycosyltransferases exist as high molecular weight complexes. Role of luminal domain 
in complex formation and localization." J Biol Chem 275(16): 11836-11845. 
213. Tu, L., W.C. Tai, et al. (2008). "Signal-mediated dynamic retention of 
glycosyltransferases in the Golgi." Science 321(5887): 404-407. 
214. Tu, L. and D.K. Banfield (2010). "Localization of Golgi-resident 
glycosyltransferases." Cell Mol Life Sci 67(1): 29-41. 
215. Sen, J., J.S. Goltz, et al. (2000). "Windbeutel is required for function and correct 
subcellular localization of the Drosophila patterning protein Pipe." Development 127(24): 
5541-5550. 
216. Ju, T. and R.D. Cummings (2002b). "A unique molecular chaperone Cosmc 
required for activity of the mammalian core 1 beta 3-galactosyltransferase." Proceedings 
of the National Academy of Sciences of the United States of America 99(26): 16613-
16618. 
217. Aryal, R.P., T. Ju, et al. (2010). "The endoplasmic reticulum chaperone Cosmc 
directly promotes in vitro folding of T-synthase." J Biol Chem 285(4): 2456-2462. 
218. Zielinska, D.F., F. Gnad, et al. (2010). "Precision mapping of an in vivo N-
glycoproteome reveals rigid topological and sequence constraints." Cell 141(5): 897-907. 
219. Kornfeld, R. and S. Kornfeld (1985). "Assembly of asparagine-linked 
oligosaccharides." Annu Rev Biochem 54: 631-664. 
220. Kelleher, D.J. and R. Gilmore (2006). "An evolving view of the eukaryotic 
oligosaccharyltransferase." Glycobiology 16(4): 47R-62R. 
221. Lederkremer, G.Z. (2009). "Glycoprotein folding, quality control and ER-
associated degradation." Curr Opin Struct Biol 19(5): 515-523. 
222. Helenius, A. and M. Aebi (2004). "Roles of N-linked glycans in the endoplasmic 
reticulum." Annu Rev Biochem 73: 1019-1049. 
223. An, H.J., P. Gip, et al. (2012). "Extensive determination of glycan heterogeneity 
reveals an unusual abundance of high mannose glycans in enriched plasma membranes of 
human embryonic stem cells." Mol Cell Proteomics 11(4): M111 010660. 
242 
 
224. Stanley, P., H. Schachter, et al. (2009). "N-Glycans." 
225. Koles, K., J.M. Lim, et al. (2007). "Identification of N-glycosylated proteins 
from the central nervous system of Drosophila melanogaster." Glycobiology 17(12): 
1388-1403. 
226. Aoki, K., M. Perlman, et al. (2007). "Dynamic developmental elaboration of N-
linked glycan complexity in the Drosophila melanogaster embryo." J Biol Chem 282(12): 
9127-9142. 
227. Cipollo, J.F., A.M. Awad, et al. (2005). "N-Glycans of Caenorhabditis elegans 
are specific to developmental stages." J Biol Chem 280(28): 26063-26072. 
228. Lau, K.S. and J.W. Dennis (2008). "N-Glycans in cancer progression." 
Glycobiology 18(10): 750-760. 
229. Lowe, J.B. and J.D. Marth (2003). "A genetic approach to Mammalian glycan 
function." Annual Review of Biochemistry 72: 643-691. 
230. Hart, G.W. (1997). "Dynamic O-linked glycosylation of nuclear and cytoskeletal 
proteins." Annu Rev Biochem 66: 315-335. 
231. Wopereis, S., D.J. Lefeber, et al. (2006). "Mechanisms in protein O-glycan 
biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: 
a review." Clin Chem 52(4): 574-600. 
232. Luther, K.B. and R.S. Haltiwanger (2009). "Role of unusual O-glycans in 
intercellular signaling." Int J Biochem Cell Biol 41(5): 1011-1024. 
233. Hashimoto, K., T. Tokimatsu, et al. (2009). "Comprehensive analysis of 
glycosyltransferases in eukaryotic genomes for structural and functional characterization 
of glycans." Carbohydr Res 344(7): 881-887. 
234. Hanisch, F.G. (2001). "O-glycosylation of the mucin type." Biol Chem 382(2): 
143-149. 
235. Hang, H.C. and C.R. Bertozzi (2005). "The chemistry and biology of mucin-type 
O-linked glycosylation." Bioorg Med Chem 13(17): 5021-5034. 
236. Halim, A., G. Brinkmalm, et al. (2011). "Site-specific characterization of 
threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-
peptides in human cerebrospinal fluid." Proc Natl Acad Sci U S A 108(29): 11848-11853. 
237. Halim, A., J. Nilsson, et al. (2012). "Human urinary glycoproteomics; attachment 
site specific analysis of N- and O-linked glycosylations by CID and ECD." Mol Cell 
Proteomics 11(4): M111 013649. 
238. Steentoft, C., S.Y. Vakhrushev, et al. (2011). "Mining the O-glycoproteome 
using zinc-finger nuclease-glycoengineered SimpleCell lines." Nat Methods 8(11): 977-
982. 
239. Schjoldager, K.T. and H. Clausen (2012). "Site-specific protein O-glycosylation 
modulates proprotein processing - deciphering specific functions of the large polypeptide 
GalNAc-transferase gene family." Biochim Biophys Acta 1820(12): 2079-2094. 
240. Gill, D.J., H. Clausen, et al. (2011). "Location, location, location: new insights 
into O-GalNAc protein glycosylation." Trends Cell Biol 21(3): 149-158. 
241. Bennett, E.P., U. Mandel, et al. (2012). "Control of mucin-type O-glycosylation: 
a classification of the polypeptide GalNAc-transferase gene family." Glycobiology 22(6): 
736-756. 
242. Tran, D.T. and K.G. Ten Hagen (2013). "Mucin-type O-glycosylation during 
development." J Biol Chem 288(10): 6921-6929. 
243. Schwientek, T., E.P. Bennett, et al. (2002). "Functional conservation of 
subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-
acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. 




244. ten Hagen, K.G., L. Zhang, et al. (2009). "Glycobiology on the fly: 
developmental and mechanistic insights from Drosophila." Glycobiology 19(2): 102-111. 
245. Hassan, H., C.A. Reis, et al. (2000). "The lectin domain of UDP-N-acetyl-D-
galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its 
glycopeptide specificities." J Biol Chem 275(49): 38197-38205. 
246. Bennett, E.P., H. Hassan, et al. (1999). "Cloning and characterization of a close 
homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-
acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not 
functional redundancy." J Biol Chem 274(36): 25362-25370. 
247. Rottger, S., J. White, et al. (1998). "Localization of three human polypeptide 
GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation 
throughout the Golgi apparatus." J Cell Sci 111 ( Pt 1): 45-60. 
248. Kato, K., C. Jeanneau, et al. (2006). "Polypeptide GalNAc-transferase T3 and 
familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-
glycosylation." J Biol Chem 281(27): 18370-18377. 
249. Schjoldager, K.T., M.B. Vester-Christensen, et al. (2010). "O-glycosylation 
modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of 
polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids." J 
Biol Chem 285(47): 36293-36303. 
250. Miwa, H.E., T.A. Gerken, et al. (2010). "Isoform-specific O-glycosylation of 
osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1." J 
Biol Chem 285(2): 1208-1219. 
251. Ju, T., V.I. Otto, et al. (2011). "The Tn antigen-structural simplicity and 
biological complexity." Angew Chem Int Ed Engl 50(8): 1770-1791. 
252. Springer, G. (1984). "T and Tn, general carcinoma autoantigens." Science 
224(4654): 1198-1206. 
253. Springer, G.F. (1997). "Immunoreactive T and Tn epitopes in cancer diagnosis, 
prognosis, and immunotherapy." Journal of molecular medicine (Berlin, Germany) 75(8): 
594-602. 
254. Desai, P. (2000). "Immunoreactive T and Tn antigens in malignancy: role in 
carcinoma diagnosis, prognosis, and immunotherapy." Transfus Med Rev 14(4): 312-325. 
255. Saeland, E., S.J. van Vliet, et al. (2007). "The C-type lectin MGL expressed by 
dendritic cells detects glycan changes on MUC1 in colon carcinoma." Cancer Immunol 
Immunother 56(8): 1225-1236. 
256. Kozarsky, K., D. Kingsley, et al. (1988). "Use of a mutant cell line to study the 
kinetics and function of O-linked glycosylation of low density lipoprotein receptors." 
Proc Natl Acad Sci U S A 85(12): 4335-4339. 
257. Kuwano, M., T. Seguchi, et al. (1991). "Glycosylation mutations of 
serine/threonine-linked oligosaccharides in low-density lipoprotein receptor: 
indispensable roles of O-glycosylation." J Cell Sci 98 ( Pt 2): 131-134. 
258. Byrne, S.L., R. Leverence, et al. (2006). "Effect of glycosylation on the function 
of a soluble, recombinant form of the transferrin receptor." Biochemistry 45(21): 6663-
6673. 
259. Liu, W., V. Ramachandran, et al. (1998). "Identification of N-terminal residues 
on P-selectin glycoprotein ligand-1 required for binding to P-selectin." J Biol Chem 
273(12): 7078-7087. 
260. Endo, T. (2007). "Dystroglycan glycosylation and its role in alpha-
dystroglycanopathies." Acta Myol 26(3): 165-170. 
261. Marcos, N.T., S. Pinho, et al. (2004). "Role of the human ST6GalNAc-I and 




262. Julien, S., E. Adriaenssens, et al. (2006). "ST6GalNAc I expression in MDA-
MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances 
their tumourigenicity." Glycobiology 16(1): 54-64. 
263. Brockhausen, I., J. Yang, et al. (1998). "Enzymatic basis for sialyl-Tn expression 
in human colon cancer cells." Glycoconj J 15(6): 595-603. 
264. Ju, T., K. Brewer, et al. (2002a). "Cloning and expression of human core 1 
beta1,3-galactosyltransferase." J Biol Chem 277(1): 178-186. 
265. Xia, L., T. Ju, et al. (2004). "Defective angiogenesis and fatal embryonic 
hemorrhage in mice lacking core 1-derived O-glycans." J Cell Biol 164(3): 451-459. 
266. Ju, T., R.P. Aryal, et al. (2008). "Regulation of protein O-glycosylation by the 
endoplasmic reticulum-localized molecular chaperone Cosmc." J Cell Biol 182(3): 531-
542. 
267. Ju, T., G.S. Lanneau, et al. (2008a). "Human tumor antigens Tn and sialyl Tn 
arise from mutations in Cosmc." Cancer Res 68(6): 1636-1646. 
268. Lee, Y.C., M. Kaufmann, et al. (1999). "Molecular cloning and functional 
expression of two members of mouse NeuAcalpha2,3Galbeta1,3GalNAc 
GalNAcalpha2,6-sialyltransferase family, ST6GalNAc III and IV." J Biol Chem 274(17): 
11958-11967. 
269. Bierhuizen, M.F. and M. Fukuda (1992). "Expression cloning of a cDNA 
encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc 
transferase by gene transfer into CHO cells expressing polyoma large tumor antigen." 
Proc Natl Acad Sci U S A 89(19): 9326-9330. 
270. Carlow, D.A., S.Y. Corbel, et al. (2001). "IL-2, -4, and -15 differentially regulate 
O-glycan branching and P-selectin ligand formation in activated CD8 T cells." J Immunol 
167(12): 6841-6848. 
271. Mitoma, J. and M. Fukuda (2010). "Core O-glycans required for lymphocyte 
homing gene knockout mice of core 1 beta1,3-N-acetylglucosaminyltransferase and core 
2 N-acetylglucosaminyltransferase." Methods Enzymol 479: 257-270. 
272. Brockhausen, I., W. Kuhns, et al. (1991). "Biosynthesis of O-glycans in 
leukocytes from normal donors and from patients with leukemia: increase in O-glycan 
core 2 UDP-GlcNAc:Gal beta 3 GalNAc alpha-R (GlcNAc to GalNAc) beta(1-6)-N-
acetylglucosaminyltransferase in leukemic cells." Cancer Res 51(4): 1257-1263. 
273. Lanteri, M., V. Giordanengo, et al. (2003). "Altered T cell surface glycosylation 
in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death." 
Glycobiology 13(12): 909-918. 
274. Vavasseur, F., J.M. Yang, et al. (1995). "Synthesis of O-glycan core 3: 
characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase 
activity from colonic mucosal tissues and lack of the activity in human cancer cell lines." 
Glycobiology 5(3): 351-357. 
275. Iwai, T., N. Inaba, et al. (2002). "Molecular cloning and characterization of a 
novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 
3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans." J Biol Chem 
277(15): 12802-12809. 
276. Byrd, J.C. and R.S. Bresalier (2004). "Mucins and mucin binding proteins in 
colorectal cancer." Cancer metastasis reviews 23(1-2): 77-99. 
277. Iwai, T., T. Kudo, et al. (2005). "Core 3 synthase is down-regulated in colon 
carcinoma and profoundly suppresses the metastatic potential of carcinoma cells." Proc 
Natl Acad Sci U S A 102(12): 4572-4577. 
278. Garner, B., A.H. Merry, et al. (2001). "Structural elucidation of the N- and O-
glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance." 
J Biol Chem 276(25): 22200-22208. 
245 
 
279. Kim, Y.S. and S.B. Ho (2010). "Intestinal goblet cells and mucins in health and 
disease: recent insights and progress." Curr Gastroenterol Rep 12(5): 319-330. 
280. Skelton, T.P., C. Zeng, et al. (1998). "Glycosylation provides both stimulatory 
and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan." J Cell 
Biol 140(2): 431-446. 
281. Stone, E.L., M.N. Ismail, et al. (2009). "Glycosyltransferase function in core 2-
type protein O glycosylation." Mol Cell Biol 29(13): 3770-3782. 
282. Ugorski, M. and A. Laskowska (2002). "Sialyl Lewis(a): a tumor-associated 
carbohydrate antigen involved in adhesion and metastatic potential of cancer cells." Acta 
Biochim Pol 49(2): 303-311. 
283. Comelli, E.M., S.R. Head, et al. (2006). "A focused microarray approach to 
functional glycomics: transcriptional regulation of the glycome." Glycobiology 16(2): 
117-131. 
284. Lanctot, P.M., Gage, F. H., Varki, A. P. (2007). "The glycans of stem cells." Curr 
Opin Chem Biol 11(4): 373-380. 
285. Gawlitzek, M., Ryll, T., Lofgren, J., Sliwkowski, M. B. (2000). "Ammonium 
alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic 
mechanisms." Biotechnol Bioeng 68(6): 637-646. 
286. McCaffrey, G. and J.C. Jamieson (1993). "Evidence for the role of a cathepsin D-
like activity in the release of Gal beta 1-4GlcNAc alpha 2-6sialyltransferase from rat and 
mouse liver in whole-cell systems." Comp Biochem Physiol B 104(1): 91-94. 
287. Nilsson, T., C.E. Au, et al. (2009). "Sorting out glycosylation enzymes in the 
Golgi apparatus." FEBS Lett 583(23): 3764-3769. 
288. Axelsson, M.A., N.G. Karlsson, et al. (2001). "Neutralization of pH in the Golgi 
apparatus causes redistribution of glycosyltransferases and changes in the O-
glycosylation of mucins." Glycobiology 11(8): 633-644. 
289. Rivinoja, A., A. Hassinen, et al. (2009). "Elevated Golgi pH impairs terminal N-
glycosylation by inducing mislocalization of Golgi glycosyltransferases." J Cell Physiol 
220(1): 144-154. 
290. Hassinen, A., F.M. Pujol, et al. (2011). "Functional organization of Golgi N- and 
O-glycosylation pathways involves pH-dependent complex formation that is impaired in 
cancer cells." J Biol Chem 286(44): 38329-38340. 
291. Maeda, Y., T. Ide, et al. (2008). "GPHR is a novel anion channel critical for 
acidification and functions of the Golgi apparatus." Nat Cell Biol 10(10): 1135-1145. 
292. Maeda, Y. and T. Kinoshita (2010). "The acidic environment of the Golgi is 
critical for glycosylation and transport." Methods Enzymol 480: 495-510. 
293. Waldman, B.C. and G. Rudnick (1990). "UDP-GlcNAc transport across the 
Golgi membrane: electroneutral exchange for dianionic UMP." Biochemistry 29(1): 44-
52. 
294. Rivinoja, A., N. Kokkonen, et al. (2006). "Elevated Golgi pH in breast and 
colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-
antigen." J Cell Physiol 208(1): 167-174. 
295. Berninsone, P.M. and C.B. Hirschberg (2000). "Nucleotide sugar transporters of 
the Golgi apparatus." Curr Opin Struct Biol 10(5): 542-547. 
296. Lubke, T., T. Marquardt, et al. (2001). "Complementation cloning identifies 
CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose 
transporter deficiency." Nat Genet 28(1): 73-76. 
297. Schwarzkopf, M., K.P. Knobeloch, et al. (2002). "Sialylation is essential for early 
development in mice." Proc Natl Acad Sci U S A 99(8): 5267-5270. 
246 
 
298. Xu, Y.X., L. Liu, et al. (2010). "Inhibition of Golgi apparatus glycosylation 
causes endoplasmic reticulum stress and decreased protein synthesis." J Biol Chem 
285(32): 24600-24608. 
299. Huang, H.-H. and P. Stanley (2010). "A testis-specific regulator of complex and 
hybrid N-glycan synthesis." The Journal of Cell Biology 190(5): 893-910. 
300. Yamaji, T., K. Nishikawa, et al. (2010). "Transmembrane BAX inhibitor motif 
containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 
synthase, and reduces Gb3 biosynthesis." J Biol Chem 285(46): 35505-35518. 
301. Smith, R.D. and V.V. Lupashin (2008). "Role of the conserved oligomeric Golgi 
(COG) complex in protein glycosylation." Carbohydr Res 343(12): 2024-2031. 
302. Podos, S.D., P. Reddy, et al. (1994). "LDLC encodes a brefeldin A-sensitive, 
peripheral Golgi protein required for normal Golgi function." J Cell Biol 127(3): 679-
691. 
303. Zeevaert, R., F. Foulquier, et al. (2008). "Deficiencies in subunits of the 
Conserved Oligomeric Golgi (COG) complex define a novel group of Congenital 
Disorders of Glycosylation." Mol Genet Metab 93(1): 15-21. 
304. Lubbehusen, J., C. Thiel, et al. (2010). "Fatal outcome due to deficiency of 
subunit 6 of the conserved oligomeric Golgi complex leading to a new type of congenital 
disorders of glycosylation." Hum Mol Genet 19(18): 3623-3633. 
305. Foulquier, F. (2009). "COG defects, birth and rise!" Biochim Biophys Acta 
1792(9): 896-902. 
306. Wu, X., Steet, R. A., Bohorov, O., Bakker, J., Newell, J., Krieger, M., Spaapen, 
L., Kornfeld, S., Freeze, H. H. (2004). "Mutation of the COG complex subunit gene 
COG7 causes a lethal congenital disorder." Nat Med 10(5): 518-523. 
307. Freeze, H.H. and B.G. Ng (2011). "Golgi glycosylation and human inherited 
diseases." Cold Spring Harb Perspect Biol 3(9): a005371. 
308. Bexiga, M.G. and J.C. Simpson (2013). "Human diseases associated with form 
and function of the Golgi complex." Int J Mol Sci 14(9): 18670-18681. 
309. Moreau, D., P. Kumar, et al. (2011). "Genome-wide RNAi screens identify genes 
required for Ricin and PE intoxications." Dev Cell 21(2): 231-244. 
310. Swamy MJ, G.D., Mahanta SK, Surolia A (1991). "Further characterization of 
the saccharide specificity of peanut (Arachis hypogaea) agglutinin." Carbohydr Res 213: 
59-67. 
311. Sen, B.H., B.G. Akdeniz, et al. (2000). "The effect of ethylenediamine-tetraacetic 
acid on Candida albicans." Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90(5): 
651-655. 
312. Debray, H., D. Decout, et al. (1981). "Specificity of twelve lectins towards 
oligosaccharides and glycopeptides related to N-glycosylproteins." Eur J Biochem 
117(1): 41-55. 
313. Schwarz, R.E., D.C. Wojciechowicz, et al. (1996). "Phytohemagglutinin-L 
(PHA-L) lectin surface binding of N-linked beta 1-6 carbohydrate and its relationship to 
activated mutant ras in human pancreatic cancer cell lines." Cancer Lett 107(2): 285-291. 
314. Cummings, R.D. and S. Kornfeld (1982). "Characterization of the structural 
determinants required for the high affinity interaction of asparagine-linked 
oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and 
erythroagglutinating lectins." J Biol Chem 257(19): 11230-11234. 
315. Kaladas, P.M., E.A. Kabat, et al. (1982). "Immunochemical studies on the 
combining site of the D-galactose/N-acetyl-D-galactosamine specific lectin from 
Erythrina cristagalli seeds." Arch Biochem Biophys 217(2): 624-637. 
316. Sun, Q., X. Kang, et al. (2009). "DSA affinity glycoproteome of human liver 
tissue." Arch Biochem Biophys 484(1): 24-29. 
247 
 
317. Crowley, J.F., I.J. Goldstein, et al. (1984). "Carbohydrate binding studies on the 
lectin from Datura stramonium seeds." Arch Biochem Biophys 231(2): 524-533. 
318. Geisler, C. and D.L. Jarvis (2011). "Effective glycoanalysis with Maackia 
amurensis lectins requires a clear understanding of their binding specificities." 
Glycobiology 21(8): 988-993. 
319. Colanzi, A. and D. Corda (2007). "Mitosis controls the Golgi and the Golgi 
controls mitosis." Curr Opin Cell Biol 19(4): 386-393. 
320. Hicks, S.W. and C.E. Machamer (2005). "Golgi structure in stress sensing and 
apoptosis." Biochim Biophys Acta 1744(3): 406-414. 
321. Hicks SW, M.C. (2005). "Golgi structure in stress sensing and apoptosis." 
Biochim Biophys Acta 1744(3): 406-414. 
322. Efimov, A., A. Kharitonov, et al. (2007). "Asymmetric CLASP-dependent 
nucleation of noncentrosomal microtubules at the trans-Golgi network." Dev Cell 12(6): 
917-930. 
323. Missiaen, L., L. Dode, et al. (2007). "Calcium in the Golgi apparatus." Cell 
Calcium 41(5): 405-416. 
324. Dolman, N.J. and A.V. Tepikin (2006). "Calcium gradients and the Golgi." Cell 
Calcium 40(5-6): 505-512. 
325. Hidalgo Carcedo, C., M. Bonazzi, et al. (2004). "Mitotic Golgi partitioning is 
driven by the membrane-fissioning protein CtBP3/BARS." Science 305(5680): 93-96. 
326. Fidalgo, M., M. Fraile, et al. (2010). "CCM3/PDCD10 stabilizes GCKIII proteins 
to promote Golgi assembly and cell orientation." J Cell Sci 123(Pt 8): 1274-1284. 
327. Mor, A., G. Campi, et al. (2007). "The lymphocyte function-associated antigen-1 
receptor costimulates plasma membrane Ras via phospholipase D2." Nat Cell Biol 9(6): 
713-719. 
328. Perez de Castro, I., T.G. Bivona, et al. (2004). "Ras activation in Jurkat T cells 
following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs 
only on the Golgi apparatus." Mol Cell Biol 24(8): 3485-3496. 
329. Yi, P., D.T. Nguyen, et al. (2010). "MAPK scaffolding by BIT1 in the Golgi 
complex modulates stress resistance." Journal of Cell Science 123(Pt 7): 1060-1072. 
330. Shorter, J. and G. Warren (2002). "Golgi architecture and inheritance." Annu Rev 
Cell Dev Biol 18: 379-420. 
331. Yang, W. and B. Storrie (1998). "Scattered Golgi elements during microtubule 
disruption are initially enriched in trans-Golgi proteins." Mol Biol Cell 9(1): 191-207. 
332. Gleeson, P.A., J.G. Lock, et al. (2004). "Domains of the TGN: coats, tethers and 
G proteins." Traffic 5(5): 315-326. 
333. Gleeson PA, L.J., Luke MR, Stow JL. (2004). "Domains of the TGN: coats, 
tethers and G proteins." Traffic 5(5): 315-326. 
334. Wilson, C. and A. Ragnini-Wilson (2010). "Conserved molecular mechanisms 
underlying homeostasis of the Golgi complex." Int J Cell Biol 2010: 758230. 
335. Munro, S. (2005). "The Golgi apparatus: defining the identity of Golgi 
membranes." Curr Opin Cell Biol 17(4): 395-401. 
336. Malsam, J. and T.H. Sollner (2011). "Organization of SNAREs within the Golgi 
stack." Cold Spring Harb Perspect Biol 3(10): a005249. 
337. Rabouille, C., N. Hui, et al. (1995). "Mapping the distribution of Golgi enzymes 
involved in the construction of complex oligosaccharides." J Cell Sci 108 ( Pt 4): 1617-
1627. 
338. Shima, D.T., K. Haldar, et al. (1997). "Partitioning of the Golgi apparatus during 
mitosis in living HeLa cells." J Cell Biol 137(6): 1211-1228. 
339. Martinez-Alonso, E., M. Tomas, et al. (2013). "Golgi tubules: their structure, 
formation and role in intra-Golgi transport." Histochem Cell Biol 140(3): 327-339. 
248 
 
340. Elbashir, S.M., J. Harborth, et al. (2001). "Duplexes of 21-nucleotide RNAs 
mediate RNA interference in cultured mammalian cells." Nature 411(6836): 494-498. 
341. Roth, J., Y. Wang, et al. (1994). "Subcellular localization of the UDP-N-acetyl-
D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-mediated O-
glycosylation reaction in the submaxillary gland." Proceedings of the National Academy 
of Sciences of the United States of America 91(19): 8935-8939. 
342. Pavelka, M. and A. Ellinger (1985). "Localization of binding sites for 
concanavalin A, Ricinus communis I and Helix pomatia lectin in the Golgi apparatus of 
rat small intestinal absorptive cells." J Histochem Cytochem 33(9): 905-914. 
343. Storrie, B., J. White, et al. (1998). "Recycling of golgi-resident 
glycosyltransferases through the ER reveals a novel pathway and provides an explanation 
for nocodazole-induced Golgi scattering." The Journal of Cell Biology 143(6): 1505-
1521. 
344. Ghosh, R.N., W.G. Mallet, et al. (1998). "An endocytosed TGN38 chimeric 
protein is delivered to the TGN after trafficking through the endocytic recycling 
compartment in CHO cells." The Journal of Cell Biology 142(4): 923-936. 
345. Hong, W. (2005). "SNAREs and traffic." Biochimica et biophysica acta 1744(2): 
120-144. 
346. Hutagalung AH, N.P. (2011). "Role of Rab GTPases in membrane traffic and cell 
physiology." Physiol Rev 91(1): 119-149. 
347. Dinter, A., Berger, E. G. (1998). "Golgi-disturbing agents." Histochem Cell Biol 
109(5-6): 571-590. 
348. Thyberg, J., Moskalewski, S. (1999). "Role of microtubules in the organization 
of the Golgi complex." Exp Cell Res 246(2): 263-279. 
349. Puthenveedu, M.A., C. Bachert, et al. (2006). "GM130 and GRASP65-dependent 
lateral cisternal fusion allows uniform Golgi-enzyme distribution." NATURE CELL 
BIOLOGY 8(3): 238-248. 
350. Duran JM, K.M., Bossard C, Rose DW, Polishchuk R, Wu CC, Yates J, 
Zimmerman T, Malhotra V (2008). "The role of GRASP55 in Golgi fragmentation and 
entry of cells into mitosis." Mol Biol Cell 19(6): 2579-2587. 
351. Valderrama, F., J.M. Durán, et al. (2001). "Actin microfilaments facilitate the 
retrograde transport from the Golgi complex to the endoplasmic reticulum in mammalian 
cells." Traffic 2(10): 717-726. 
352. Young, J., Stauber, T., del Nery, E., Vernos, I., Pepperkok, R., Nilsson, T. 
(2005). "Regulation of microtubule-dependent recycling at the trans-Golgi network by 
Rab6A and Rab6A'." Mol Biol Cell 16(1): 162-177. 
353. Bard, F., L. Mazelin, et al. (2003). "Src regulates Golgi structure and KDEL 
receptor-dependent retrograde transport to the endoplasmic reticulum." J Biol Chem 
278(47): 46601-46606. 
354. Racine, V., M. Sachse, et al. (2007). "Visualization and quantification of vesicle 
trafficking on a three-dimensional cytoskeleton network in living cells." J Microsc 225(Pt 
3): 214-228. 
355. Boser, B.E., I.M. Guyon, et al. (1992). "A training algorithm for optimal margin 
classifiers." 5th Annual ACM Workshop on COLT. 
356. Moreau, D., P. Kumar, et al. (2011). "Genome-Wide RNAi Screens Identify 
Genes Required for Ricin and PE Intoxications." Developmental cell: 1-14. 
357. Manning, G., D.B. Whyte, et al. (2002). "The protein kinase complement of the 
human genome." Science (New York, NY) 298(5600): 1912-1934. 
358. Vicinanza M, D.A.G., Di Campli A, De Matteis MA. (2008). "Function and 




359. Weixel KM, B.-P.A., Watkins SC, Aridor M, Weisz OA. (2005). "Distinct Golgi 
populations of phosphatidylinositol 4-phosphate regulated by phosphatidylinositol 4-
kinases." The Journal of biological chemistry 280(11): 10501-10508. 
360. Santiago-Tirado FH, B.A. (2011). "Membrane-trafficking sorting hubs: 
cooperation between PI4P and small GTPases at the trans-Golgi network." Trends in Cell 
Biology 21(9): 515-525. 
361. Farhan, H., M. Weiss, et al. (2008). "Adaptation of endoplasmic reticulum exit 
sites to acute and chronic increases in cargo load." The EMBO journal 27(15): 2043-
2054. 
362. Godi, A., P. Pertile, et al. (1999). "ARF mediates recruitment of PtdIns-4-OH 
kinase-beta and stimulates synthesis of PtdIns(4,5)P2 on the Golgi complex." NATURE 
CELL BIOLOGY 1(5): 280-287. 
363. Siddhanta, A., J.M. Backer, et al. (2000). "Inhibition of phosphatidic acid 
synthesis alters the structure of the Golgi apparatus and inhibits secretion in endocrine 
cells." The Journal of biological chemistry 275(16): 12023-12031. 
364. Jones, D.H. (2000). "Type I Phosphatidylinositol 4-Phosphate 5-Kinase Directly 
Interacts with ADP-ribosylation Factor 1 and Is Responsible for Phosphatidylinositol 4,5-
Bisphosphate Synthesis in the Golgi Compartment." Journal of Biological Chemistry 
275(18): 13962-13966. 
365. Sweeney, D.A., A. Siddhanta, et al. (2002). "Fragmentation and re-assembly of 
the Golgi apparatus in vitro. A requirement for phosphatidic acid and 
phosphatidylinositol 4,5-bisphosphate synthesis." J Biol Chem 277(4): 3030-3039. 
366. Wu, Y., D. Dowbenko, et al. (2001). "PTEN 2, a Golgi-associated testis-specific 
homologue of the PTEN tumor suppressor lipid phosphatase." The Journal of biological 
chemistry 276(24): 21745-21753. 
367. Roth, M.G. (2004). "Phosphoinositides in constitutive membrane traffic." 
Physiological reviews 84(3): 699-730. 
368. De Matteis, M.A., A. Di Campli, et al. (2005). "The role of the phosphoinositides 
at the Golgi complex." Biochimica et biophysica acta 1744(3): 396-405. 
369. Lindmo, K. and H. Stenmark (2006). "Regulation of membrane traffic by 
phosphoinositide 3-kinases." Journal of Cell Science 119(Pt 4): 605-614. 
370. Low, P.C., R. Misaki, et al. (2010). "Phosphoinositide 3-kinase δ regulates 
membrane fission of Golgi carriers for selective cytokine secretion." The Journal of Cell 
Biology 190(6): 1053-1065. 
371. Jin, T.-G. (2001). "Role of the CDC25 Homology Domain of Phospholipase 
Cepsilon in Amplification of Rap1-dependent Signaling." Journal of Biological 
Chemistry 276(32): 30301-30307. 
372. Blayney, L., P. Gapper, et al. (1998). "Identification of phospholipase C beta 
isoforms and their location in cultured vascular smooth muscle cells of pig, human and 
rat." Cardiovascular research 40(3): 564-572. 
373. Orlando, K.A. and R.N. Pittman (2006). "Rho kinase regulates phagocytosis, 
surface expression of GlcNAc, and Golgi fragmentation of apoptotic PC12 cells." 
Experimental cell research 312(17): 3298-3311. 
374. Foletta, V.C., N. Moussi, et al. (2004). "LIM kinase 1, a key regulator of actin 
dynamics, is widely expressed in embryonic and adult tissues." Experimental cell 
research 294(2): 392-405. 
375. Miserey-Lenkei, S., G. Chalancon, et al. (2010). "Rab and actomyosin-dependent 
fission of transport vesicles at the Golgi complex." NATURE CELL BIOLOGY 12(7): 
645-654. 
376. Bard, F., L. Casano, et al. (2006). "Functional genomics reveals genes involved 
in protein secretion and Golgi organization." Nature 439(7076): 604-607. 
250 
 
377. von Blume, J., J.M. Duran, et al. (2009). "Actin remodeling by ADF/cofilin is 
required for cargo sorting at the trans-Golgi network." The Journal of Cell Biology 
187(7): 1055-1069. 
378. Salvarezza, S.B., S. Deborde, et al. (2009). "LIM kinase 1 and cofilin regulate 
actin filament population required for dynamin-dependent apical carrier fission from the 
trans-Golgi network." Molecular Biology of the Cell 20(1): 438-451. 
379. Egea, G., F. Lázaro-Diéguez, et al. (2006). "Actin dynamics at the Golgi complex 
in mammalian cells." Current Opinion in Cell Biology 18(2): 168-178. 
380. Sanders, L.C., F. Matsumura, et al. (1999). "Inhibition of myosin light chain 
kinase by p21-activated kinase." Science (New York, NY) 283(5410): 2083-2085. 
381. Even-Faitelson, L., M. Rosenberg, et al. (2005). "PAK1 regulates myosin II-B 
phosphorylation, filament assembly, localization and cell chemotaxis." Cellular 
Signalling 17(9): 1137-1148. 
382. Deacon, S.W., A. Beeser, et al. (2008). "An isoform-selective, small-molecule 
inhibitor targets the autoregulatory mechanism of p21-activated kinase." Chemistry 
&amp; Biology 15(4): 322-331. 
383. Cayrol, C., C. Cougoule, et al. (2002). "The beta2-adaptin clathrin adaptor 
interacts with the mitotic checkpoint kinase BubR1." Biochemical and biophysical 
research communications 298(5): 720-730. 
384. Simmen, T., S. Höning, et al. (2002). "AP-4 binds basolateral signals and 
participates in basolateral sorting in epithelial MDCK cells." NATURE CELL 
BIOLOGY 4(2): 154-159. 
385. Fingerhut, A., K. von Figura, et al. (2001). "Binding of AP2 to sorting signals is 
modulated by AP2 phosphorylation." The Journal of biological chemistry 276(8): 5476-
5482. 
386. Vollert, C.S. (2004). "The Phox Homology (PX) Domain Protein Interaction 
Network in Yeast." Molecular &amp; cellular proteomics : MCP 3(11): 1053-1064. 
387. Kanehisa, M., S. Goto, et al. (2010). "KEGG for representation and analysis of 
molecular networks involving diseases and drugs." Nucleic acids research 38(Database 
issue): D355-360. 
388. Qi, W., Z. Tang, et al. (2006). "Phosphorylation- and polo-box-dependent 
binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1." Molecular 
Biology of the Cell 17(8): 3705-3716. 
389. Wang, Y., J. Seemann, et al. (2003). "A direct role for GRASP65 as a mitotically 
regulated Golgi stacking factor." The EMBO journal 22(13): 3279-3290. 
390. Bandyopadhyay, S., C.-Y. Chiang, et al. (2010). "A human MAP kinase 
interactome." Nature Methods 7(10): 801-805. 
391. Plotnikov, A., E. Zehorai, et al. (2011). "The MAPK cascades: Signaling 
components, nuclear roles and mechanisms of nuclear translocation." BBA - Molecular 
Cell Research 1813(9): 1619-1633. 
392. Farhan, H., M.W. Wendeler, et al. (2010). "MAPK signaling to the early 
secretory pathway revealed by kinase/phosphatase functional screening." The Journal of 
Cell Biology 189(6): 997-1011. 
393. Zacharogianni, M., V. Kondylis, et al. (2011). "ERK7 is a negative regulator of 
protein secretion in response to amino-acid starvation by modulating Sec16 membrane 
association." The EMBO journal 30(18): 3684-3700. 
394. Bisel, B., Y. Wang, et al. (2008). "ERK regulates Golgi and centrosome 




395. Harada, T., O. Matsuzaki, et al. (2003). "AKRL1 and AKRL2 activate the JNK 
pathway." [Some factors, with an impact on the outcome of the Hungarian Liver 
Transplant Program, with special consideration of the hepatitis C virus]. 8(5): 493-500. 
396. Akhmanova, A. and J.A.H. Iii (2010). "Linking molecular motors to membrane 
cargo." Current Opinion in Cell Biology 22(4): 479-487. 
397. Shaywitz DA, E.P., Gimeno RE, Kaiser CA. (1997). "COPII subunit interactions 
in the assembly of the vesicle coat." J Biol Chem 272(41): 25413-25416. 
398. Galli T, C.T., Mundigl O, Binz T, Niemann H, De Camilli P. (1994). "Tetanus 
toxin-mediated cleavage of cellubrevin impairs exocytosis of transferrin receptor-
containing vesicles in CHO cells." J Cell Biol 125(5): 1015-1024. 
399. Kean MJ, W.K., Skalski M, Myers D, Burtnik A, Foster D, Coppolino MG. 
(2009). "VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix 
metalloproteinases, degradation of the extracellular matrix and cell invasion." J Cell Sci 
122(Pt 22): 4089-4098. 
400. Holt, M., F. Varoqueaux, et al. (2006). "Identification of SNAP-47, a novel Qbc-
SNARE with ubiquitous expression." The Journal of biological chemistry 281(25): 
17076-17083. 
401. Mallard, F., B.L. Tang, et al. (2002). "Early/recycling endosomes-to-TGN 
transport involves two SNARE complexes and a Rab6 isoform." The Journal of Cell 
Biology 156(4): 653-664. 
402. Amessou, M., A. Fradagrada, et al. (2007). "Syntaxin 16 and syntaxin 5 are 
required for efficient retrograde transport of several exogenous and endogenous cargo 
proteins." Journal of Cell Science 120(Pt 8): 1457-1468. 
403. Gromada J, B.C., Smidt K, Efanov AM, Janson J, Mandic SA, Webb DL, Zhang 
W, Meister B, Jeromin A, Berggren PO. (2005). "Neuronal calcium sensor-1 potentiates 
glucose-dependent exocytosis in pancreatic beta cells through activation of 
phosphatidylinositol 4-kinase beta." Proc Natl Acad Sci U S A 102(29): 10303-10308. 
404. Routt SM, R.M., Tyeryar K, Rizzieri KE, Mousley C, Roumanie O, Brennwald 
PJ, Bankaitis VA. (2005). "Nonclassical PITPs activate PLD via the Stt4p PtdIns-4-
kinase and modulate function of late stages of exocytosis in vegetative yeast." Traffic 
6(12): 1157-1172. 
405. Wenk MR, D.C.P. (2004). "Protein-lipid interactions and phosphoinositide 
metabolism in membrane traffic: insights from vesicle recycling in nerve terminals." Proc 
Natl Acad Sci U S A 101(22): 8262-8269. 
406. Zilberstein, A., M.D. Snider, et al. (1980). "Mutants of vesicular stomatitis virus 
blocked at different stages in maturation of the viral glycoprotein." Cell 21(2): 417-427. 
407. Stanley, P. (2011). "Golgi glycosylation." Cold Spring Harbor perspectives in 
biology 3(4). 
408. Sciaky, N., J. Presley, et al. (1997). "Golgi tubule traffic and the effects of 
brefeldin A visualized in living cells." J Cell Biol 139(5): 1137-1155. 
409. Sengupta, D. and A.D. Linstedt (2011). "Control of organelle size: the Golgi 
complex." Annu Rev Cell Dev Biol 27: 57-77. 
410. Altan-Bonnet, N., R. Sougrat, et al. (2004). "Molecular basis for Golgi 
maintenance and biogenesis." Curr Opin Cell Biol 16(4): 364-372. 
411. Pfeffer, S.R. (1996). "Transport vesicle docking: SNAREs and associates." Annu 
Rev Cell Dev Biol 12: 441-461. 
412. Jahn, R. and R.H. Scheller (2006). "SNAREs--engines for membrane fusion." 
Nat Rev Mol Cell Biol 7(9): 631-643. 
413. Zacharogianni, M., V. Kondylis, et al. (2011). "ERK7 is a negative regulator of 
protein secretion in response to amino-acid starvation by modulating Sec16 membrane 
association." EMBO J 30(18): 3684-3700. 
252 
 
414. Simpson, J.C., B. Joggerst, et al. (2012). "Genome-wide RNAi screening 
identifies human proteins with a regulatory function in the early secretory pathway." Nat 
Cell Biol 14(7): 764-774. 
415. Burman, J.L., J.N.R. Hamlin, et al. (2010). "Scyl1 regulates Golgi morphology." 
PloS one 5(3): e9537. 
416. Burman, J.L., L. Bourbonniere, et al. (2008). "Scyl1, mutated in a recessive form 
of spinocerebellar neurodegeneration, regulates COPI-mediated retrograde traffic." J Biol 
Chem 283(33): 22774-22786. 
417. Duwel, M. and E.J. Ungewickell (2006). "Clathrin-dependent association of 
CVAK104 with endosomes and the trans-Golgi network." Mol Biol Cell 17(10): 4513-
4525. 
418. Nakamura, N., J.H. Wei, et al. (2012). "Modular organization of the mammalian 
Golgi apparatus." Curr Opin Cell Biol 24(4): 467-474. 
419. Cheong, F.Y., V. Sharma, et al. (2010). "Spatial regulation of Golgi 
phosphatidylinositol-4-phosphate is required for enzyme localization and glycosylation 
fidelity." Traffic 11(9): 1180-1190. 
420. Miserey-Lenkei, S., G. Chalancon, et al. (2010). "Rab and actomyosin-dependent 
fission of transport vesicles at the Golgi complex." Nat Cell Biol 12(7): 645-654. 
421. Ron, D. and P. Walter (2007). "Signal integration in the endoplasmic reticulum 
unfolded protein response." Nat Rev Mol Cell Biol 8(7): 519-529. 
422. Pulvirenti, T., M. Giannotta, et al. (2008). "A traffic-activated Golgi-based 
signalling circuit coordinates the secretory pathway." NATURE CELL BIOLOGY 10(8): 
912-922. 
423. Sumara, G., I. Formentini, et al. (2009). "Regulation of PKD by the MAPK 
p38delta in insulin secretion and glucose homeostasis." Cell 136(2): 235-248. 
424. Stanley, P. (2011). "Golgi glycosylation." Cold Spring Harb Perspect Biol 3(4). 
425. Yamaguchi, N. and M.N. Fukuda (1995). "Golgi retention mechanism of beta-
1,4-galactosyltransferase. Membrane-spanning domain-dependent homodimerization and 
association with alpha- and beta-tubulins." The Journal of biological chemistry 270(20): 
12170-12176. 
426. Wassler, M.J., C.I. Foote, et al. (2001). "Functional interaction between the 
SSeCKS scaffolding protein and the cytoplasmic domain of beta1,4-
galactosyltransferase." J Cell Sci 114(Pt 12): 2291-2300. 
427. Quintero, C.A., J. Valdez-Taubas, et al. (2008). "Calsenilin and CALP interact 
with the cytoplasmic tail of UDP-Gal:GA2/GM2/GD2 beta-1,3-galactosyltransferase." 
Biochem J 412(1): 19-26. 
428. Schmitz, K.R., J. Liu, et al. (2008). "Golgi localization of glycosyltransferases 
requires a Vps74p oligomer." Dev Cell 14(4): 523-534. 
429. Lauc, G., I. Rudan, et al. (2010). "Complex genetic regulation of protein 
glycosylation." Mol Biosyst 6(2): 329-335. 
430. Lanctot, P.M., F.H. Gage, et al. (2007). "The glycans of stem cells." Curr Opin 
Chem Biol 11(4): 373-380. 
431. Orlando, K.A. and R.N. Pittman (2006). "Rho kinase regulates phagocytosis, 
surface expression of GlcNAc, and Golgi fragmentation of apoptotic PC12 cells." Exp 
Cell Res 312(17): 3298-3311. 
432. Kellokumpu, S., R. Sormunen, et al. (2002). "Abnormal glycosylation and altered 
Golgi structure in colorectal cancer: dependence on intra-Golgi pH." FEBS Lett 516(1-3): 
217-224. 
433. Wollscheid, B., D. Bausch-Fluck, et al. (2009). "Mass-spectrometric 
identification and relative quantification of N-linked cell surface glycoproteins." Nat 
Biotechnol 27(4): 378-386. 
253 
 
434. Narimatsu, H., H. Sawaki, et al. (2010). "A strategy for discovery of cancer 
glyco-biomarkers in serum using newly developed technologies for glycoproteomics." 
FEBS J 277(1): 95-105. 
435. Boscher, C., J.W. Dennis, et al. (2011). "Glycosylation, galectins and cellular 
signaling." Curr Opin Cell Biol 23(4): 383-392. 
436. Steentoft, C., S.Y. Vakhrushev, et al. (2013). "Precision mapping of the human 
O-GalNAc glycoproteome through SimpleCell technology." EMBO J 32(10): 1478-1488. 
437. Kato K, J.C., Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, 
Mandel U, Strom TM, Clausen H. (2006). "Polypeptide GalNAc-transferase T3 and 
familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-
glycosylation." The Journal of biological chemistry 281(27): 18370-18377. 
438. Springer, G.F. and H. Tegtmeyer (1983). "Tn, a universal carcinoma (CA) 
marker, frequently strongly expressed in anaplastic, aggressive CA." Die 
Naturwissenschaften 70(12): 621-622. 
439. Newman, R.A. and G.G. Uhlenbruck (1977). "Investigation into the occurrence 
and structure of lectin receptors on human and bovine erythrocytes milk fat globule and 
lymphocyte plasma-membrane glycoproteins." European journal of biochemistry / FEBS 
76(1): 149-155. 
440. Egea, G., C. Franci, et al. (1993). "cis-Golgi resident proteins and O-glycans are 
abnormally compartmentalized in the RER of colon cancer cells." J Cell Sci 105 ( Pt 3): 
819-830. 
441. Beck, R., M. Rawet, et al. (2009). "The COPI system: molecular mechanisms and 
function." FEBS Letters 583(17): 2701-2709. 
442. Szul, T. and E. Sztul (2011). "COPII and COPI traffic at the ER-Golgi interface." 
Physiology (Bethesda) 26(5): 348-364. 
443. Chia, J., G. Goh, et al. (2012). "RNAi screening reveals a large signaling network 
controlling the Golgi apparatus in human cells." Mol Syst Biol 8: 629. 
444. Abe, M.K., M.P. Saelzler, et al. (2002). "ERK8, a new member of the mitogen-
activated protein kinase family." J Biol Chem 277(19): 16733-16743. 
445. Swamy, M.J., D. Gupta, et al. (1991). "Further characterization of the saccharide 
specificity of peanut (Arachis hypogaea) agglutinin." Carbohydr Res 213: 59-67. 
446. Fujiwara T, O.K., Yokota S, Takatsuki A, Ikehara, Y. (1988). "Brefeldin A 
causes disassembly of the Golgi complex and accumulation of secretory proteins in the 
endoplasmic reticulum." J Biol Chem 263(34): 18545-18552. 
447. Jensen, L.J., M. Kuhn, et al. (2009). "STRING 8--a global view on proteins and 
their functional interactions in 630 organisms." Nucleic Acids Res 37(Database issue): 
D412-416. 
448. Safran, M., I. Dalah, et al. (2010). "GeneCards Version 3: the human gene 
integrator." Database (Oxford) 2010: baq020. 
449. Uhlen, M., P. Oksvold, et al. (2010). "Towards a knowledge-based Human 
Protein Atlas." Nat Biotechnol 28(12): 1248-1250. 
450. Jensen LJ, K.M., Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, 
Roth A, Simonovic M, Bork P, von Mering C. (2009). "STRING 8--a global view on 
proteins and their functional interactions in 630 organisms." Nucleic Acids Res 
37(Database issue): D412-416. 
451. Safran M, D.I., Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, 
Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D. 




452. Uhlen M, O.P., Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, 
Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F (2010). "Towards a 
knowledge-based Human Protein Atlas." Nat Biotechnol 28(12): 1248-1250. 
453. Nakagawa, T. (1996). "Cloning, expression and localization of 230 kDa 
phosphatidylinositol 4-kinase." J. Biol. Chem 271: 12088–12094. 
454. Ren, M., J. Zeng, et al. (1996). "In its active form, the GTP-binding protein rab8 
interacts with a stress-activated protein kinase." Proc Natl Acad Sci U S A 93(10): 5151-
5155. 
455. Liu, F., J.J. Stanton, et al. (1997). "The human Myt1 kinase preferentially 
phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and 
Golgi complex." Mol Cell Biol 17(2): 571-583. 
456. Wood, C.S., K.R. Schmitz, et al. (2009). "PtdIns4P recognition by 
Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking." J Cell 
Biol 187(7): 967-975. 
457. Nakajima, H., S. Yonemura, et al. (2008). "Myt1 protein kinase is essential for 
Golgi and ER assembly during mitotic exit." J Cell Biol 181(1): 89-103. 
458. Nakajima H, Y.S., Murata M, Nakamura N, Piwnica-Worms H, Nishida E. 
(2008). "Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit." 
J Cell Biol 181(1): 89-103. 
459. Dowd, S., A.A. Sneddon, et al. (1998). "Isolation of the human genes encoding 
the pyst1 and Pyst2 phosphatases: characterisation of Pyst2 as a cytosolic dual-specificity 
MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases." J 
Cell Sci 111 ( Pt 22): 3389-3399. 
460. Colland, F., X. Jacq, et al. (2004). "Functional proteomics mapping of a human 
signaling pathway." Genome Res 14(7): 1324-1332. 
461. Dou, Z., X. Ding, et al. (2004). "TTK kinase is essential for the centrosomal 
localization of TACC2." FEBS Lett 572(1-3): 51-56. 
462. Sowa, M.E., E.J. Bennett, et al. (2009). "Defining the human deubiquitinating 
enzyme interaction landscape." Cell 138(2): 389-403. 
463. Cui, Y., X. Cheng, et al. (2010). "Degradation of the human mitotic checkpoint 
kinase Mps1 is cell cycle-regulated by APC-cCdc20 and APC-cCdh1 ubiquitin ligases." J 
Biol Chem 285(43): 32988-32998. 
464. Wells, N.J., N. Watanabe, et al. (1999). "The C-terminal domain of the Cdc2 
inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of 
G(2)/M progression." J Cell Sci 112 ( Pt 19): 3361-3371. 
465. Yoshimura, Y. and H. Miki (2011). "Dynamic regulation of GEF-H1 localization 
at microtubules by Par1b/MARK2." Biochem Biophys Res Commun 408(2): 322-328. 
466. Palmer, K.J., P. Watson, et al. (2005). "The role of microtubules in transport 
between the endoplasmic reticulum and Golgi apparatus in mammalian cells." 
Biochemical Society symposium(72): 1-13. 
467. Spang, A. (2013). "Retrograde traffic from the Golgi to the endoplasmic 
reticulum." Cold Spring Harbor perspectives in biology 5(6). 
468. Galliher, A.J. and W.P. Schiemann (2007). "Src phosphorylates Tyr284 in TGF-
beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast 
cancer cell proliferation and invasion." Cancer Res 67(8): 3752-3758. 
469. Chadee, D.N., T. Yuasa, et al. (2002). "Direct activation of mitogen-activated 
protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter 
protein TRAF2." Mol Cell Biol 22(3): 737-749. 
470. Eddy SF, G.S., Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin 
DC, and Sonenshein GE (2005). "Inducible IkappaB kinase/IkappaB kinase epsilon 
255 
 
expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in 
breast cancer cells." Cancer Res 65(24): 11375-11383. 
471. Shimada, T., T. Kawai, et al. (1999). "IKK-i, a novel lipopolysaccharide-
inducible kinase that is related to IkappaB kinases." Int Immunol 11(8): 1357-1362. 
472. Stefansson, B. and D.L. Brautigan (2006). "Protein phosphatase 6 subunit with 
conserved Sit4-associated protein domain targets IkappaBepsilon." J Biol Chem 281(32): 
22624-22634. 
473. Klevernic, I.V., M.J. Stafford, et al. (2006). "Characterization of the reversible 
phosphorylation and activation of ERK8." Biochem J 394(Pt 1): 365-373. 
474. Chafin, D.R., H. Guo, et al. (1995). "Action of alpha-amanitin during 
pyrophosphorolysis and elongation by RNA polymerase II." J Biol Chem 270(32): 
19114-19119. 
475. Laughlin, S.T. and C.R. Bertozzi (2007). "Metabolic labeling of glycans with 
azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation." 
Nat Protoc 2(11): 2930-2944. 
476. Sessions, O.M., N.J. Barrows, et al. (2009). "Discovery of insect and human 
dengue virus host factors." Nature 458(7241): 1047-1050. 
477. Rhee, S.W., T. Starr, et al. (2005). "The steady-state distribution of 
glycosyltransferases between the Golgi apparatus and the endoplasmic reticulum is 
approximately 90:10." Traffic 6(11): 978-990. 
478. Qiao, Y., H. Molina, et al. (2006). "Chemical rescue of a mutant enzyme in living 
cells." Science 311(5765): 1293-1297. 
479. Beck, R., M. Rawet, et al. (2009). "The COPI system: molecular mechanisms and 
function." FEBS Lett 583(17): 2701-2709. 
480. Saenz, J.B., W.J. Sun, et al. (2009). "Golgicide A reveals essential roles for 
GBF1 in Golgi assembly and function." Nat Chem Biol 5(3): 157-165. 
481. D'Souza-Schorey, C. and P. Chavrier (2006). "ARF proteins: roles in membrane 
traffic and beyond." Nat Rev Mol Cell Biol 7(5): 347-358. 
482. Popoff, V., J.D. Langer, et al. (2011). "Several ADP-ribosylation factor (Arf) 
isoforms support COPI vesicle formation." J Biol Chem 286(41): 35634-35642. 
483. Antonny, B., J. Bigay, et al. (2005). "Membrane curvature and the control of 
GTP hydrolysis in Arf1 during COPI vesicle formation." Biochem Soc Trans 33(Pt 4): 
619-622. 
484. Morohashi, Y., Z. Balklava, et al. (2010). "Phosphorylation and membrane 
dissociation of the ARF exchange factor GBF1 in mitosis." Biochem J 427(3): 401-412. 
485. Brandvold, K.R., M.E. Steffey, et al. (2012). "Development of a highly selective 
c-Src kinase inhibitor." ACS chemical biology 7(8): 1393-1398. 
486. Henrich, L.M., J.A. Smith, et al. (2003). "Extracellular signal-regulated kinase 7, 
a regulator of hormone-dependent estrogen receptor destruction." Mol Cell Biol 23(17): 
5979-5988. 
487. Hakomori, S. (2001). "Tumor-associated carbohydrate antigens defining tumor 
malignancy: basis for development of anti-cancer vaccines." Advances in experimental 
medicine and biology 491: 369-402. 
488. Feizi, T. (1985). "Carbohydrate antigens in human cancer." Cancer surveys 4(1): 
245-269. 
489. Xu, Y., A. Sette, et al. (2005). "Tumor-associated carbohydrate antigens: a 
possible avenue for cancer prevention." Immunology and cell biology 83(4): 440-448. 
490. Dube, D.H. and C.R. Bertozzi (2005). "Glycans in cancer and inflammation--




491. Springer, G. (1997). "Immunoreactive T and Tn epitopes in cancer diagnosis, 
prognosis, and immunotherapy." J Mol Med (Berl) 75(8): 594-602. 
492. Gill, D.J., J. Chia, et al. (2010). "Regulation of O-glycosylation through Golgi-to-
ER relocation of initiation enzymes." The Journal of cell biology 189(5): 843-858. 
493. Wortzel, I. and R. Seger (2011). "The ERK Cascade: Distinct Functions within 
Various Subcellular Organelles." Genes Cancer 2(3): 195-209. 
494. Bind, E., Y. Kleyner, et al. (2004). "A novel mechanism for mitogen-activated 
protein kinase localization." Molecular Biology of the Cell 15(10): 4457-4466. 
495. Patwardhan, P. and M.D. Resh (2010). "Myristoylation and membrane binding 
regulate c-Src stability and kinase activity." Mol Cell Biol 30(17): 4094-4107. 
496. Lu, D., H.Q. Sun, et al. (2012). "Phosphatidylinositol 4-kinase IIalpha is 
palmitoylated by Golgi-localized palmitoyltransferases in cholesterol-dependent 
manner." J Biol Chem 287(26): 21856-21865. 
497. Chuderland, D., A. Konson, et al. (2008). "Identification and characterization of 
a general nuclear translocation signal in signaling proteins." Mol Cell 31(6): 850-861. 
498. Cha, H. and P. Shapiro (2001). "Tyrosine-phosphorylated extracellular signal--
regulated kinase associates with the Golgi complex during G2/M phase of the cell cycle: 
evidence for regulation of Golgi structure." J Cell Biol 153(7): 1355-1367. 
499. Aebersold, D.M., Y.D. Shaul, et al. (2004). "Extracellular signal-regulated kinase 
1c (ERK1c), a novel 42-kilodalton ERK, demonstrates unique modes of regulation, 
localization, and function." Mol Cell Biol 24(22): 10000-10015. 
500. Bendetz-Nezer, S. and R. Seger (2007). "Role of non-phosphorylated activation 
loop residues in determining ERK2 dephosphorylation, activity, and subcellular 
localization." J Biol Chem 282(34): 25114-25122. 
501. Formstecher, E., J.W. Ramos, et al. (2001). "PEA-15 mediates cytoplasmic 
sequestration of ERK MAP kinase." Dev Cell 1(2): 239-250. 
502. Burman, J.L., L. Bourbonniere, et al. (2008). "Scyl1, mutated in a recessive form 
of spinocerebellar neurodegeneration, regulates COPI-mediated retrograde traffic." The 
Journal of biological chemistry 283(33): 22774-22786. 
503. Muppirala, M., V. Gupta, et al. (2012). "Tyrosine phosphorylation of a SNARE 
protein, syntaxin 17: implications for membrane trafficking in the early secretory 
pathway." Biochim Biophys Acta 1823(12): 2109-2119. 
504. Dirac-Svejstrup, A.B., J. Shorter, et al. (2000). "Phosphorylation of the vesicle-
tethering protein p115 by a casein kinase II-like enzyme is required for Golgi reassembly 
from isolated mitotic fragments." The Journal of Cell Biology 150(3): 475-488. 
505. Groehler, A.L. and D.A. Lannigan (2010). "A chromatin-bound kinase, ERK8, 
protects genomic integrity by inhibiting HDM2-mediated degradation of the DNA clamp 
PCNA." J Cell Biol 190(4): 575-586. 
506. Cerone, M.A., D.J. Burgess, et al. (2011). "High-throughput RNAi screening 
reveals novel regulators of telomerase." Cancer Res 71(9): 3328-3340. 
507. Colecchia, D., A. Strambi, et al. (2012). "MAPK15/ERK8 stimulates autophagy 
by interacting with LC3 and GABARAP proteins." Autophagy 8(12): 1724-1740. 
508. Saelzler, M.P., C.C. Spackman, et al. (2006). "ERK8 down-regulates 
transactivation of the glucocorticoid receptor through Hic-5." J Biol Chem 281(24): 
16821-16832. 
509. Rossi, M., D. Colecchia, et al. (2011). "Extracellular signal-regulated kinase 8 
(ERK8) controls estrogen-related receptor alpha (ERRalpha) cellular localization and 
inhibits its transcriptional activity." J Biol Chem 286(10): 8507-8522. 
510. Duran, J.M., M. Kinseth, et al. (2008). "The role of GRASP55 in Golgi 
fragmentation and entry of cells into mitosis." Mol Biol Cell 19(6): 2579-2587. 
257 
 
511. Preisinger, C., R. Korner, et al. (2005). "Plk1 docking to GRASP65 
phosphorylated by Cdk1 suggests a mechanism for Golgi checkpoint signalling." EMBO 
J 24(4): 753-765. 
512. Condon, K.H., J. Ho, et al. (2013). "The Angelman syndrome protein 
Ube3a/E6AP is required for Golgi acidification and surface protein sialylation." J 
Neurosci 33(9): 3799-3814. 
513. Tjhi, W.C., K.K. Lee, et al. (2011). "Exploratory analysis of cell-based screening 
data for phenotype identification in drug-siRNA study." Int J Comput Biol Drug Des 
4(2): 194-215. 
514. Ibarrola, N., D.E. Kalume, et al. (2003). "A proteomic approach for quantitation 
of phosphorylation using stable isotope labeling in cell culture." Anal Chem 75(22): 
6043-6049. 
515. Kumar, N.V., S.T. Eblen, et al. (2004). "Identifying specific kinase substrates 
through engineered kinases and ATP analogs." Methods 32(4): 389-397. 
516. Aoki D, L.N., Yamaguchi N, Dubois C, Fukuda MN. (1992). "Golgi retention of 
a trans-Golgi membrane protein, galactosyltransferase, requires cysteine and histidine 
residues within the membrane-anchoring domain." Proc Natl Acad Sci U S A. 
517. Burke J, P.J., Humphris D, Gleeson PA. (1994). "Medial-Golgi retention of N-
acetylglucosaminyltransferase I. Contribution from all domains of the enzyme." J Biol 
Chem 269(16): 12049-12059. 
518. El-Battari (2006). "Autofluorescent proteins for monitoring the intracellular 
distribution of glycosyltransferases." Methods Enzymol 416: 102-120. 
519. Nilsson T, R.C., Hui N, Watson R, Warren G. (1996). "The role of the 
membrane-spanning domain and stalk region of N-acetylglucosaminyltransferase I in 
retention, kin recognition and structural maintenance of the Golgi apparatus in HeLa 
cells." J Cell Sci 109 ( Pt 7): 1975-1989. 
520. Uemura, S., S. Yoshida, et al. (2009). "The cytoplasmic tail of GM3 synthase 
defines its subcellular localization, stability, and in vivo activity." Mol Biol Cell 20(13): 
3088-3100. 
521. Pelkmans, L., E. Fava, et al. (2005). "Genome-wide analysis of human kinases in 
clathrin- and caveolae/raft-mediated endocytosis." Nature 436(7047): 78-86. 
522. Collinet, C., M. Stoter, et al. (2010). "Systems survey of endocytosis by 
multiparametric image analysis." Nature 464(7286): 243-249. 
523. Bard, F., L. Casano, et al. (2006). "Functional genomics reveals genes involved 
in protein secretion and Golgi organization." Nature 439(7076): 604-607. 
524. Wendler, F., A.K. Gillingham, et al. (2010). "A genome-wide RNA interference 
screen identifies two novel components of the metazoan secretory pathway." EMBO J 
29(2): 304-314. 
525. Pasquale, E.B. (2005). "Eph receptor signalling casts a wide net on cell 
behaviour." Nat Rev Mol Cell Biol 6(6): 462-475. 
526. Riedemann, J. and V.M. Macaulay (2006). "IGF1R signalling and its inhibition." 
Endocr Relat Cancer 13 Suppl 1: S33-43. 
527. Taniguchi, C.M., B. Emanuelli, et al. (2006). "Critical nodes in signalling 
pathways: insights into insulin action." Nat Rev Mol Cell Biol 7(2): 85-96. 
528. Beenken, A. and M. Mohammadi (2009). "The FGF family: biology, 
pathophysiology and therapy." Nat Rev Drug Discov 8(3): 235-253. 
529. Janik, M.E., A. Litynska, et al. (2010). "Cell migration-the role of integrin 
glycosylation." Biochim Biophys Acta 1800(6): 545-555. 
530. Guo, H.B., H. Johnson, et al. (2009). "Regulation of homotypic cell-cell adhesion 
by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains." J Biol 
Chem 284(50): 34986-34997. 
258 
 
531. Cargnello, M. and P.P. Roux (2011). "Activation and function of the MAPKs and 
their substrates, the MAPK-activated protein kinases." Microbiol Mol Biol Rev 75(1): 
50-83. 
532. Bozulic, L. and B.A. Hemmings (2009). "PIKKing on PKB: regulation of PKB 
activity by phosphorylation." Curr Opin Cell Biol 21(2): 256-261. 
533. Perkins, N.D. (2012). "The diverse and complex roles of NF-kappaB subunits in 
cancer." Nat Rev Cancer 12(2): 121-132. 
 
 
